WO2004038007A2 - Dna polymerases with reduced base analog detection activity - Google Patents

Dna polymerases with reduced base analog detection activity Download PDF

Info

Publication number
WO2004038007A2
WO2004038007A2 PCT/US2003/033997 US0333997W WO2004038007A2 WO 2004038007 A2 WO2004038007 A2 WO 2004038007A2 US 0333997 W US0333997 W US 0333997W WO 2004038007 A2 WO2004038007 A2 WO 2004038007A2
Authority
WO
WIPO (PCT)
Prior art keywords
substitution
mutant
valine
dna polymerase
polymerase
Prior art date
Application number
PCT/US2003/033997
Other languages
French (fr)
Other versions
WO2004038007A3 (en
Inventor
Joseph A. Sorge
Holly H. Hogrefe
Madhushree Ghosh
Original Assignee
Stratagene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/280,962 external-priority patent/US20040081965A1/en
Priority claimed from US10/298,680 external-priority patent/US20040091873A1/en
Priority claimed from US10/408,601 external-priority patent/US20040086890A1/en
Application filed by Stratagene filed Critical Stratagene
Priority to EP03809647A priority Critical patent/EP1578951A4/en
Priority to JP2005501697A priority patent/JP2006507012A/en
Priority to AU2003301590A priority patent/AU2003301590A1/en
Priority to CA002503038A priority patent/CA2503038A1/en
Publication of WO2004038007A2 publication Critical patent/WO2004038007A2/en
Publication of WO2004038007A3 publication Critical patent/WO2004038007A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing

Definitions

  • the invention relates to mutant archaeal DNA polymerases with reduced base analog detection activity.
  • archaeal DNA polymerases e.g., Pfu, Vent
  • possess a "read-ahead" function that detects uracil (dU) residues in the template strand and stalls synthesis (Greagg et al., 1999, PNAS USA, 96:9405).
  • Uracil detection is thought to represent the first step in a pathway to repair DNA cytosine deamination (dCMP-»dUMP) in archaea (Greagg et al, 1999, Supra). Stalling of DNA synthesis opposite uracil has significant implications for high-fidelity PCR amplification with archaeal DNA polymerases.
  • dUTP e.g., dUTP/UDG decontamination methods, Longo et al. 1990, Gene, 93:125
  • uracil-containing ohgonucleotides can not be performed with proofreading DNA polymerases (Slupphaug et al. 1993, Anal. Biochem., 211:164; Sakaguchi et al. 1996, Biotechniques, 21:368). But more importantly, uracil stalling has been shown to compromise the performance of archaeal DNA polymerases under standard PCR conditions (Hogrefe et al. 2002, PNAS USA, 99:596).
  • uracil may also arise as a result of cytosine deamination in template DNA.
  • the extent to which cytosine deamination occurs during temperature cycling has not been determined; however, any uracil generated would presumably impair the PCR performance of archaeal DNA polymerases.
  • Uracil arising from cytosine deamination in template DNA is unaffected by adding dUTPase, which only prevents incorporation of dUTP (created by dCTP deamination).
  • uracil DNA glycosylase which excise uracil from the sugar backbone of DNA
  • UDG mismatch-specific UDGs
  • the problem of uracil stalling may be overcome by introducing mutations or deletions in archaeal DNA polymerases that reduce, or ideally, eliminate uracil detection, and therefore, allow synthesis to continue opposite incorporated uracil (non-mutagenic uracil) and deaminated cytosine (pro-mutagenic uracil).
  • Such mutants would be expected to produce higher product yields and amplify longer targets compared to wild type archaeal DNA polymerases.
  • mutants that lack uracil detection should be compatible with dUTP/UNG decontamination methods employed in real-time Q-PCR. At present, only Tag and Taq-related enzymes , can be used in clean-up methods based on dUTP incorporation.
  • thermostable DNA polymerases that can amplify DNA in the presence of dUTP without compromising proofreading or polymerization activity and efficiency.
  • Pavlov et al., 2002, Proc. Natl. Acad. Sci. USA, 99:13510-13515 and WO 01/92501 Al describe polymerase chimeras comprising a domain that increases processivity and or increases salt resistance.
  • thermostable DNA polymerases that can amplify DNA in the presence of dUTP without compromising proofreading or polymerization activity and efficiency, and wherein the thermostable DNA polymerase exhibits increased processivity and/or increased salt resistance.
  • the invention relates to the construction and characterization of archaeal Family B-type DNA polymerases mutants with reduced base analog detection activity that retain the essential PCR attributes of proofreading DNA polymerases (e.g., polymerase activity, 3'-5' exonuclease activity, fidelity) and also improve the success rate of long-range amplification, e.g., higher yield, longer targets amplified.
  • proofreading DNA polymerases e.g., polymerase activity, 3'-5' exonuclease activity, fidelity
  • the invention relates to mutant archaeal DNA polymerases, and in particular mutant Pfu DNA polymerases, with a reduced base analog detection activity, and comprising a mutation at position V93, that is a Valine substituted to Arginine, Glutamic acid, Lysine, Aspartic acid, or Asparagine, or wherein the mutant archaeal DNA polymerase comprises a truncation, deletion or insertion, as defined herein.
  • the mutant archaeal DNA polymerase comprises a Pfu DNA polymerase comprising a mutation at position V93 wherein Valine is substituted to Arginine, Lysine, Aspartic Acid, or Glutamic Acid. More preferably, the Valine at position 93 is substituted with Lysine.
  • the archaeal DNA polymerase is a Pfu DNA polymerase comprising a deletion at one or more of D92, V93, and P94.
  • the invention provides a mutant archaeal DNA polymerase of one or more of SEQ ID NOS: 28-32 (encoded by SEQ ID Nos: 18-22) having an amino acid mutation at one or more residues between residues 87 and 100, wherein a candidate amino acid may be substituted for an amino acid residue within this region.
  • a candidate amino acid may be substituted for an amino acid residue within this region.
  • an amino acid within the region of residues 87 to 100 is substituted with one of Arginine, Glutamic acid, Lysine, Aspartic acid, Glutamine, or Asparagine.
  • the mutation is at position N93.
  • the invention provides a mutant archaeal D ⁇ A polymerase of one or more of SEQ ID ⁇ OS: 27, or 33-36 (encoded by SEQ ID os: 17, 23-26) having an amino acid mutation at one or more residues between residues 87 and 100, wherein a candidate amino acid may be substituted for an amino acid residue within this region.
  • an amino acid within the region of residues 87 to 100 is substituted with one of Arginine, Glutamic acid, Lysine, Aspartic acid, or Asparagine.
  • the mutation is at position N93.
  • mutant archael D ⁇ A polymerases including mutant Pfu D ⁇ A polymerases that further comprise a Glycine to Proline substitution at amino acid position 387 (G387P; SEQ ID NO: 33; encoded by SEQ ID NO: 23) that confers a reduced DNA polymerization phenotype to said mutant DNA polymerases or that further comprise an N93D/D141A/E143A or Pfu N93 ⁇ /D141 A/E143A triple mutant DNA polymerase, Taq in combination with a Pfu G387P/N93R or G387P/ N93 E or G387P/ N93 K or G387P/ N93 D or G387P/ N93 ⁇ double mutant, a Thermus DNA ligase or a FEN-1 nuclease, either alone or in combination with a PCR enhancing factor and/or an additive.
  • mutant Pfu D ⁇ A polymerases that further comprise a Glycine to Proline substitution at amino acid position 387
  • the invention also provides for compositions comprising any of the single, double or triple mutant archael DNA polymerases described herein, any mutant archael DNA polymerases comprising an insertion, described herein, or any of the truncated, or deleted mutant archael DNA polymerases described herein, in combination with a polypeptide that increases processivity and or salt resistance, thereby forming a chimera, as defined herein.
  • chimeras can be provided in combination with a PCR enhancing factor and/or an additive.
  • kits comprising a mutant archaeal DNA polymerase, having a reduced base analog detection activity, wherein the mutant archaeal DNA polymerase comprises a mutation at position N93 that is a Naline substituted to Arginine, Glutamic acid, Lysine, Aspartic acid, Glutamine, or Asparagine wherein the mutant archaeal D ⁇ A polymerase comprises a truncation, deletion or insertion as defined herein, and packaging materials therefore, h one embodiment, the kit comprises a Pfu D ⁇ A polymerase having a mutation at position N93 that is a Naline substituted to Arginine, Glutamic acid, Lysine, Aspartic acid, or Asparagine.
  • the kit comprises a Pfu D ⁇ A polymerase comprising a deletion at one or more of D92, N93, or P94.
  • the kits of the invention may further comprise a PCR enhancing factor and/or an additive, Taq D ⁇ A polymerase, for example wherein said Taq D ⁇ A polymerase is at a 5 fold, 10 fold or 100 fold lower concentration than said mutant Pfu D ⁇ A polymerase, either alone or in combination with a PCR enhancing factor and/or an additive, or a Pfu G387P/N93R or G387P/ N93 E or G387P/ N93 K or G387P/ N93 D or G387P/ N93 ⁇ double mutant DNA polymerase, a Pfu N93R/D141A/E143A, Pfu N93E/D141 A/E143A, Pfu N93K7D141 A/E143A, Pfu N93D/D141A/E143A or Pfu N93 ⁇ /D141
  • kits comprising any of the single, double or triple mutant archael DNA polymerases described herein, any mutant archael DNA polymerases comprising an insertion, described herein, or any of the truncated, or deleted mutant archael DNA polymerases described herein, in combination with a polypeptide that increases processivity and or salt resistance, thereby forming a chimera, as defined herein.
  • chimeras can be provided in combination with a PCR enhancing factor and/or an additive.
  • compositions of the invention can further comprise a chimera comprising a wild-type polymerase in combination with a polypeptide that increases processivity and/or salt resistance.
  • the invention also provides for a method for DNA synthesis comprising providing a mutant archaeal DNA polymerase of the invention; and contacting the enzyme with a nucleic acid template, wherein the enzyme permits DNA synthesis.
  • DNA synthesis is performed in the presence of dUTP, for example as described in Example 3.
  • the invention also provides for a method for cloning of a DNA synthesis product comprising providing a mutant archaeal DNA polymerase of the invention, contacting the mutant archaeal DNA polymerase with a nucleic acid template, wherein the mutant archaeal DNA polymerase permits DNA synthesis to generate a synthesized DNA product; and inserting the synthesized DNA product into a cloning vector.
  • Any of the methods of amplification or cloning of the invention can further comprise a Thermus DNA ligase or a FEN-1 nuclease.
  • the invention also provides for a method for sequencing DNA comprising the step of providing a mutant archaeal DNA polymerase of the invention, generating chain terminated fragments from the DNA template to be sequenced with the mutant archaeal DNA polymerase in the presence of at least one chain terminating agent and one or more nucleotide triphosphates, and determining the sequence of the DNA from the sizes of said fragments.
  • This method can be performed in the presence of Taq DNA polymerase, for example, wherein the Taq DNA polymerase is at a 5 fold, 10 fold or 100 fold lower concentration than said mutant Pfu DNA polymerase.
  • sequencing is performed using an polymerase that is deficient in 3' to 5' exonuclease activity, for example D141A/E143A.
  • This method can also be carried out in the presence of a double or triple mutant DNA polymerase, as described herein, either alone or in combination with PCR enhancing factor and/or an additive.
  • the invention also provides a method of linear or exponential PCR amplification for site- directed or random mutagenesis comprising the steps of: incubating a reaction mixture comprising a nucleic acid template, a PCR primer, and a mutant archaeal DNA polymerase under conditions which permit amplification of the nucleic acid template by the archaeal DNA polymerase mutant to produce a mutated amplified product.
  • the mutant archaeal DNA polymerase comprises a mutation at N93 wherein Naline is substituted for one of Arginine, Glutamic acid, Lysine, Aspartic acid, Glutamine, or Asparagine.
  • mutant base analog detection refers to a DNA polymerase with a reduced ability to recognize a base analog, for example, uracil or inosine, present in a DNA template.
  • mutant DNA polymerase with "reduced” base analog detection activity is a DNA polymerase mutant having a base analog detection activity which is lower than that of the wild-type enzyme, i.e., having less than 10% (e.g., less than 8%, 6%, 4%, 2% or less than 1%) of the base analog detection activity of that of the wild-type enzyme, base analog detection activity may be determined according to the assays similar to those described for the detection of DNA polymerases having a reduced uracil detection as described in Greagg et al.
  • “reduced" base analog detection refers to a mutant DNA polymerase with a reduced ability to recognize a base analog, the "reduced" recognition of a base analog being evident by an increase in the amount of >10Kb PCR of at least 10%, preferably 50%, more preferably 90%, most preferably 99% or more, as compared to a wild type DNA polymerase without a reduced base analog detection activity.
  • the amount of a > 10Kb PCR product is measured either by spectorophotometer-absorbance assays of gel eluted > 10Kb PCR DNA product or by fluorometric analysis of > 10Kb PCR products in an ethidium bromide stained agarose electrophoresis gel using, for example, a Molecular Dynamics (MD) FluorlmagerTM (Amersham Biosciences, catalogue #63-0007- 79).
  • MD Molecular Dynamics
  • mutant DNA polymerase with "reduced” uracil detection activity is a DNA polymerase mutant having a uracil detection activity which is lower than that of the wild-type enzyme, i.e., having less than 10% (e.g., less than 8%, 6%, 4%, 2% or less than 1%) of the uracil detection activity of that of the wild-type enzyme.
  • Uracil detection activity may be determined according to the assays described
  • "reduced" uracil detection refers to a mutant DNA polymerase with a reduced ability to recognize uracil, the "reduced” recognition of uracil being evident by an increase in the amount of >10Kb PCR of at least 10%, preferably 50%, more preferably 90%, most preferably 99% or more, as compared to a wild type DNA polymerase without a reduced uracil detection activity.
  • the amount of a > 10Kb PCR product is measured either by spectorophotometer-absorbance assays of gel eluted > 10Kb PCR DNA product or by fluorometric analysis of > 10Kb PCR products in an ethidium bromide stained agarose electrophoresis gel using, for example, a Molecular Dynamics (MD) FluorlmagerTM (Amersham Biosciences, catalogue #63-0007- 79).
  • MD Molecular Dynamics
  • the invention contemplates mutant DNA polymerase that exhibits reduced base analog detection (for example, reduced detection of a particular base analog such as uracil or inosine or reduced detection of at least two base analogs).
  • base analogs refer to bases that have undergone a chemical modification as a result of the elevated temperatures required for PCR reactions.
  • base analog refers to uracil that is generated by deamination of cytosine.
  • base analog refers to inosine that is generated by deamination of adenine.
  • synthesis refers to any in vitro method for making new strand of polynucleotide or elongating existing polynucleotide (i.e., DNA or RNA) in a template dependent manner.
  • Synthesis includes amplification, which increases the number of copies of a polynucleotide template sequence with the use of a polymerase.
  • Polynucleotide synthesis e.g., amplification
  • the formed polynucleotide molecule and its template can be used as templates to synthesize additional polynucleotide molecules.
  • DNA synthesis includes, but is not limited to, PCR, the labelling of polynucleotide (i.e., for probes and oligonucleotide primers), polynucleotide sequencing.
  • polymerase refers to an enzyme that catalyzes the polymerization of nucleotide (i.e., the polymerase activity). Generally, the enzyme will initiate synthesis at the 3 1 - end of the primer annealed to a polynucleotide template sequence, and will proceed toward the 5' end of the template strand.
  • DNA polymerase catalyzes the polymerization of deoxynucleotides.
  • the "DNA polymerase” of the invention is an archaeal DNA polymerase.
  • a "DNA polymerase” useful according to the invention includes, but is not limited to those included in the section of the present specification entitled “Polymerases”.
  • the DNA polymerase is a polymerase having the amino acid sequence shown in one of SEQ ID Nos. 27-38.
  • the DNA polymerase is a polymerase having an amino acid sequence encoded by the nucleotide sequence shown in one of SEQ ID Nos 17-26.
  • the DNA polymerase according to the invention is thermostable. In another preferred embodiment, the DNA polymerase according to the invention is Pfu DNA polymerase.
  • Hieraeal DNA polymerase refers to DNA polymerases that belong to either the Family B/pol I-type group (e.g., Pfu, KOD, Pfx, Vent, Deep Nent, Tgo, Pwo) or the pol II group (e.g., Pyrococcus furiosus DP1/DP22-subunit D ⁇ A polymerase).
  • Family B/pol I-type group e.g., Pfu, KOD, Pfx, Vent, Deep Nent, Tgo, Pwo
  • pol II group e.g., Pyrococcus furiosus DP1/DP22-subunit D ⁇ A polymerase
  • archaeal D ⁇ A polymerase refers to thermostable archaeal D ⁇ A polymerases (PCR-able) and include, but are not limited to, D ⁇ A polymerases isolated from Pyrococcus species (furiosus, species GB-D, woesii, abysii, horikoshii), Thermococcus species
  • mutant polymerase refers to an archaeal DNA polymerase, as defined herein, comprising one or more mutations that alter one or more activities of the DNA polymerase, for example, DNA polymerization, 3 '-5' exonuclease activity or base analog detection activities.
  • the "mutant" polymerase of the invention refers to a DNA polymerase containing one or more mutations that reduce one or more base analog detection activities of the DNA polymerase.
  • the "mutant" polymerase of the invention has a reduced uracil detection activity. In a preferred embodiment, the "mutant" polymerase of the invention has a reduced inosine detection activity. In another preferred embodiment, the “mutant” polymerase of the invention has a reduced uracil and inosine detection activity.
  • a “mutant” polymerase as defined herein, includes a polymerase comprising one or more amino acid substitutions, one or more amino acid insertions, a truncation or an internal deletion.
  • a "mutant" polymerase as defined herein also includes a chimeric polymerase wherein any of the single, double or triple mutant archael DNA polymerases described herein, any mutant archael DNA polymerases comprising an insertion, described herein, or any of the truncated, or deleted mutant archael DNA polymerases described herein, occur in combination with a polypeptide that increases processivity and or salt resistance, thereby forming a chimera, as defined herein.
  • a polypeptide that increases processivity and or salt resistance is described in WO 01/92501 Al and Pavlov et al., 2002, Proc. Natl. Acad. Sci. USA, 99:13510-13515, herein incorporated by reference in their entirety.
  • a "mutant" polymerase as defined herein has a sequence selected from one of SEQ ID Nos: 28-32, wherein Valine at position 93 is replaced by one of Arginine, Glutamic acid, Lysine, Aspartic acid, Glutamine, or Asparagine.
  • a "mutant" polymerase as defined herein has a sequence selected from one of SEQ ID Nos: 27, 33-36, wherein Valine at position 93 is replaced by one of Arginine, Glutamic acid, Lysine, Aspartic acid, or Asparagine.
  • a "mutant" polymerase as defined herein has an amino acid sequence encoded by SEQ ID Nos: 18-22, wherein the codon encoding the Valine residue at position 93 is replaced by a codon encoding an amino acid selected from Arginine, Glutamic acid, Lysine, Aspartic acid, Glutamine, or Asparagine.
  • a "mutant" polymerase as defined herein has an amino acid sequence encoded by SEQ ID Nos: 17, 23-26, wherein the codon encoding the Valine residue at position 93 is replaced by a codon encoding an amino acid selected from Arginine, Glutamic acid, Lysine, Aspartic acid, or Asparagine.
  • a "mutant" DNA polymerase is a Pfu polymerase wherein V93 is substituted with one of Arginine, Glutamic acid, Lysine, Asparagine, or Aspartic Acid.
  • a "mutant" DNA polymerase is a Pfu polymerase wherein V93 is substituted with one of Arginine, Glutamic acid.
  • a "mutant" DNA polymerase is a KOD DNA polymerase wherein V93 is substituted with one of Arginine, Glutamic acid, Aspartic Acid, Lysine, or Glutamine.
  • a "mutant" DNA polymerase is a Vent polymerase wherein V93 is substituted with one of Arginine, Glutamic acid, Lysine, Asparagine, Aspartic acid, or Glutamine.
  • a "mutant" DNA polymerase is a Vent polymerase wherein V93 is substituted with one of Arginine or Glutamic acid.
  • a "mutant" DNA polymerase is a Deep Vent polymerase wherein V93 is substituted with one of Arginine, Glutamic acid, Lysine, Asparagine, Aspartic acid, or Glutamine.
  • a "mutant" DNA polymerase is a Deep Vent polymerase wherein V93 is substituted with one of Arginine or Glutamic acid.
  • a "mutant" DNA polymerase is a JDF-3 polymerase wherein V93 is substituted with one of Arginine, Glutamic acid, Lysine, Asparagine, Aspartic acid, or Glutamine.
  • a "mutant" DNA polymerase is a JDF-3 polymerase, wherein V93 is substituted with one of Arginine, Glutamic acid, or Lysine.
  • a "mutant" DNA polymerase is a Tgo polymerase wherein V93 is substituted with one of Arginine, Glutamic acid, Lysine, Asparagine, Glutamine, or Aspartic acid.
  • a “chimera” as defined herein, is a fusion of a first amino acid sequence (protein) comprising a wild type or mutant archael DNA polymerase of the invention, joined to a second amino acid sequence (protein) comprising a wild type or mutant archael DNA polymerase of the invention, joined to a second amino acid sequence (protein) comprising a wild type or mutant archael DNA polymerase of the invention, joined to a second
  • a "chimera” according to the invention contains two or more amino acid sequences (for example a sequence encoding a wild type or mutant archael DNA polymerase and a polypeptide that increases processivity and/or salt resistance) from unrelated proteins, joined to form a new functional protein .
  • a chimera of the invention may present a foreign polypeptide which is found (albeit in a different protein) in an organism which also expresses the first protein, or it may be an "interspecies", “intergenic”, etc. fusion of protein structures expressed by different kinds of organisms.
  • the invention encompasses chimeras wherein the polypeptide that increases processivity and/or salt resistance is joined N-terminally or C-terminally to a wild-type archael DNA polymerase or to any of the mutant archael DNA polymerases described herein.
  • polypeptide that increases processivity and/or salt resistance refers to a domain that is a protein or a region of a protein or a protein complex, comprising a polypeptide sequence, or a plurality of peptide sequences wherein that region increases processivity, as defined herein, or increases salt resistance, as defined herein.
  • a "polypeptide that increases processivity and or salt resistance useful according to the invention includes but is not limited to any of the domains included in Pavlov et al., supra or WO 01/92501, for example Sso7d, Sac7d, HMF-like proteins, PCNA homologs, and helix-hairpin-helix domains, for example derived from Topoisomerase V.
  • joined refers to any method known in the art for functionally connecting polypeptide domains, including without limitation recombinant fusion with or without intervening domains, intein-mediated fusion, non-covalent association, and covalent bonding, including disulfide bonding, hydrogen bonding, electrostatic bonding, and conformational bonding.
  • processivity refers to the ability of a nucleic acid modifying enzyme, for example a polymerase, to remain attached to the template or substrate and perform multiple modification reactions.
  • Modification reactions include but are not limited to polymerization, and exonucleolytic cleavage.
  • Processivity also refers to the ability of a nucleic acid modifying enzyme, for example a polymerase, to modify relatively long (for example 0.5-lkb, l-5kb or 5kb or more) tracts of nucleotides.
  • Processivity also refers to the ability of a nucleic acid modifying enzyme, for example a DNA polymerase, to perform a sequence of polymerization
  • Processivity can depend on the nature of the polymerase, the sequence of a DNA template, and reaction conditions, for example, salt concentration, temperature or the presence of specific proteins.
  • Processivity and increased processivity can be measured according the methods defined herein and in Pavlov et al., supra and WO 01/92501 Al.
  • a polymerase with increased processivity that is a chimera comprising a polypeptide that increases processivity, as defined herein, is described in Pavlov et al. supra and WO 01/92501 Al.
  • “increased salt resistance” refers to a polymerase that exhibits >50% activity at a salt concentration that is know to be greater than the maximum salt concentration at which the wild-type polymerase is active.
  • the maximum salt concentration differs for each polymerase and is known in the art, or can be experimentally determined according to methods in the art. For example, Pfu is inhibited at 30mM (in PCR) so a Pfu enzyme with increased salt resistance would have significant activity (>50%) at salt concentrations above 30mM.
  • a polymerase with increased salt resistance that is a chimera comprising a polypeptide that increases salt resistance, as defined herein, is described in Pavlov et al. supra and WO 01/92501 Al.
  • a DNA polymerase with a "reduced DNA polymerization activity” is a DNA polymerase mutant comprising a DNA polymerization activity which is lower than that of the wild-type enzyme, e.g., comprising less than 10% DNA (e.g., less than 8%, 6%, 4%, 2% or less than 1%) polymerization activity of that of the wild-type enzyme.
  • Methods used to generate characterize Pfu DNA polymerases with reduced DNA polymerization activity are disclosed in the pending U.S. patent application Serial No.: 10/035,091 (Hogrefe, et al.; filed: December 21, 2001); the pending U.S.
  • 3' to 5' exonuclease deficient or “3' to 5' exo-” refers to an enzyme that substantially lacks the ability to remove incorporated nucleotides from the 3' end of a DNA polymer.
  • DNA polymerase exonuclease activities such as the 3' to 5' exonuclease activity exemplified by members of the Family B polymerases, can be lost through mutation, yielding an exonuclease-deficient polymerase.
  • a DNA polymerase that is deficient in 3 ' to 5' exonuclease activity substantially lacks 3' to 5' exonuclease activity.
  • Substantially lacks encompasses a complete lack of activity, for example, 0.03%, 0.05%, 0.1%, 1%, 5%, 10%, 20% or even up to 50%o of the exonuclease activity relative to the parental enzyme.
  • Methods used to generate and characterize 3'-5' exonuclease DNA polymerases including the D141 A and E143A mutations as well as other mutations that reduce or eliminate 3 '-5 ' exonuclease activity are disclosed in the pending U.S. patent application Serial No.: 09/698,341 (Sorge et al; filed October 27, 2000). Additional mutations that reduce or eliminate 3' to 5' exonuclease activity are known in the art and contemplated herein.
  • mutation refers to a change introduced into a parental or wild type DNA sequence that changes the amino acid sequence encoded by the DNA, including, but not limited to, substitutions, insertions, deletions or truncations.
  • the consequences of a mutation include, but are not limited to, the creation of a new character, property, function, or trait not found in the protein encoded by the parental DNA, including, but not limited to, N terminal truncation, C terminal truncation or chemical modification.
  • thermostable refers to an enzyme which is stable and active at temperatures as great as preferably between about 90-100 C and more preferably between about 70-98°C to heat as compared, for example, to a non-thermostable form of an enzyme with a similar activity.
  • a thermostable nucleic acid polymerase derived from thermophilic organisms such as P. furiosus, M. jannaschii, A. fulgidus or P. horikoshii are more stable and active at elevated temperatures as compared to a nucleic acid polymerase from E. coli.
  • furiosus is described in Lundberg et al., 1991, Gene, 108:1-6.
  • Additional representative temperature stable polymerases include, e.g., polymerases extracted from the thermophilic bacteria Thermus flavus, Thermus ruber, Thermus thermophilus, Bacillus stearothermophilus (which has a somewhat lower temperature optimum than the others listed), Thermus lacteus, Thermus rubens,
  • thermophilic archaea Thermococcus litoralis or from thermophilic archaea Thermococcus litoralis, and Methanothermus fervidus .
  • Temperature stable polymerases are preferred in a thermocycling process wherein double stranded nucleic acids are denatured by exposure to a high temperature (about 95 C) during the PCR cycle.
  • template DNA molecule refers to that strand of a nucleic acid from which a complementary nucleic acid strand is synthesized by a DNA polymerase, for example, in a primer extension reaction.
  • template dependent manner is intended to refer to a process that involves the template dependent extension of a primer molecule (e.g., DNA synthesis by DNA polymerase).
  • template dependent manner refers to polynucleotide synthesis of RNA or DNA wherein the sequence of the newly synthesized strand of polynucleotide is dictated by the well-known rules of complementary base pairing (see, for example, Watson, J. D. et al., In: Molecular Biology of the Gene, 4th Ed., W. A. Benjamin, Inc., Menlo Park, Calif. (1987)).
  • fidelity refers to the accuracy of DNA polymerization by template-dependent DNA polymerase.
  • the fidelity of a DNA polymerase is measured by the error rate (the frequency of incorporating an inaccurate nucleotide, i.e., a nucleotide that is not incorporated at a template-dependent manner).
  • the accuracy or fidelity of DNA polymerization is maintained by both the polymerase activity and the 3 '-5 ' exonuclease activity of a DNA polymerase.
  • high fidelity refers to an error rate of 5 x 10 "6 per base pair or lower.
  • the fidelity or error rate of a DNA polymerase may be measured using assays known to the art.
  • the error rates of DNA polymerase mutants can be tested using the lacl PCR fidelity assay described in Cline, J., Braman, J.C., and Hogrefe, H.H. (96) NAR 24:3546-3551. Briefly, a 1.9kb fragment encoding the lacIOlacZa target gene is amplified from pPRlAZ plasmid DNA using 2.5L DNA polymerase (i.e. amount of enzyme necessary to incorporate 25 nmoles of total dNTPs in 30 min. at 72°C) in the appropriate PCR buffer.
  • 2.5L DNA polymerase i.e. amount of enzyme necessary to incorporate 25 nmoles of total dNTPs in 30 min. at 72°C
  • MF percentage of lacl mutants
  • Error rates are expressed as mutation frequency per bp per duplication (MF/bp/d), where bp is the number of detectable sites in the lacl
  • an "amplified product” refers to the double strand polynucleotide population at the end of a PCR amplification reaction.
  • the amplified product contains the original polynucleotide template and polynucleotide synthesized by DNA polymerase using the polynucleotide template during the PCR reaction.
  • polynucleotide template or “target polynucleotide template” or “template” refers to a polynucleotide containing an amplified region.
  • the "amplified region,” as used herein, is a region of a polynucleotide that is to be either synthesized by polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • an amplified region of a polynucleotide template resides between two sequences to which two PCR primers are complementary to.
  • primer refers to a single stranded DNA or RNA molecule that can hybridize to a polynucleotide template and prime enzymatic synthesis of a second polynucleotide strand.
  • a primer useful according to the invention is between 10 to 100 nucleotides in length, preferably 17-50 nucleotides in length and more preferably 17-45 nucleotides in length.
  • “Complementary” refers to the broad concept of sequence complementarity between regions of two polynucleotide strands or between two nucleotides through base-pairing. It is known that an adenine nucleotide is capable of forming specific hydrogen bonds ("base pairing") with a nucleotide which is thymine or uracil. Similarly, it is known that a cytosine nucleotide is capable of base pairing with a guanine nucleotide.
  • wild-type refers to a gene or gene product which has the characteristics of that gene or gene product when isolated from a naturally occurring source.
  • modified or mutant refers to a gene or gene product which displays altered characteristics when compared to the wild-type gene or gene product.
  • a mutant DNA polymerase in the present invention is a DNA polymerase which exhibits a reduced uracil detection activity.
  • FEN-1 nuclease refers to thermostable FEN-1 endonucleases useful according to the invention and include, but are not limited to, FEN-1 endonuclease purified from
  • the addition of FEN-1 in the amplification reaction dramatically increases the efficiency of the multi-site mutagenesis.
  • 400 ng to 4000 ng of FEN-1 may be used in each amplification reaction.
  • 400-1000 ng, more preferably, 400-600 ng of FEN-1 is used in the amplification reaction.
  • I-n a preferred embodiment of the invention, 400 ng FEN-1 is used.
  • Thermus DNA ligase refers to a thermostable DNA ligase that is used in the multi-site mutagenesis amplification reaction to ligate the mutant fragments synthesized by extending each mutagenic primer so to form a circular mutant strand.
  • Tth and Taq DNA ligase require NAD as a cofactor.
  • 1-20 U DNA ligase is used in each amplification reaction, more preferably, 2- 15 U DNA ligase is used in each amplification reaction.
  • Taq DNA ligase cofactor NAD is used at a concentration of 0-1 mM, preferably between 0.02- 0.2 mM, more preferably at 0.1 mM.
  • PCR enhancing factor or a “Polymerase Enhancing Factor” (PEF) refers to a complex or protein possessing polynucleotide polymerase enhancing activity including, but not limited to, PCNA, RFC, helicases etc (Hogrefe et al., 1997, Strategies 10:93- 96; and U.S. Patent No. 6,183,997, both of which are hereby inco ⁇ orated by reference). '
  • the invention also contemplates mutant archael DNA polymerases in combination with accessory factors, for example as described in U.S. 6,333,158, and WO 01/09347 A2, hereby inco ⁇ orated by reference in its entirety.
  • a mutant archaeal or Pfu DNA polymerase comprising a truncation refers to a truncated DNA polymerase with reduced base analog detection activity, preferably reduced uracil detection activity, that is 3 '-5' exonuclease deficient and comprises an N terminal truncation from amino acid 1 - 4, preferably amino acid 1 - 93 or most preferably amino acid 1 - 337.
  • a mutant archaeal or Pfu DNA polymerase comprising a truncation refers to a truncated DNA polymerase with reduced base analog detection activity, preferably reduced uracil detection activity, that is 3 '-5' exonuclease deficient and comprises an N terminal truncation wherein at least the first N terminal amino acid is removed and wherein no more than the first 337 N terminal amino acids are removed or wherein at least the first 1-7 N-terminal amino acids are removed and wherein no more than the first 337 N-terminal amino acids are removed.
  • a mutant archaeal or Pfu DNA polymerase comprising a truncation is a truncated DNA polymerase with 3 '-5' exonuclease activity and reduced base analog detection activity, preferably reduced uracil detection activity, that comprises an N terminal truncation from amino acid 1-7, preferably 1-38, more preferably 1-93 , more preferably 1-116 or most preferably amino acid 1 to amino acid 136.
  • a mutant archaeal or Pfu DNA polymerase comprising a truncation is a truncated DNA polymerase with 3 '-5' exonuclease activity and reduced base analog detection activity, preferably reduced uracil detection activity, that comprises an N terminal truncation wherein at least the first 1 to 7 N-terminal amino acid is/are removed and wherein no more than the first 136 N-terminal amino acids are removed.
  • a mutant archaeal or Pfu DNA polymerase with an internal deletion refers to a mutant archaeal or Pfu DNA polymerase with reduced base analog detection activity, preferably reduced uracil detection activity, that contains an internal deletion of 1 amino acid, 2-4 amino acids, 5-10 amino acids, 10-25 amino acids, 25-50 amino acids, 50-75 amino acids, 75-100 amino acids, or most preferably 136 amino acids within the first N terminal 136 amino acids of the mutant archaeal or Pfu DNA polymerase.
  • a mutant archaeal or Pfu DNA polymerase with an internal deletion refers to a mutant archaeal or Pfu DNA polymerase with reduced base analog detection activity, preferably reduced uracil detection activity, that is 3 '-5' exonuclease deficient and comprises an internal deletion of 1 amino acid, 1-5 amino acids, 5-10 amino acids, 10-25 amino acids, 25-50 amino acids, 50-100 amino acids, 100-150 amino acids, 150-200 amino acids, preferably 200-250 amino acids, preferably 250-300 amino acids, or most preferably 337 amino acids within the first N terminal 337 amino acids of the mutant archaeal or Pfu DNA polymerase.
  • the mutant archaeal or Pfu DNA polymerase with an internal deletion is a DNA polymerase with 3 '-5' exonuclease activity and reduced base analog detection activity, preferably reduced uracil detection activity, and comprises an internal deletion of one or more amino acids in the regions of amino acids 6-8, amino acids 36-38, amino acids 90-97 and amino acids 111-116.
  • the mutant archaeal or Pfu DNA polymerase with an internal deletion is a DNA polymerase with reduced base analog detection activity, preferably reduced uracil detection activity, that is 3 '-5' exonuclease deficient and comprises an internal deletion of one or more amino acids in the regions of amino acids 6-8, amino acids 36-38, amino acids 90- 97 and amino acids 111-116.
  • FIG. 1 Oligonucleotide Primers for QuikChange Mutagenesis (SEQ ID Nos: 6-14, 43-55)
  • Figure 2 (a) dUTP inco ⁇ oration of V93E and V93R mutants compared to wild type Pfu
  • Figure 4 Comparison of the efficacy of PCR amplification of Pfu DNA polymerase mutants and wt enzyme in the presence of different TTP:dUTP concentration ratios.
  • Figure 5 Comparison of the efficacy of "long” PCR amplification of Pfu DNA polymerase mutants and wt enzyme.
  • Figure 6 6A. DNA sequence of mutant archeael DNA polymerases
  • FIG. 7 DNA and Amino acid sequence of wild type Pfu DNA polymerase
  • Figure 9 DNA polymerase activity of N-terminal Pfu DNA polymerase truncation mutants.
  • FIG. 10 Oligonucleotide Primers for QuikChange Mutagenesis (SEQ ID Nos: 56-74).
  • Figure 11 DNA polymerase activity of KOD V93 polymerase mutants.
  • Figure 12 DNA polymerase activity of Tgo V93 DNA polymerase mutants and comparison with JDF-3 V93 polymerase mutants.
  • Figure 13 DNA polymerase activity of JDF-3 polymerase mutants.
  • Figure 14 DNA polymerase activity of Pfu polymerase deletion mutants.
  • Base deamination and other base modifications greatly increase as a consequence of PCR reaction conditions, for example, elevated temperature. This results in the progressive accumulation of base analogs (for example uracil or inosine) in the PCR reaction that ultimately inhibit archaeal proofreading DNA polymerases, such as Pfu, Vent and Deep Vent DNA polymerases, severely limiting their efficiency.
  • base analogs for example uracil or inosine
  • the present invention provides a remedy to the problem of base analog contamination of PCR reactions by disclosing methods for the isolation and characterization of archaeal DNA polymerases with reduced base analog detection activities.
  • mutant archael DNA polymerases of the invention may provide for the use of fewer units of polymerase, may allow assays to be done using shorter extension times and/or may provide greater success in achieving higher yields and or longer products.
  • DNA polymerases There are 2 different classes of DNA polymerases which have been identified in archaea: 1. Family B/pol I type (homologs of Pfu from Pyrococcus furiosus) and 2. pol II type (homologs of P. furiosus DP1/DP2 2-subunit polymerase). DNA polymerases from both classes have been shown to naturally lack an associated 5' to 3' exonuclease activity and to possess 3' to 5' exonuclease (proofreading) activity. Suitable DNA polymerases (pol I or pol II) can be derived from archaea with optimal growth temperatures that are similar to the desired assay temperatures.
  • Thermostable archaeal DNA polymerases isolated from Pyrococcus species (furiosus, species GB-D, woesii, abysii, horikoshii), Thermococcus species (kodakaraensis KODl, litoralis, species 9 degrees North-7, species JDF-3, gorgonarius), Pyrodictium occultum, and Archaeoglobus fulgidus. It is estimated that suitable archaea would exhibit maximal growth temperatures of >80-85°C or optimal growth temperatures of >70-80°C.
  • PCR enzymes from the archaeal pol I DNA polymerase group are commercially available, including Pfu (Stratagene), KOD (Toyobo), Pfx (Life Technologies, Inc.), Vent (New England BioLabs), Deep Vent (New England BioLabs), Tgo (Roche), and Pwo (Roche).
  • the invention therefore provides for thermostable archaeal DNA polymerases of either Family B/pol I type or pol II type with a reduced base analog detection activity.
  • DBSOURCE swissprot locus DPOL_PYRAB, accession P77916
  • DBSOURCE swissprot locus DPOLJPYRSE, accession P77932
  • DBSOURCE swissprot locus DPOL_PYRFU, accession P80061
  • DBSOURCE swissprot locus DPOL_THEFM, accession P74918
  • thermoautotrophicum ACCESSION 027276 PH g3913522
  • DBSOURCE swissprot locus DPOL_METTH, accession 027276
  • DBSOURCE swissprot locus DPOL_ARCFU, accession 029753
  • the archaeal polymerase is a mutant polymerase having reduced uracil base detection.
  • the mutant DNA polymerase is encoded by a nucleic acid sequence selected from SEQ ID Nos 17-24, wherein the codon encoding amino acid residue Valine at position 93 is replaced by the one of the following codons:
  • a mutant DNA polymerase has an amino acid sequence selected from the sequences of SEQ ID NOS: 27-34, wherein Valine at position 93 is replaced by one of Arginine, Glutamic acid, Aspartic acid, Lysine, Glutamine, and Asparagine.
  • the mutant DNA polymerase may be a Pfu DNA polymerase having a deletion of Valine at position 93 as shown in SEQ ID NO: 35, or alternatively, having a deletion of Aspartic acid at position 92, Valine at position 93, and Proline at position 94 as shown in SEQ H) NO: 36.
  • the mutant DNA polymerase may be a Pfu DNA polymerase having a
  • Cloned wild-type DNA polymerases may be modified to generate forms exhibiting reduced base analog detection activity by a number of methods. These include the methods described below and other methods known in the art. Any proofreading archaeal DNA polymerase can be used to prepare for DNA polymerase with reduced base analog detection activity in the invention.
  • DNA polymerase I involved in metal binding, single-stranded DNA binding, and catalysis of the 3'->5' exonuclease reaction are located in the amino-terminal half and in the same linear arrangement in several prokaryotic and eukaryotic DNA polymerases. The location of these conserved regions provides a useful model to direct genetic modifications for preparing DNA polymerase with reduced base analog detection activity whilst conserving essential functions e.g. DNA polymerization and proofreading activity.
  • the preferred method of preparing a DNA polymerase with reduced base analog detection activity is by genetic modification (e.g., by modifying the DNA sequence of a wild- type DNA polymerase).
  • genetic modification e.g., by modifying the DNA sequence of a wild- type DNA polymerase.
  • a number of methods are known in the art that permit the random as well as targeted mutation of DNA sequences (see for example, Ausubel et. al. Short Protocols in
  • kits for site-directed mutagenesis including both conventional and PCR- based methods. Examples include the EXSITETM PCR-Based Site-directed Mutagenesis Kit available from Stratagene (Catalog No. 200502) and the QUIKCHANGETM Site-directed mutagenesis Kit from Stratagene (Catalog No. 200518), and the CHAMELEON ® double- stranded Site-directed mutagenesis kit, also from Stratagene (Catalog No. 200509).
  • DNA polymerases with reduced base analog detection activity may be generated by insertional mutation or truncation (N-terminal, internal or C-terminal) according to methodology known to a person skilled in the art.
  • Older methods of site-directed mutagenesis known in the art rely on sub-cloning of the sequence to be mutated into a vector, such as an Ml 3 bacteriophage vector, that allows the isolation of single-stranded DNA template.
  • a mutagenic primer i.e., a primer capable of annealing to the site to be mutated but bearing one or mismatched nucleotides at the site to be mutated
  • the resulting duplexes are then transformed into host bacteria and plaques are screened for the desired mutation.
  • site-directed mutagenesis has employed PCR methodologies, which have the advantage of not requiring a single-stranded template.
  • methods have been developed that do not require sub-cloning.
  • Several issues must be considered when PCR-based site-directed mutagenesis is performed.
  • First, in these methods it is desirable to reduce the number of PCR cycles to prevent expansion of undesired mutations introduced by the polymerase.
  • Second, a selection must be employed in order to reduce the number of non- mutated parental molecules persisting in the reaction.
  • an extended-length PCR method is preferred in order to allow the use of a single PCR primer set.
  • fourth, because of the non- template-dependent terminal extension activity of some thermostable polymerases it is often necessary to inco ⁇ orate an end-polishing step into the procedure prior to blunt-end ligation of the PCR-generated mutant product.
  • the template concentration used is approximately 1000-fold higher than that used in
  • Plasmid template DNA (approximately 0.5 pmole) is added to a PCR cocktail containing: lx mutagenesis buffer (20 mM Tris HCl, pH 7.5; 8 mM MgCl 2 ; 40 ⁇ g/ml BSA); 12-20 pmole of each primer (one of skill in the art may design a mutagenic primer as necessary, giving consideration to those factors such as base composition, primer length and intended buffer salt concentrations that affect the annealing characteristics of oligonucleotide primers; one primer must contain the desired mutation, and one (the same or the other) must contain a 5' phosphate to facilitate later ligation), 250 ⁇ M each dNTP, 2.5 U Taq DNA polymerase, and 2.5 U of Taq Extender (Available from Stratagene; See Nielson et al.
  • the PCR cycling is performed as follows: 1 cycle of 4 min at 94°C, 2 min at 50°C and 2 min at 72°C; followed by 5-10 cycles of 1 min at 94°C, 2 min at 54°C and 1 min at 72°C.
  • the parental template DNA and the linear, PCR-generated DNA inco ⁇ orating the mutagenic primer are treated with Dpnl (10 U) and Pfu DNA polymerase (2.5U). This results in the Dpnl digestion of the in vivo methylated parental template and hybrid DNA and the removal, by Pfu DNA polymerase, of the non-template-directed Taq DNA polymerase-extended base(s) on the linear PCR product.
  • Methods of random mutagenesis which will result in a panel of mutants bearing one or more randomly situated mutations, exist in the art. Such a panel of mutants may then be screened for those exhibiting reduced uracil detection activity relative to the wild-type polymerase (e.g., by measuring the inco ⁇ oration of lOnmoles of dNTPs into polymeric form in 30 minutes in the presence of 200 ⁇ M dUTP and at the optimal temperature for a given DNA polymerase).
  • An example of a method for random mutagenesis is the so-called "error-prone PCR method". As the name implies, the method amplifies a given sequence under conditions in which the DNA polymerase does not support high fidelity inco ⁇ oration.
  • a key variable for many DNA polymerases in the fidelity of amplification is, for example, the type and concentration of divalent metal ion in the buffer.
  • the use of manganese ion and/or variation of the magnesium or manganese ion concentration may therefore be applied to influence the error rate of the polymerase.
  • Genes for desired mutant DNA polymerases generated by mutagenesis may be sequenced to identify the sites and number of mutations. For those mutants comprising more than one mutation, the effect of a given mutation may be evaluated by introduction of the identified mutation to the wild-type gene by site-directed mutagenesis in isolation from the other mutations borne by the particular mutant. Screening assays of the single mutant thus produced will then allow the determination of the effect of that mutation alone.
  • the enzyme with reduced uracil detection activity is derived from archaeal DNA polymerase containing one or more mutations.
  • the enzyme with reduced uracil detection activity is derived from Pfu DNA polymerase.
  • polymerases with reduced uracil detection activity derived from other exo + DNA polymerases including Vent DNA polymerase, JDF-3 DNA polymerase, Tgo DNA polymerase, and the like may be suitably used in the subject compositions.
  • the invention provides DNA polymerase selected from Tgo , JDF-3 and KOD comprising one or more mutations at V93, and which demonstrate reduced uracil detection activity.
  • the enzyme of the subject composition may comprise DNA polymerases that have not yet been isolated.
  • the mutant Pfu DNA polymerase harbors an amino acid substitution at amino acid position, V93.
  • the mutant Pfu DNA polymerase of the invention contains a Valine to Arginine, Valine to Glutamic acid, Valine to Lysine, Valine to Aspartic Acid, or Valine to Asparagine substitution at amino acid position 93.
  • the invention further provides for mutant archaeal DNA polymerases with reduced base analog detection activity that contains a Valine to Arginine, Valine to Glutamic acid, Valine to Lysine, Valine to Aspartic Acid, Valine to Glutamine, or Valine to Asparagine substitution at amino acid position 93.
  • Figure 6 shows mutant archaeal DNA polymerases of the invention with reduced base analog detection activity.
  • V93 mutant Pfu DNA polymerases with reduced uracil detection activity may contain one or more additional mutations that reduce or abolish one or more additional activities of V93 Pfu DNA polymerases, e.g., DNA polymerization activity or 3 '-5' exonuclease activity.
  • the V93 mutant Pfu DNA polymerase according to the invention contains one or more mutations that renders the DNA polymerase 3 '-5' exonuclease deficient.
  • the V93 mutant Pfu DNA polymerase according to the invention contains one or more mutations that renders the DNA polymerase 3 '-5' exonuclease deficient.
  • 30 to the invention contains one or more mutations that the DNA polymerization activity of the V93 Pfu DNA polymerase.
  • a mutant archael DNA polymerase is a chimera that further comprises a polypeptide that increases processivity and/or increases salt resistance.
  • a polypeptide useful according to the invention and methods of preparing chimeras are described in WO 01/92501 Al and Pavlov et al., 2002, Proc. Natl. Acad. Sci USA, 99:13510-13515. Both references are herein inco ⁇ orated in their entirety.
  • the invention provides for V93Rmutant Pfu DNA polymerases with reduced uracil detection activity containing one or mutations that reduce DNA polymerization as disclosed in the pending U.S. patent application Serial No.: 10/035,091 (Hogrefe, et al.; filed: December 21, 2001); the pending U.S. patent application Serial No.: 10/079,241 (Hogrefe, et al.; filed February 20, 2002); the pending U.S. patent application Serial No.: 10/208,508 (Hogrefe et al.; filed July 30, 2002); and the pending U.S. patent application Serial No.: 10/227,110 (Hogrefe et al.; filed August 23, 2002), the contents of which are hereby inco ⁇ orated in their entirety.
  • the invention provides for a V93R/ G387P, V93E/ G387P,
  • the invention further provides for V93R, V93E, V93D, V93K and V93N mutant Pfu DNA polymerases with reduced uracil detection activity containing one or mutations that reduce or eliminate 3 '-5' exonuclease activity as disclosed in the pending U.S. patent application Serial No.: 09/698,341 (Sorge et al; filed October 27, 2000).
  • the invention provides for a V93R/D141 A/E143A triple mutant Pfu DNA polymerase with reduced 3 '-5' exonuclease activity and reduced uracil detection activity.
  • the invention further provides for combination of one or more mutations that may increase or eliminate base analog detection activity of an archaeal DNA polymerase.
  • DNA polymerases containing additional mutations are generated by site directed mutagenesis using the Pfu DNA polymerase or Pfu V93R cDNA as a template DNA molecule, according to methods that are well known in the art and are described herein.
  • 09/698,341 (Sorge et al; filed October 27, 2000) would have no difficulty introducing both the corresponding D141A and E143A mutations or other 3 '-5' exonuclease mutations into the V93 Pfu DNA polymerase cDNA, as disclosed in the pending U.S. patent application Serial No.: 09/698,341, using established site directed mutagenesis methodology.
  • the Pfu mutants are expressed and purified as described in U.S. Patent No. 5,489,523, hereby inco ⁇ orated by reference in its entirety.
  • Random or site-directed mutants generated as known in the art or as described herein and expressed in bacteria may be screened for reduced uracil detection activity by several different assays. Embodiments for the expression of mutant and wild type enzymes is described herein. In one method, exo + DNA polymerase proteins expressed in lytic lambda phage plaques
  • Mutant polymerase libraries may be screened using a variation of the technique used by
  • the assay cocktail consists of IX cloned Pfu (cPfu) magnesium free buffer (IX buffer is 20 mM Tris-HCl (pH 8.8), 10 mM KCI, 10 mM (NH4) 2 SO 4 , 100 ⁇ g/ml bovine serum albumin (BSA), and 0.1% Triton X- 100; Pfu Magnesium-free buffer may be obtained from Stratagene (Catalog No.
  • Filters are then exposed to X-ray film (approximately 16 hours), and plaques that inco ⁇ orate label in the presence of 200 ⁇ M dUTP or 200 ⁇ M dTTP are identified by aligning the filters with the original plate bearing the phage clones. Plaques identified in this way are re-plated at more dilute concentrations and assayed under similar conditions to allow the isolation of purified plaques.
  • the signal generated by the label is a direct measurement of the polymerization activity of the polymerase in the presence of 200 ⁇ M dUTP as compared to the polymerase activity of the same mutant polymerase in the presence of 200 ⁇ M dTTP.
  • a plaque comprising a mutant DNA polymerase with reduced uracil detection activity as compared to that of the wild-type enzyme can then be identified and further tested in primer extension assays in which template dependent DNA synthesis is measured in the presence
  • Extension reactions are then quenched on ice, and 5 ⁇ l aliquots are spotted immediately onto DE81 ion-exchange filters (2.3cm; Whatman #3658323). Uninco ⁇ orated label is removed by 6 washes with 2 x SCC (0.3M NaCl, 30mM sodium citrate, pH 7.0), followed by a brief wash with 100% ethanol.
  • Inco ⁇ orated radioactivity is then measured by scintillation counting. Reactions that lack enzyme are also set up along with sample incubations to determine “total cpms” (omit filter wash steps) and "minimum cpms”(wash filters as above). Cpms bound is proportional to the amount of polymerase activity present per volume of bacterial extract. Mutants that can inco ⁇ orate significant radioactivity in the presence of dUTP are selected for further analysis.
  • Mutant DNA polymerases with reduced uracil recognition can also be identified as those that can synthesize PCR products in the presence of 100%) dUTP(See Example 3).
  • the "uracil detection” activity can also be determined using the long range primer extension assay on single uracil templates as described by Greagg et al., (1999) Proc. Natl. Acad. Sci. 96, 9045-9050. Briefly, the assay requires a 119- mer template that is generated by PCR amplification of a segment of pUC19 spanning the polylinker cloning site.
  • PCR primer sequences are:
  • the 119- mer oligonucleotide inco ⁇ orating either a U or T nucleotide 23 bases from the terminus of one strand was synthesized by using Taq polymerase under standard PCR conditions, using primer C and either primer A or primer B. PCR products are then purified on agarose gels and extracted by using Qiagen columns.
  • primer C is annealed to one strand of the 119- bp PCR product by heating to 65 °C in reaction buffer and cooling to room temperature.
  • the dNTPs, [ ⁇ - [ 32 P] dATP, and 5 units of DNA polymerase ( Pfu, Taq and mutant Pfu DNA polymerase to be tested) are added in polymerase reaction buffer ( as specified by the suppliers of each polymerase) to a final volume of 20 ⁇ l, and the reaction is allowed to proceed for 60 min at 55 °C.
  • Reaction products are subjected to electrophoresis in a denaturing acrylamide gel and scanned and recorded on a Fuji FLA- 2000 phosphorimager.
  • the ability of the DNA polymerases from the thermophilic archaea Pyrococcus furiosus ( Pfu) and the test mutant Pfu DNA polymerase to extend a primer across a template containing a single deoxyuridine can then be determined and directly compared.
  • Methods known in the art may be applied to express and isolate the mutated forms of DNA polymerase (i.e., the second enzyme) according to the invention.
  • the methods described here can be also applied for the expression of wild-type enzymes useful (e.g., the first enzyme) in the invention.
  • Many bacterial expression vectors contain sequence elements or combinations of sequence elements allowing high level inducible expression of the protein encoded by a foreign sequence.
  • bacteria expressing an integrated inducible form of the T7 RNA polymerase gene may be transformed with an expression vector bearing a mutated DNA polymerase gene linked to the T7 promoter.
  • an appropriate inducer for example, isopropyl- ⁇ -D-thiogalactopyranoside (IPTG) for a lac-inducible promoter
  • E. coli strain BL-21 is commonly used for expression of exogenous proteins since it is protease deficient relative to other strains of E. coli.
  • BL-21 strains bearing an inducible T7 RNA polymerase gene include WJ56 and ER2566 (Gardner & Jack, 1999, supra).
  • codon usage for the particular polymerase gene differs from that normally seen in E. coli genes, there are strains of BL-21 that are modified to carry tRNA genes encoding tRNAs with rarer anticodons (for example, argU,
  • cloned protein genes 35 ileY, leuW, and proL tRNA genes), allowing high efficiency expression of cloned protein genes, for example, cloned archaeal enzyme genes (several BL21 -CODON PLUSTM cell strains carrying rare-codon tRNAs are available from Stratagene, for example).
  • DNA polymerase mutants may be isolated by an ammonium sulfate fractionation, followed by Q Sepharose and DNA cellulose columns, or by adso ⁇ tion of contaminants on a HiTrap Q column, followed by gradient elution from a HiTrap heparin column.
  • the invention further provides for mutant V93R, V93E, V93D, V93K or V93N Pfu DNA polymerases that contain one or more additional mutations with improved reverse transcriptase activity.
  • the invention further provides for compositions in which V93 archaeal or Pfu mutant DNA polymerases with reduced base analog detection activity contain additional mutations that reduced DNA polymerization activity for example, G387P (polymerase minus) or 3 '-5' exonuclease activity, for example, D141A/E143A (3'-5' exonuclease minus)
  • the invention further provides for compositions comprising mutant archeal polymerases that are chimeras, as described herein.
  • the invention provides for compositions wherein n the archael or Pfu mutant DNA polymerases are mixed as described in Table 2.
  • the invention further provides for compositions in which any of the archaeal or Pfu mutant DNA polymerases with reduced base analog detection activity are mixed with either a.) Pfu G387P (polymerase minus)
  • the invention also provides for mixtures of V93 mutant archaeal or Pfu DNA polymerases, preferably V93R, with additional compositions that include, but are not limited to:
  • the invention also contemplates a mixture comprising the combination of a mutant archael DNA polymerase of the invention, dUTP and uracil N-glycosylase.
  • the invention further provides for the archaeal DNA polymerases of the invention with reduced base analog detection activity be combined with the Easy A composition that contains a blend of Taq (5U/ul), recombinant PEF (4U/ul), and Pfu G387P/V93R, E, N, D, K or N mutant (40ng/ul) as disclosed in the pending U.S. patent application Serial No.: 10/035,091 (Hogrefe, et
  • the ratio of Taq:Pfu is preferably 1 : 1 or more preferably 2: 1 or more.
  • the invention provides a method for DNA synthesis using the compositions of the subject invention.
  • synthesis of a polynucleotide requires a synthesis primer, a synthesis template, polynucleotide precursors for inco ⁇ oration into the newly synthesized polynucleotide, (e.g. dATP, dCTP, dGTP, dTTP), and the like.
  • polynucleotide precursors for inco ⁇ oration into the newly synthesized polynucleotide e.g. dATP, dCTP, dGTP, dTTP
  • Detailed methods for carrying out polynucleotide synthesis are well known to the person of ordinary skill in the art and can be found, for example, in Molecular Cloning second edition, Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).
  • PCR Polymerase chain reaction
  • PCR refers to an in vitro method for amplifying a specific polynucleotide template sequence.
  • the technique of PCR is described in numerous publications, including, PCR: A Practical Approach, M. J. McPherson, et al., IRL Press (1991 ), PCR Protocols: A Guide to Methods and Applications, by Innis, et al., Academic Press (1990), and PCR Technology: Principals and Applications for DNA Amplification, H. A. Erlich, Stockton Press (1989).
  • PCR is also described in many U.S. Patents, including U.S. Patent Nos.
  • the PCR reaction involves a repetitive series of temperature cycles and is typically performed in a volume of 50-100 ⁇ l.
  • the reaction mix comprises dNTPs (each of the four deoxynucleotides dATP, dCTP, dGTP, and dTTP), primers, buffers, DNA polymerase, and polynucleotide template.
  • dNTPs deoxynucleotides dATP, dCTP, dGTP, and dTTP
  • primers primers
  • buffers buffers
  • DNA polymerase DNA polymerase
  • polynucleotide template polynucleotide template
  • target polynucleotide sequence to be amplified In PCR, this double-stranded target sequence is denatured and one primer is annealed to each strand of the denatured target. The primers anneal to the target polynucleotide at sites removed from one another and in orientations such that the extension product of one primer, when separated from its complement, can hybridize to the other primer. Once a given primer hybridizes to the target sequence, the primer is extended by the action of a DNA polymerase. The extension product is then denatured from the target sequence, and the process is repeated.
  • the amplification product is a discrete double-stranded DNA molecule comprising: a first strand which contains the sequence of the first primer, eventually followed by the sequence complementary to the second primer, and a second strand which is complementary to the first strand.
  • the enzymes provided herein are also useful for dUTP/UNG cleanup methods that require PCR enzymes that inco ⁇ orate dUTP (Longo et al., Supra).
  • Mutations that reduce uracil sensitivity are expected to improve the success rate of long-range amplification (higher yield, longer targets amplified). It is expected that mutations eliminating uracil detection will also increase the error rate of archaeal DNA polymerases. If uracil stalling contributes to fidelity by preventing synthesis opposite promutagenic uracil (arising from cytosine deamination), then uracil insensitive mutants are
  • thermostable exonucleases e.g., polymerase reduced proofreading DNA polymerases, exonuclease in
  • additional mutations that increase fidelity.
  • thermostable refers to an enzyme which is stable to heat, is heat resistant, and functions at high temperatures, e.g., 50 to
  • the thermostable enzyme according to the present invention must satisfy a single criterion to be effective for the amplification reaction, i.e., the enzyme must not become irreversibly denatured (inactivated) when subjected to the elevated temperatures for the time necessary to effect denaturation of double-stranded polynucleotides.
  • irreversible denaturation as used in this connection, is meant a process bringing a pennanent and complete loss of enzymatic activity.
  • the heating conditions necessary for denaturation will depend, e.g., on the buffer salt concentration and the length and nucleotide composition of the polynucleotides being denatured, but typically range from 85 C ? for shorter polynucleotides, to 105°C for a time depending mainly on the temperature and the polynucleotide length, typically from 0.25 minutes for shorter polynucleotides, to 4.0 minutes for longer pieces of DNA. Higher temperatures may be tolerated as the buffer salt concentration and/or GC composition of the polynucleotide is increased.
  • the enzyme will not become irreversibly denatured at 90 to 100°C.
  • An enzyme that does not become irreversibly denatured, according to the invention retains at least 10%, or at least 25%, or at least 50% or more function or activity during the amplification reaction.
  • PCR fidelity may be affected by factors such as changes in dNTP concentration, units of enzyme used per reaction, pH, and the ratio of Mg 2+ to dNTPs present in the reaction (Mattila et al., 1991, supra).
  • Mg 2+ concentration affects the annealing of the oligonucleotide primers to the template DNA by stabilizing the primer-template interaction, it also stabilizes the replication complex of polymerase with template-primer. It can therefore also increases non-specific annealing and produced undesirable PCR products (give ' s multiple bands in gel).
  • Mg 2+ may need to be lowered or EDTA can be added to chelate Mg 2+ to increase the accuracy and specificity of the amplification.
  • divalent cations such as Mn 2+ , or Co 2+ can also affect DNA polymerization. Suitable cations for each DNA polymerase are known in the art (e.g., in DNA Replication 2 nd edition, supra). Divalent cation is supplied in the form of a salt such MgCl , Mg(OAc) 2 , MgSO 4 , MnCl 2 , Mn(OAc) 2 , or MnSO .
  • Usable cation concentrations in a Tris-HCl buffer are for MnCl 2 from 0.5 to 7 mM, preferably, between 0.5 and 2 mM, and for MgCl from 0.5 to 10 mM.
  • Usable cation concentrations in a Bicine/KOAc buffer are from 1 to 20 mM for Mn(OAc) 2 , preferably between 2 and 5 mM.
  • Monovalent cation required by DNA polymerase may be supplied by the potassium, sodium, ammonium, or lithium salts of either chloride or acetate.
  • the concentration is between 1 and 200 mM, preferably the concentration is between 40 and 100 mM, although the optimum concentration may vary depending on the polymerase used in the reaction.
  • Deoxyribonucleotide triphosphates are added as solutions of the salts of dATP, dCTP, dGTP, dUTP, and dTTP, such as disodium or lithium salts.
  • a final concentration in the range of 1 ⁇ M to 2 mM each is suitable, and 100-600 ⁇ M is preferable, although the optimal concentration of the nucleotides may vary in the PCR reaction depending on the total dNTP and divalent metal ion concentration, and on the buffer, salts, particular primers, and template. For longer products, i.e., greater than 1500 bp, 500 ⁇ M each dNTP may be preferred when using a Tris-HCl buffer.
  • dNTPs chelate divalent cations, therefore amount of divalent cations used may need to be changed according to the dNTP concentration in the reaction. Excessive amount of dNTPs (e.g., larger than 1.5 mM) can increase the error rate and possibly inhibit DNA polymerases. Lowering the dNTP (e.g., to 10-50 ⁇ M) may therefore reduce error rate. PCR reaction for amplifying larger size template may need more dNTPs.
  • Tris-HCl preferably pH 8.3, although the pH may be in the range 8.0-8.8.
  • the Tris-HCl concentration is from 5-250 mM, although 10-100 mM is most preferred.
  • a preferred buffering agent is Bicine-KOH, preferably pH 8.3, although pH may be in the range 7.8-8.7. Bicine acts both as a pH buffer and as a metal buffer. Tricine may also be used.
  • PCR is a very powerful tool for DNA amplification and therefore very little template DNA is needed.
  • a higher DNA concentration may be used, though too many templates may increase the amount of contaminants and reduce efficiency.
  • primers usually, up to 3 ⁇ M of primers may be used, but high primer to template ratio can results in non-specific amplification and primer-dimer formation. Therefore it is usually necessary to check primer sequences to avoid primer-dimer formation.
  • the invention provides for Pfu V93R, V93E, V93K , V93D , or V93N DNA polymerases with reduced uracil detection activity that enhance PCR of GC rich DNA templates by minimizing the effect of cytosine deamination in the template and by allowing the use of higher denaturation times and denaturation temperatures.
  • Denaturation time may be increased if template GC content is high. Higher annealing temperature may be needed for primers with high GC content or longer primers. Gradient PCR is a useful way of determining the annealing temperature. Extension time should be extended for larger PCR product amplifications. However, extension time may need to be reduced whenever possible to limit damage to enzyme.
  • the number of cycle can be increased if the number of template DNA is very low, and decreased if high amount of template DNA is used.
  • PCR enhancing factors may also be used to improve efficiency of the amplification.
  • a "PCR enhancing factor” or a “Polymerase Enhancing Factor” (PEF) refers to a complex or protein possessing polynucleotide polymerase enhancing activity (Hogrefe et al.,
  • PEF comprises either P45 in native form (as a complex of P50 and P45) or as a recombinant protein. In the native complex of Pfu P50 and P45, only P45 exhibits PCR enhancing activity.
  • the P50 protein is similar in structure to a bacterial flavoprotein.
  • the P45 protein is similar in structure to dCTP deaminase and dUTPase, but it functions only as a dUTPase converting dUTP to dUMP and pyrophosphate.
  • PEF can also be selected from the group consisting of: an isolated or purified naturally occurring polymerase enhancing protein obtained from an archeabacteria source (e.g., Pyrococcus furiosus); a wholly or partially synthetic protein having the same amino acid sequence as Pfu P45, or analogs thereof possessing polymerase enhancing activity; polymerase- enhancing mixtures of one or more of said naturally occurring or wholly or partially synthetic proteins; polymerase-enhancing protein complexes of one or more of said naturally occurring or wholly or partially synthetic proteins; or polymerase-enhancing partially purified cell extracts containing one or more of said naturally occurring proteins (U.S. Patent No. 6,183,997, supra).
  • an isolated or purified naturally occurring polymerase enhancing protein obtained from an archeabacteria source (e.g., Pyrococcus furiosus); a wholly or partially synthetic protein having the same amino acid sequence as Pfu P45, or analogs thereof possessing polymerase enhancing activity
  • the PCR enhancing activity of PEF is defined by means well l ⁇ iown in the art.
  • the unit definition for PEF is based on the dUTPase activity of PEF (P45), which is determined by monitoring the production of pyrophosphate (PPi) from dUTP.
  • PEF is incubated with dUTP (lOmM dUTP in lx cloned Pfu PCR buffer) during which time PEF hydrolyzes dUTP to dUMP and PPi.
  • the amount of PPi formed is quantitated using a coupled enzymatic assay system that is commercially available from Sigma (#P7275).
  • One unit of activity is functionally defined as 4.0 nmole of PPi formed per hour (at 85°C).
  • PCR additives may also affect the accuracy and specificity of PCR reaction.
  • EDTA less than 0.5 mM may be present in the amplification reaction mix.
  • Detergents such as Tween-20TM and NonidetTM P-40 are present in the enzyme dilution buffers.
  • glycerol is often present in enzyme preparations and is generally diluted to a concentration of 1-20% in the reaction mix. Glycerol (5-10%), formamide (1-5%) or DMSO (2-10%) can be added in PCR for template DNA with high GC content or long length (e.g., > lkb).
  • BSA melting temperature
  • Betaine (0.5-2M) is also useful for PCR over high GC content and long fragments of DNA.
  • TMAC Tetramethylammonium chloride
  • TEAC Tetraethylammonium chloride
  • TMANO Trimethlamine N-oxide
  • the invention provides for additive including, but not limited to antibodies (for hot start PCR) and ssb (higher specificity).
  • the invention also contemplates mutant archael DNA polymerases in combination with accessory factors, for example as described in U.S. 6,333,158, and WO 01/09347 A2, hereby incorporated by reference in its entirety.
  • the subject invention can be used in PCR applications including, but are not limited to, i) hot-start PCR which reduces non-specific amplification; ii) touch-down PCR which starts at high annealing temperature, then decreases annealing temperature in steps to reduce non-specific PCR product; iii) nested PCR which synthesizes more reliable product using an outer set of primers and an inner set of primers; iv) inverse PCR for amplification of regions flanking a known sequence.
  • DNA is digested, the desired fragment is circularized by ligation, then PCR using primer complementary to the known sequence extending outwards; v) AP-PCR (arbitrary primed)/RAPD (random amplified polymorphic DNA).
  • RT-PCR which uses RNA-directed DNA polymerase (e.g., reverse transcriptase) to synthesize cDNAs which is then used for PCR.
  • RNA-directed DNA polymerase e.g., reverse transcriptase
  • This method is extremely sensitive for detecting the expression of a specific sequence in a tissue or cells. It may also be use to quantify mRNA transcripts;
  • RACE rapid amplification of cDNA ends). This is used where information about DNA/protein sequence is limited. The method amplifies 3' or 5' ends of cDNAs generating fragments of cDNA with only one specific primer each (plus one adaptor primer).
  • DD-PCR differential display PCR
  • Ohgonucleotides used in this method are complementary to stretches of a gene (>80 bases), alternately to the sense and to the antisense strands with ends overlapping ( ⁇ 20 bases); xii) Asymmetric PCR; xiii) In situ PCR; xiv) Site-directed PCR Mutagenesis.
  • the amplified product produced using the subject enzyme can be cloned by any method known in the art.
  • the invention provides a composition which allows direct cloning of PCR amplified product.
  • the most common method for cloning PCR products involves inco ⁇ oration of flanking restriction sites onto the ends of primer molecules.
  • the PCR cycling is carried out and the amplified DNA is then purified, restricted with an appropriate endonuclease(s) and ligated to a compatible vector preparation.
  • a method for directly cloning PCR products eliminates the need for preparing primers having restriction recognition sequences and it would eliminate the need for a restriction step to prepare the PCR product for cloning. Additionally, such method would preferably allow cloning PCR products directly without an intervening purification step.
  • U.S. Patent Nos. 5,827,657 and 5,487,993 disclose methods for direct cloning of PCR products using a DNA polymerase which takes advantage of the single 3'-deoxy-adenosine monophosphate (dAMP) residues attached to the 3' termini of PCR generated nucleic acids.
  • Vectors are prepared with recognition sequences that afford single 3'- terminal deoxy-thymidine monophosphate (dTMP) residues upon reaction with a suitable restriction enzyme.
  • dTMP deoxy-thymidine monophosphate
  • Taq DNA polymerase exhibits terminal transferase activity that adds a single dATP to the 3' ends of PCR products in the absence of template. This activity is the basis for the TA cloning method in which PCR products amplified with Taq are directly ligated into vectors containing single 3'dT overhangs.
  • Pfu DNA polymerase on the other hand, lacks terminal transferase activity, and thus produces blunt-ended PCR products that are efficiently cloned into blunt-ended vectors.
  • the invention provides for a PCR product, generated in the presence of a mutant DNA polymerase with reduced uracil detection activity, that is subsequently incubated with Taq DNA polymerase in the presence of dATP at 72°C for 15-30 minutes. Addition of 3 '-dAMP to the ends of the amplified DNA product then permits cloning into TA cloning vectors according to methods that are well known to a person skilled in the art.
  • the invention further provides for dideoxynucleotide DNA sequencing methods using thermostable DNA polymerases having a reduced base analog detection activity to catalyze the primer extension reactions.
  • Methods for dideoxynucleotide DNA sequencing are well known in the art and are disclosed in U.S. Patent Nos. 5,075,216, 4,795,699 and 5,885,813, the contents of which are hereby inco ⁇ orated in their entirety.
  • the mutant archaeal DNA polymerases of the invention also provide enhanced efficacy for PCR-based or linear amplification-based mutagenesis.
  • the invention therefore provides for the use of the mutant archaeal DNA polymerases with reduced base analog detection activity for site-directed mutagenesis and their inco ⁇ oration into commercially available kits, for example, QuikChange Site-directed Mutagenesis, QuikChange Multi-Site-Directed Mutagenesis (Stratagene). Site-directed mutagenesis methods and reagents are disclosed in the pending U.S. Patent Application No.
  • kits which comprises a package unit having one or more containers of the subject composition and in some embodiments including containers of various reagents used for polynucleotide synthesis, including synthesis in PCR.
  • the kit may also contain one or more of the following items: polynucleotide precursors, primers, buffers, instructions, and controls.
  • Kits may include containers of reagents mixed together in suitable proportions for performing the methods in accordance with the invention.
  • Reagent containers preferably contain reagents in unit quantities that obviate measuring steps when performing the subject methods.
  • the invention contemplates a kit comprising a combination of a mutant archael DNA polymerase of the invention, dUTP and uracil N-glycosylase.
  • Mutations were introduced into Pfu DNA polymerase that were likely to reduce uracil detection, while having minimal effects on polymerase or proofreading activity.
  • the DNA template used for mutagenesis contained the Pfu pol gene, cloned into pBluescript (pF72 clone described in US 5,489,523). Point mutations were introduced using the QuikChange or the
  • QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene). With the QuikChange kit, point mutations are introduced using a pair of mutagenic primers (V93E, H, K, R, and N). With the QuikChange Multi kit, specific point mutations are introduced by inco ⁇ orating one phosphorylated mutagenic primer or by selecting random mutants from a library of Pfu V93 variants, created by inco ⁇ orating a degenerate codon (N93G and L). Clones were sequenced to identify the inco ⁇ orated mutations.
  • Plasmid D ⁇ A was purified with the StrataPrep® Plasmid Miniprep Kit (Stratagene), and used to transform BL26-CodonPlus-RIL cells. Ampicillin resistant colonies were grown up in 1- 5 liters of LB media containing Turbo AmpTM (lOO ⁇ g/ ⁇ l) and chloramphenicol (30 ⁇ g/ ⁇ l) at 30°C with moderate aeration. The cells were collected by centrifugation and stored at -80°C until use.
  • lysis buffer buffer A: 50mM Tris HCl (pH 8.2), ImM EDTA, and lOmM ⁇ ME). Lysozyme (1 mg/g cells) and PMSF (ImM) were added and the cells were lysed for 1 hour at 4°C. The cell mixture was sonicated, and the debris removed by centrifugation at 15,000 rpm for 30 minutes (4°C). Tween 20 and Igepal CA-630 were added to final concentrations of 0.1 % and the supernatant was heated at 72°C for 10 minutes. Heat denatured E. coli proteins were then removed by centrifugation at 15,000 ⁇ m for 30 minutes (4°C).
  • Partially-purified Pfu mutant preparations were assayed for dUTP inco ⁇ oration during PCR.
  • a 2.3kb fragment containing the Pfu pol gene was from plasmid D ⁇ A using PCR primers: ( ⁇ PfuL ⁇ C) 5'- gACgACgACAAgATgATTTTAgATgTggAT-3' (SEQ ID NO: n and (RPfuL ⁇ C) 5'- ggAACAAgACCCgTCTAggATTTTTTAATg-3' (SEQ ID NO: 2).
  • Amplification reactions consisted of lx cloned Pfu PCR buffer, 7 ng plasmid DNA, lOOng of each primer, 2.5U of Pfu mutant (or wild type Pfu), and 200 ⁇ M each dGTP, dCTP, and dATP.
  • various amounts of dUTP (0-400 ⁇ M) and/or TTP (0-200 ⁇ M) were added to the
  • PCR reaction cocktail The amplification reactions were cycled as described in example 6.
  • Pfu mutants Bacterial expression of Pfu mutants.
  • Pfu mutants can be purified as described in US
  • Fractions containing Pfu D ⁇ A polymerase mutants were dialyzed overnight against buffer D (50mM Tris HCl (pH 7.5), 5mM ⁇ ME, 5% (v/v) glycerol, 0.2% (v/v) Igepal CA-630, 0.2% (v/v) Tween 20, and 0.5M ⁇ aCl) and then applied to a Hydroxyapatite column ( ⁇ 5ml), equilibrated in buffer D.
  • buffer D 50mM Tris HCl (pH 7.5), 5mM ⁇ ME, 5% (v/v) glycerol, 0.2% (v/v) Igepal CA-630, 0.2% (v/v) Tween 20, and 0.5M ⁇ aCl
  • the column was washed and Pfu D ⁇ A polymerase mutants were eluted with buffer D2 containing 400 mM KPO 4 , (pH 7.5), 5mM ⁇ ME, 5% (v/v) glycerol, 0.2% (v/v) Igepal CA-630, 0.2% (v/v) Tween 20, and 0.5 M ⁇ aCl.
  • Purified proteins were spin concentrated using Centricon YM30 devices, and exchanged into Pfu final dialysis buffer (50mM Tris-HCl (pH 8.2), O.lmM EDTA, ImM dithiothreitol (DTT), 50% (v/v) glycerol, 0.1% (v/v) Igepal CA- 630, and 0.1% (v/v) Tween 20).
  • Protein samples were evaluated for size, purity, and approximate concentration by SDS- PAGE using Tris-Glycine 4-20% acrylamide gradient gels. Gels were stained with silver stain or Sypro Orange (Molecular Probes). Protein concentration was determined relative to a BSA standard (Pierce) using the BCA assay (Pierce).
  • the unit concentration of purified Pfu mutant preparations was determined by PCR.
  • a 500bp lacZ target is amplified from transgenic mouse genomic DNA using the forward primer: 5'-GACAGTCACTCCGGCCCG-3' (SEQ ID NO: 15 and the reverse primer: 5'-CGACGACTCGTGGAGCCC-3' (SEQ ID NO: 16).
  • Amplification reactions consisted of lx cloned Pfu PCR buffer, lOOng genomic DNA, 150ng each primer, 200 ⁇ M each dNTP, and varying amounts of either wild type Pfu (1.25U to 5U) or Pfu mutant (0.625-12.5U).
  • Amplification was performed using a RoboCycler® temperature cycler (Stratagene) with the following program: (1 cycle) 95°C for 2 minute; (30 cycles) 95°C for 1 minute, 58°C for 1 minute, 72°C for 1.5 minutes; (1 cycle) 72°C for 7 minutes. PCR products were examined on 1%> agarose gels containing ethidium bromide.
  • Figure 3 contains a table listing the protein concentration, unit concentration, and specific activity of the purified Pfu V93R and V93E mutants.
  • PCR reactions are conducted under standard conditions in cloned Pfu PCR buffer (lOmM KCI, lOmM (NH 4 ) 2 SO 4 , 20mM Tris HCl (pH 8.8), 2mM Mg SO 4 , 0.1% Triton X-100, and lOO ⁇ g/ml BSA) with various amounts of cloned Pfu, PfuTurbo, or mutant Pfu DNA polymerase.
  • genomic targets 0.3-9kb in length PCR reactions contained lOOng of human genomic DNA, 200 ⁇ M each dNTP, and lOOng of each primer.
  • genomic targets >9kb in length PCR reactions contained 250ng of human genomic DNA, 500 ⁇ M each dNTP, and 200ng of each primer.
  • Figure 8 shows the results of additional Pfu mutations on dUTP incorporation.
  • Pfu V93K and V93R mutants show significantly improved dUTP inco ⁇ oration compared to wild type Pfu.
  • the Pfu V93W, V93 V93W, V93Y and V93M mutants showed little to no improvement in dUTP inco ⁇ oration (see Figure 8A).
  • both V93D and V93R mutants showed significantly improved dUTP inco ⁇ oration, compared to wild type ( Figure 8B), while the V93N mutation showed a very small improvement in dTUP inco ⁇ oration ( Figure 8C).
  • the Pfu V93G mutation showed little to no improvement in dUTP inco ⁇ oration.
  • Valine 93 was substituted with Glutamine (Q), asparagine (N), arginine [R], lysine (K), glutamic acid (E), and aspartic acid (D).
  • Pfu mutants were constructed: deletions of residues 93, 92, 94, 92-93, 93- 94, and 92-94, and insertions of one, two, or three glycines between residues 92 and 93.
  • Plasmid DNA was purified with the StrataPrep® Plasmid Miniprep Kit (Stratagene), and used to transform BL26-CodonPlus-RIL cells. Ampicillin resistant colonies were grown up in 1- 5 liters of LB media containing Turbo AmpTM (lOO ⁇ g/ ⁇ l) and chloramphenicol (30 ⁇ g/ ⁇ l) at
  • the cells were collected by centrifugation and stored at -80°C until use.
  • lysis buffer buffer A: 50mM Tris HCl (pH 8.2), ImM EDTA, and lOmM ⁇ ME). Lysozyme (1 mg/g cells) and PMSF (ImM) were added and the cells were lysed for 1 hour at 4°C. The cell mixture was sonicated, and the debris removed by centrifugation at 15,000 ipm for 30 minutes (4°C). Tween 20 and Igepal CA-630 were added to final concentrations of 0.1% and the supernatant was heated at 72°C for 10 minutes. Heat denatured E. coli proteins were then removed by centrifugation at 15,000 ⁇ ra for 30 minutes (4°C).
  • fragments of 0.6kb, 0.97kb, 2.6kb, or 6kb were amplified from genomic or lambda DNA in the presence of 100% dUTP.
  • PCRs employing ⁇ 6kb targets consisted of lx PCR buffer (Stratagene's cloned Pfu buffer for Pfu mutants; Stratagene's 7 ⁇ g2000 buffer for JDF-3 mutants; Roche's Tgo buffer for Tgo mutants; Novagen's KOD Hi Fi buffer for KOD mutants), 50ng lambda DNA or lOOng genomic DNA, lOOng of each primer, 2 ⁇ l of mutant extract (or 2.5U of purified DNA polymerase), and 200 ⁇ M each dGTP, dCTP, dATP and either 200 ⁇ M dUTP or 200 ⁇ M TTP.
  • PCRs employing the 6kb genomic target consisted of 1.5x PCR buffer, 240ng genomic DNA, 200ng of each primer, 2 ⁇ l of mutant extract (or 2.5U of purified DNA polymerase), and 500 ⁇ M each dGTP, dCTP, dATP and either 500 ⁇ M dUTP or 500 ⁇ M TTP.
  • the amplification reactions were cycled using a RoboCycler (0.6kb, 0.97kb) or PE9600 (2.6kb, 6kb) thermocycler as described in the Table above.
  • DNA polymerase mutant preparations were also assayed for dU-primer utilization during PCR. Amplification was performed in the absence (100% TTP) or presence (0% TTP) of dUTP to determine the relative degree of uracil insensitivity. In this example, a 970bp fragment was amplified from lambda DNA using dU-containing primers (FU/RU) or T-containing primers (FT/RT). Amplification reactions consisted of lx PCR buffer, 50ng lambda DNA, lOOng of each primer, 2 ⁇ l of mutant extract (or 2.5U of purified DNA polymerase), and 200 ⁇ M each dGTP,
  • KOD Partially-purified preparations of KOD V93D, E, K, Q, and R showed reduced uracil sensitivity as evidenced by successful amplification of the 970bp amplicon using dU- containing primers and TTP ( Figure 11).
  • wild type KOD and the KOD V93N mutant were unable to amplify using dU-primers and TTP.
  • Only the KOD V93K and V93R mutants showed complete or nearly complete elimination of uracil sensitivity as shown by successful amplification in the presence of 100% dUTP ( Figure 11).
  • the KOD V93D, E, and Q substitutions only partially reduce uracil sensitivity since these mutants are unable to amplify in the presence of 100% dUTP.
  • Tgo Only the Tgo V93R mutant successfully amplified the 0.97kb amplicon in the presence of 100%) dUTP ( Figure 12), indicating that the arginine substitution was most effective in reducing uracil sensitivity.
  • JDF-3 Only the JDF-3 V93R and V93K mutants successfully amplified the 0.97kb amplicon in the presence of 100% dUTP ( Figure 12), indicating that the arginine and lysine substitutions were the most effective in reducing uracil sensitivity.
  • Product yields with 100% dUTP were noticeably lower than yields with 100% TTP suggesting that in JDF-3, the V93R mutation does not completely eliminate uracil sensitivity ( Figure 13).
  • Pfu V93R, Tgo V93R, and KOD V93R produce similar yields with TTP and dUTP, indicating that uracil sensitivity is almost completely eliminated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to the generation and characterization of archaeal DNA polymerase mutants with reduced base analog detection activity. The invention further provides for archaeal DNA polymerase mutants with reduced base analog detection activity containing additional mutations that modulate other DNA polymerase activities including DNA polymerization or 3'-5' exonuclease activity. The invention also discloses methods and applications of DNA polymerases with reduced base analog detection activity.

Description

DNA POLYMERASES WITH REDUCED BASE ANALOG DETECTION
ACTIVITY
FIELD OF THE INVENTION
The invention relates to mutant archaeal DNA polymerases with reduced base analog detection activity.
BACKGROUND
Unlike Taq, archaeal DNA polymerases (e.g., Pfu, Vent) possess a "read-ahead" function that detects uracil (dU) residues in the template strand and stalls synthesis (Greagg et al., 1999, PNAS USA, 96:9405). Uracil detection is thought to represent the first step in a pathway to repair DNA cytosine deamination (dCMP-»dUMP) in archaea (Greagg et al, 1999, Supra). Stalling of DNA synthesis opposite uracil has significant implications for high-fidelity PCR amplification with archaeal DNA polymerases. Techniques requiring dUTP (e.g., dUTP/UDG decontamination methods, Longo et al. 1990, Gene, 93:125) or uracil-containing ohgonucleotides can not be performed with proofreading DNA polymerases (Slupphaug et al. 1993, Anal. Biochem., 211:164; Sakaguchi et al. 1996, Biotechniques, 21:368). But more importantly, uracil stalling has been shown to compromise the performance of archaeal DNA polymerases under standard PCR conditions (Hogrefe et al. 2002, PNAS USA, 99:596).
During PCR amplification, a small amount of dCTP undergoes deamination to dUTP (%dUTP varies with cycling time), and is subsequently incorporated by archaeal DNA polymerases. Once incorporated, uracil-containing DNA inhibits archaeal DNA polymerases, limiting their efficiency. We found that adding a thermostable dUTPase (dUTP -» dUMP + PP;) to amplification reactions carried out with Pfu, KOD, Vent, and Deep Vent DNA polymerases significantly increases PCR product yields by preventing dUTP incorporation (Hogrefe et al. 2002, Supra). Moreover, the target-length capability of Pfu DNA polymerase is dramatically improved in the presence of dUTPase (from <2kb to 14kb), indicating that uracil poisoning severely limits long-range PCR due to the use of prolonged extension times (1-2 min per kb @ 72°C) that promote dUTP formation.
In addition to dUTP incorporation, uracil may also arise as a result of cytosine deamination in template DNA. The extent to which cytosine deamination occurs during temperature cycling has not been determined; however, any uracil generated would presumably impair the PCR performance of archaeal DNA polymerases. Uracil arising from cytosine deamination in template DNA is unaffected by adding dUTPase, which only prevents incorporation of dUTP (created by dCTP deamination). Adding enzymes such as uracil DNA glycosylase (UGD), which excise uracil from the sugar backbone of DNA, or mismatch-specific UDGs (MUG), which additionally excise G:T mismatches, is one way to eliminate template uracil that impedes polymerization.
Alternatively, the problem of uracil stalling may be overcome by introducing mutations or deletions in archaeal DNA polymerases that reduce, or ideally, eliminate uracil detection, and therefore, allow synthesis to continue opposite incorporated uracil (non-mutagenic uracil) and deaminated cytosine (pro-mutagenic uracil). Such mutants would be expected to produce higher product yields and amplify longer targets compared to wild type archaeal DNA polymerases. Moreover, mutants that lack uracil detection should be compatible with dUTP/UNG decontamination methods employed in real-time Q-PCR. At present, only Tag and Taq-related enzymes, can be used in clean-up methods based on dUTP incorporation.
There is therefore a need for thermostable DNA polymerases that can amplify DNA in the presence of dUTP without compromising proofreading or polymerization activity and efficiency.
Pavlov et al., 2002, Proc. Natl. Acad. Sci. USA, 99:13510-13515 and WO 01/92501 Al describe polymerase chimeras comprising a domain that increases processivity and or increases salt resistance.
There is also a need in the art for thermostable DNA polymerases that can amplify DNA in the presence of dUTP without compromising proofreading or polymerization activity and efficiency, and wherein the thermostable DNA polymerase exhibits increased processivity and/or increased salt resistance.
SUMMARY OF THE INVENTION
The invention relates to the construction and characterization of archaeal Family B-type DNA polymerases mutants with reduced base analog detection activity that retain the essential PCR attributes of proofreading DNA polymerases (e.g., polymerase activity, 3'-5' exonuclease activity, fidelity) and also improve the success rate of long-range amplification, e.g., higher yield, longer targets amplified.
The invention relates to mutant archaeal DNA polymerases, and in particular mutant Pfu DNA polymerases, with a reduced base analog detection activity, and comprising a mutation at position V93, that is a Valine substituted to Arginine, Glutamic acid, Lysine, Aspartic acid, or Asparagine, or wherein the mutant archaeal DNA polymerase comprises a truncation, deletion or insertion, as defined herein.
Preferably, the mutant archaeal DNA polymerase comprises a Pfu DNA polymerase comprising a mutation at position V93 wherein Valine is substituted to Arginine, Lysine, Aspartic Acid, or Glutamic Acid. More preferably, the Valine at position 93 is substituted with Lysine.
In one embodiment the archaeal DNA polymerase is a Pfu DNA polymerase comprising a deletion at one or more of D92, V93, and P94.
In a further embodiment, the invention provides a mutant archaeal DNA polymerase of one or more of SEQ ID NOS: 28-32 (encoded by SEQ ID Nos: 18-22) having an amino acid mutation at one or more residues between residues 87 and 100, wherein a candidate amino acid may be substituted for an amino acid residue within this region. Preferably, an amino acid within the region of residues 87 to 100 is substituted with one of Arginine, Glutamic acid, Lysine, Aspartic acid, Glutamine, or Asparagine. Preferably the mutation is at position N93.
In a further embodiment, the invention provides a mutant archaeal DΝA polymerase of one or more of SEQ ID ΝOS: 27, or 33-36 (encoded by SEQ ID os: 17, 23-26) having an amino acid mutation at one or more residues between residues 87 and 100, wherein a candidate amino acid may be substituted for an amino acid residue within this region. Preferably, an amino acid within the region of residues 87 to 100 is substituted with one of Arginine, Glutamic acid, Lysine, Aspartic acid, or Asparagine. Preferably the mutation is at position N93.
The invention also provides for mutant archael DΝA polymerases, including mutant Pfu DΝA polymerases that further comprise a Glycine to Proline substitution at amino acid position 387 (G387P; SEQ ID NO: 33; encoded by SEQ ID NO: 23) that confers a reduced DNA polymerization phenotype to said mutant DNA polymerases or that further comprise an N93D/D141A/E143A or Pfu N93Ν/D141 A/E143A triple mutant DNA polymerase, Taq in combination with a Pfu G387P/N93R or G387P/ N93 E or G387P/ N93 K or G387P/ N93 D or G387P/ N93Ν double mutant, a Thermus DNA ligase or a FEN-1 nuclease, either alone or in combination with a PCR enhancing factor and/or an additive. The invention also provides for compositions comprising any of the single, double or triple mutant archael DNA polymerases described herein, any mutant archael DNA polymerases comprising an insertion, described herein, or any of the truncated, or deleted mutant archael DNA polymerases described herein, in combination with a polypeptide that increases processivity and or salt resistance, thereby forming a chimera, as defined herein. These chimeras can be provided in combination with a PCR enhancing factor and/or an additive.
The invention also provides for kits comprising a mutant archaeal DNA polymerase, having a reduced base analog detection activity, wherein the mutant archaeal DNA polymerase comprises a mutation at position N93 that is a Naline substituted to Arginine, Glutamic acid, Lysine, Aspartic acid, Glutamine, or Asparagine wherein the mutant archaeal DΝA polymerase comprises a truncation, deletion or insertion as defined herein, and packaging materials therefore, h one embodiment, the kit comprises a Pfu DΝA polymerase having a mutation at position N93 that is a Naline substituted to Arginine, Glutamic acid, Lysine, Aspartic acid, or Asparagine. In one embodiment, the kit comprises a Pfu DΝA polymerase comprising a deletion at one or more of D92, N93, or P94. The kits of the invention may further comprise a PCR enhancing factor and/or an additive, Taq DΝA polymerase, for example wherein said Taq DΝA polymerase is at a 5 fold, 10 fold or 100 fold lower concentration than said mutant Pfu DΝA polymerase, either alone or in combination with a PCR enhancing factor and/or an additive, or a Pfu G387P/N93R or G387P/ N93 E or G387P/ N93 K or G387P/ N93 D or G387P/ N93Ν double mutant DNA polymerase, a Pfu N93R/D141A/E143A, Pfu N93E/D141 A/E143A, Pfu N93K7D141 A/E143A, Pfu N93D/D141A/E143A or Pfu N93Ν/D141 A/E143A triple mutant DNA polymerase, a Thermus DNA ligase or a FEN-1 nuclease, either alone or in combination with a PCR enhancing factor and/or an additive. The invention also provides for kits comprising any of the single, double or triple mutant archael DNA polymerases described herein, any mutant archael DNA polymerases comprising an insertion, described herein, or any of the truncated, or deleted mutant archael DNA polymerases described herein, in combination with a polypeptide that increases processivity and or salt resistance, thereby forming a chimera, as defined herein.
These chimeras can be provided in combination with a PCR enhancing factor and/or an additive.
5 The compositions of the invention can further comprise a chimera comprising a wild-type polymerase in combination with a polypeptide that increases processivity and/or salt resistance.
The invention also provides for a method for DNA synthesis comprising providing a mutant archaeal DNA polymerase of the invention; and contacting the enzyme with a nucleic acid template, wherein the enzyme permits DNA synthesis.
In one embodiment, DNA synthesis is performed in the presence of dUTP, for example as described in Example 3.
The invention also provides for a method for cloning of a DNA synthesis product comprising providing a mutant archaeal DNA polymerase of the invention, contacting the mutant archaeal DNA polymerase with a nucleic acid template, wherein the mutant archaeal DNA polymerase permits DNA synthesis to generate a synthesized DNA product; and inserting the synthesized DNA product into a cloning vector.
Any of the methods of amplification or cloning of the invention can further comprise a Thermus DNA ligase or a FEN-1 nuclease.
The invention also provides for a method for sequencing DNA comprising the step of providing a mutant archaeal DNA polymerase of the invention, generating chain terminated fragments from the DNA template to be sequenced with the mutant archaeal DNA polymerase in the presence of at least one chain terminating agent and one or more nucleotide triphosphates, and determining the sequence of the DNA from the sizes of said fragments. This method can be performed in the presence of Taq DNA polymerase, for example, wherein the Taq DNA polymerase is at a 5 fold, 10 fold or 100 fold lower concentration than said mutant Pfu DNA polymerase. Preferably sequencing is performed using an polymerase that is deficient in 3' to 5' exonuclease activity, for example D141A/E143A.
This method can also be carried out in the presence of a double or triple mutant DNA polymerase, as described herein, either alone or in combination with PCR enhancing factor and/or an additive.
The invention also provides a method of linear or exponential PCR amplification for site- directed or random mutagenesis comprising the steps of: incubating a reaction mixture comprising a nucleic acid template, a PCR primer, and a mutant archaeal DNA polymerase under conditions which permit amplification of the nucleic acid template by the archaeal DNA polymerase mutant to produce a mutated amplified product.
In one embodiment, the mutant archaeal DNA polymerase comprises a mutation at N93 wherein Naline is substituted for one of Arginine, Glutamic acid, Lysine, Aspartic acid, Glutamine, or Asparagine.
DEFINITIONS
As used herein, "reduced base analog detection" refers to a DNA polymerase with a reduced ability to recognize a base analog, for example, uracil or inosine, present in a DNA template. In this context, mutant DNA polymerase with "reduced" base analog detection activity is a DNA polymerase mutant having a base analog detection activity which is lower than that of the wild-type enzyme, i.e., having less than 10% (e.g., less than 8%, 6%, 4%, 2% or less than 1%) of the base analog detection activity of that of the wild-type enzyme, base analog detection activity may be determined according to the assays similar to those described for the detection of DNA polymerases having a reduced uracil detection as described in Greagg et al. (1999) Proc. Natl. Acad. Sci. 96, 9045-9050 and Example 3. Alternatively, "reduced" base analog detection refers to a mutant DNA polymerase with a reduced ability to recognize a base analog, the "reduced" recognition of a base analog being evident by an increase in the amount of >10Kb PCR of at least 10%, preferably 50%, more preferably 90%, most preferably 99% or more, as compared to a wild type DNA polymerase without a reduced base analog detection activity. The amount of a > 10Kb PCR product is measured either by spectorophotometer-absorbance assays of gel eluted > 10Kb PCR DNA product or by fluorometric analysis of > 10Kb PCR products in an ethidium bromide stained agarose electrophoresis gel using, for example, a Molecular Dynamics (MD) Fluorlmager™ (Amersham Biosciences, catalogue #63-0007- 79).
As used herein, "reduced uracil detection" refers to a DNA polymerase with a reduced ability to recognize a uracil base present in a DNA template. In this context, mutant DNA polymerase with "reduced" uracil detection activity is a DNA polymerase mutant having a uracil detection activity which is lower than that of the wild-type enzyme, i.e., having less than 10% (e.g., less than 8%, 6%, 4%, 2% or less than 1%) of the uracil detection activity of that of the wild-type enzyme. Uracil detection activity may be determined according to the assays described
7 in Greagg et al. (1999) Proc. Natl. Acad. Sci. 96, 9045-9050 and Example 3. Alternatively, "reduced" uracil detection refers to a mutant DNA polymerase with a reduced ability to recognize uracil, the "reduced" recognition of uracil being evident by an increase in the amount of >10Kb PCR of at least 10%, preferably 50%, more preferably 90%, most preferably 99% or more, as compared to a wild type DNA polymerase without a reduced uracil detection activity. The amount of a > 10Kb PCR product is measured either by spectorophotometer-absorbance assays of gel eluted > 10Kb PCR DNA product or by fluorometric analysis of > 10Kb PCR products in an ethidium bromide stained agarose electrophoresis gel using, for example, a Molecular Dynamics (MD) Fluorlmager™ (Amersham Biosciences, catalogue #63-0007- 79).
The invention contemplates mutant DNA polymerase that exhibits reduced base analog detection (for example, reduced detection of a particular base analog such as uracil or inosine or reduced detection of at least two base analogs).
As used herein, "base analogs" refer to bases that have undergone a chemical modification as a result of the elevated temperatures required for PCR reactions. In a preferred embodiment, "base analog" refers to uracil that is generated by deamination of cytosine. In another preferred embodiment, "base analog" refers to inosine that is generated by deamination of adenine.
As used herein, "synthesis" refers to any in vitro method for making new strand of polynucleotide or elongating existing polynucleotide (i.e., DNA or RNA) in a template dependent manner. Synthesis, according to the invention, includes amplification, which increases the number of copies of a polynucleotide template sequence with the use of a polymerase. Polynucleotide synthesis (e.g., amplification) results in the incorporation of nucleotides into a polynucleotide (i.e., a primer), thereby forming a new polynucleotide molecule complementary to the polynucleotide template. The formed polynucleotide molecule and its template can be used as templates to synthesize additional polynucleotide molecules.
"DNA synthesis", according to the invention, includes, but is not limited to, PCR, the labelling of polynucleotide (i.e., for probes and oligonucleotide primers), polynucleotide sequencing. As used herein, "polymerase" refers to an enzyme that catalyzes the polymerization of nucleotide (i.e., the polymerase activity). Generally, the enzyme will initiate synthesis at the 31- end of the primer annealed to a polynucleotide template sequence, and will proceed toward the 5' end of the template strand. "DNA polymerase" catalyzes the polymerization of deoxynucleotides. In a preferred embodiment, the "DNA polymerase" of the invention is an archaeal DNA polymerase. A "DNA polymerase" useful according to the invention includes, but is not limited to those included in the section of the present specification entitled "Polymerases".
In a preferred embodiment of the invention, the DNA polymerase is a polymerase having the amino acid sequence shown in one of SEQ ID Nos. 27-38.
In a preferred embodiment of the invention, the DNA polymerase is a polymerase having an amino acid sequence encoded by the nucleotide sequence shown in one of SEQ ID Nos 17-26.
In a preferred embodiment, the DNA polymerase according to the invention is thermostable. In another preferred embodiment, the DNA polymerase according to the invention is Pfu DNA polymerase.
As used herein, "archaeal" DNA polymerase refers to DNA polymerases that belong to either the Family B/pol I-type group (e.g., Pfu, KOD, Pfx, Vent, Deep Nent, Tgo, Pwo) or the pol II group (e.g., Pyrococcus furiosus DP1/DP22-subunit DΝA polymerase). In one embodiment, "archaeal" DΝA polymerase refers to thermostable archaeal DΝA polymerases (PCR-able) and include, but are not limited to, DΝA polymerases isolated from Pyrococcus species (furiosus, species GB-D, woesii, abysii, horikoshii), Thermococcus species
(kodakaraensis KOD1, litoralis, species 9 degrees Νorth-7, species JDF-3, gorgonarius), Pyrodictium occultum, and Archaeoglobus fulgidus. It is estimated that suitable archaea would exhibit maximal growth temperatures of >80-85°C or optimal growth temperatures of >70-80°C. Appropriate PCR enzymes from the archaeal pol I DNA polymerase group are commercially available, including Pfu (Stratagene), KOD (Toyobo), Pfx (Life Technologies, Inc.), Nent (New England BioLabs), Deep Vent (New England BioLabs), Tgo (Roche), and Pwo (Roche). Additional archaea related to those listed above are described in the following references: Archaea: A Laboratory Manual (Robb, F.T. and Place, A.R., eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1995 As used herein, "mutant" polymerase refers to an archaeal DNA polymerase, as defined herein, comprising one or more mutations that alter one or more activities of the DNA polymerase, for example, DNA polymerization, 3 '-5' exonuclease activity or base analog detection activities. In one embodiment, the "mutant" polymerase of the invention refers to a DNA polymerase containing one or more mutations that reduce one or more base analog detection activities of the DNA polymerase. h a preferred embodiment, the "mutant" polymerase of the invention has a reduced uracil detection activity. In a preferred embodiment, the "mutant" polymerase of the invention has a reduced inosine detection activity. In another preferred embodiment, the "mutant" polymerase of the invention has a reduced uracil and inosine detection activity. A "mutant" polymerase as defined herein, includes a polymerase comprising one or more amino acid substitutions, one or more amino acid insertions, a truncation or an internal deletion.
A "mutant" polymerase as defined herein also includes a chimeric polymerase wherein any of the single, double or triple mutant archael DNA polymerases described herein, any mutant archael DNA polymerases comprising an insertion, described herein, or any of the truncated, or deleted mutant archael DNA polymerases described herein, occur in combination with a polypeptide that increases processivity and or salt resistance, thereby forming a chimera, as defined herein. A polypeptide that increases processivity and or salt resistance is described in WO 01/92501 Al and Pavlov et al., 2002, Proc. Natl. Acad. Sci. USA, 99:13510-13515, herein incorporated by reference in their entirety.
In one embodiment a "mutant" polymerase as defined herein has a sequence selected from one of SEQ ID Nos: 28-32, wherein Valine at position 93 is replaced by one of Arginine, Glutamic acid, Lysine, Aspartic acid, Glutamine, or Asparagine.
In one embodiment a "mutant" polymerase as defined herein has a sequence selected from one of SEQ ID Nos: 27, 33-36, wherein Valine at position 93 is replaced by one of Arginine, Glutamic acid, Lysine, Aspartic acid, or Asparagine.
In one embodiment of the invention, a "mutant" polymerase as defined herein has an amino acid sequence encoded by SEQ ID Nos: 18-22, wherein the codon encoding the Valine residue at position 93 is replaced by a codon encoding an amino acid selected from Arginine, Glutamic acid, Lysine, Aspartic acid, Glutamine, or Asparagine.
10 In one embodiment of the invention, a "mutant" polymerase as defined herein has an amino acid sequence encoded by SEQ ID Nos: 17, 23-26, wherein the codon encoding the Valine residue at position 93 is replaced by a codon encoding an amino acid selected from Arginine, Glutamic acid, Lysine, Aspartic acid, or Asparagine.
In one embodiment of the invention, a "mutant" DNA polymerase is a Pfu polymerase wherein V93 is substituted with one of Arginine, Glutamic acid, Lysine, Asparagine, or Aspartic Acid. Preferably, a "mutant" DNA polymerase is a Pfu polymerase wherein V93 is substituted with one of Arginine, Glutamic acid.
In one embodiment of the invention, a "mutant" DNA polymerase is a KOD DNA polymerase wherein V93 is substituted with one of Arginine, Glutamic acid, Aspartic Acid, Lysine, or Glutamine.
In one embodiment of the invention, a "mutant" DNA polymerase is a Vent polymerase wherein V93 is substituted with one of Arginine, Glutamic acid, Lysine, Asparagine, Aspartic acid, or Glutamine. Preferably, a "mutant" DNA polymerase is a Vent polymerase wherein V93 is substituted with one of Arginine or Glutamic acid.
In one embodiment of the invention, a "mutant" DNA polymerase is a Deep Vent polymerase wherein V93 is substituted with one of Arginine, Glutamic acid, Lysine, Asparagine, Aspartic acid, or Glutamine. Preferably, a "mutant" DNA polymerase is a Deep Vent polymerase wherein V93 is substituted with one of Arginine or Glutamic acid.
In one embodiment of the invention, a "mutant" DNA polymerase is a JDF-3 polymerase wherein V93 is substituted with one of Arginine, Glutamic acid, Lysine, Asparagine, Aspartic acid, or Glutamine. Preferably, a "mutant" DNA polymerase is a JDF-3 polymerase, wherein V93 is substituted with one of Arginine, Glutamic acid, or Lysine.
In one embodiment of the invention, a "mutant" DNA polymerase is a Tgo polymerase wherein V93 is substituted with one of Arginine, Glutamic acid, Lysine, Asparagine, Glutamine, or Aspartic acid.
A "chimera" as defined herein, is a fusion of a first amino acid sequence (protein) comprising a wild type or mutant archael DNA polymerase of the invention, joined to a second
11 amino acid sequence defining a polypeptide that increases processivity and or increases salt resistance, wherein the first and second amino acids are not found in the same relationship in nature. A "chimera" according to the invention contains two or more amino acid sequences (for example a sequence encoding a wild type or mutant archael DNA polymerase and a polypeptide that increases processivity and/or salt resistance) from unrelated proteins, joined to form a new functional protein . A chimera of the invention may present a foreign polypeptide which is found (albeit in a different protein) in an organism which also expresses the first protein, or it may be an "interspecies", "intergenic", etc. fusion of protein structures expressed by different kinds of organisms. The invention encompasses chimeras wherein the polypeptide that increases processivity and/or salt resistance is joined N-terminally or C-terminally to a wild-type archael DNA polymerase or to any of the mutant archael DNA polymerases described herein.
As used herein, "polypeptide that increases processivity and/or salt resistance" refers to a domain that is a protein or a region of a protein or a protein complex, comprising a polypeptide sequence, or a plurality of peptide sequences wherein that region increases processivity, as defined herein, or increases salt resistance, as defined herein. A "polypeptide that increases processivity and or salt resistance useful according to the invention includes but is not limited to any of the domains included in Pavlov et al., supra or WO 01/92501, for example Sso7d, Sac7d, HMF-like proteins, PCNA homologs, and helix-hairpin-helix domains, for example derived from Topoisomerase V.
As used herein, "joined" refers to any method known in the art for functionally connecting polypeptide domains, including without limitation recombinant fusion with or without intervening domains, intein-mediated fusion, non-covalent association, and covalent bonding, including disulfide bonding, hydrogen bonding, electrostatic bonding, and conformational bonding.
As used herein, "processivity" refers to the ability of a nucleic acid modifying enzyme, for example a polymerase, to remain attached to the template or substrate and perform multiple modification reactions. "Modification reactions" include but are not limited to polymerization, and exonucleolytic cleavage. "Processivity" also refers to the ability of a nucleic acid modifying enzyme, for example a polymerase, to modify relatively long (for example 0.5-lkb, l-5kb or 5kb or more) tracts of nucleotides. "Processivity" also refers to the ability of a nucleic acid modifying enzyme, for example a DNA polymerase, to perform a sequence of polymerization
12 steps without intervening dissociation of the enzyme from the growing DNA chains. "Processivity" can depend on the nature of the polymerase, the sequence of a DNA template, and reaction conditions, for example, salt concentration, temperature or the presence of specific proteins.
As used herein, "increased processivity" refers to an increase of 5-10%, preferably 10-
50%, more preferably 50-100% or more, as compared to a wild type or mutant archael DNA polymerase that lacks a polypeptide that increases processivity and/or salt resistance as defined herein. Processivity and increased processivity can be measured according the methods defined herein and in Pavlov et al., supra and WO 01/92501 Al. A polymerase with increased processivity that is a chimera comprising a polypeptide that increases processivity, as defined herein, is described in Pavlov et al. supra and WO 01/92501 Al.
As used herein, "increased salt resistance" refers to a polymerase that exhibits >50% activity at a salt concentration that is know to be greater than the maximum salt concentration at which the wild-type polymerase is active. The maximum salt concentration differs for each polymerase and is known in the art, or can be experimentally determined according to methods in the art. For example, Pfu is inhibited at 30mM (in PCR) so a Pfu enzyme with increased salt resistance would have significant activity (>50%) at salt concentrations above 30mM. A polymerase with increased salt resistance that is a chimera comprising a polypeptide that increases salt resistance, as defined herein, is described in Pavlov et al. supra and WO 01/92501 Al.
As used herein, a DNA polymerase with a "reduced DNA polymerization activity" is a DNA polymerase mutant comprising a DNA polymerization activity which is lower than that of the wild-type enzyme, e.g., comprising less than 10% DNA (e.g., less than 8%, 6%, 4%, 2% or less than 1%) polymerization activity of that of the wild-type enzyme. Methods used to generate characterize Pfu DNA polymerases with reduced DNA polymerization activity are disclosed in the pending U.S. patent application Serial No.: 10/035,091 (Hogrefe, et al.; filed: December 21, 2001); the pending U.S. patent application Serial No.: 10/079,241 (Hogrefe, et al.; filed February 20, 2002); the pending U.S. patent application Serial No.: 10/208,508 (Hogrefe et al.; filed July 30, 2002); and the pending U.S. patent application Serial No.: 10/227,110 (Hogrefe et al.; filed August 23, 2002), the contents of which are hereby incorporated in their entirety.
13 As used herein, "3' to 5' exonuclease deficient" or "3' to 5' exo-" refers to an enzyme that substantially lacks the ability to remove incorporated nucleotides from the 3' end of a DNA polymer. DNA polymerase exonuclease activities, such as the 3' to 5' exonuclease activity exemplified by members of the Family B polymerases, can be lost through mutation, yielding an exonuclease-deficient polymerase. As used herein, a DNA polymerase that is deficient in 3 ' to 5' exonuclease activity substantially lacks 3' to 5' exonuclease activity. "Substantially lacks" encompasses a complete lack of activity, for example, 0.03%, 0.05%, 0.1%, 1%, 5%, 10%, 20% or even up to 50%o of the exonuclease activity relative to the parental enzyme. Methods used to generate and characterize 3'-5' exonuclease DNA polymerases including the D141 A and E143A mutations as well as other mutations that reduce or eliminate 3 '-5 ' exonuclease activity are disclosed in the pending U.S. patent application Serial No.: 09/698,341 (Sorge et al; filed October 27, 2000). Additional mutations that reduce or eliminate 3' to 5' exonuclease activity are known in the art and contemplated herein.
As used herein, "mutation" refers to a change introduced into a parental or wild type DNA sequence that changes the amino acid sequence encoded by the DNA, including, but not limited to, substitutions, insertions, deletions or truncations. The consequences of a mutation include, but are not limited to, the creation of a new character, property, function, or trait not found in the protein encoded by the parental DNA, including, but not limited to, N terminal truncation, C terminal truncation or chemical modification.
As used herein, "thermostable" refers to an enzyme which is stable and active at temperatures as great as preferably between about 90-100 C and more preferably between about 70-98°C to heat as compared, for example, to a non-thermostable form of an enzyme with a similar activity. For example, a thermostable nucleic acid polymerase derived from thermophilic organisms such as P. furiosus, M. jannaschii, A. fulgidus or P. horikoshii are more stable and active at elevated temperatures as compared to a nucleic acid polymerase from E. coli. A representative thermostable nucleic acid polymerase isolated from P. furiosus (Pfu) is described in Lundberg et al., 1991, Gene, 108:1-6. Additional representative temperature stable polymerases include, e.g., polymerases extracted from the thermophilic bacteria Thermus flavus, Thermus ruber, Thermus thermophilus, Bacillus stearothermophilus (which has a somewhat lower temperature optimum than the others listed), Thermus lacteus, Thermus rubens,
14 Thermotoga maritima, or from thermophilic archaea Thermococcus litoralis, and Methanothermus fervidus .
Temperature stable polymerases are preferred in a thermocycling process wherein double stranded nucleic acids are denatured by exposure to a high temperature (about 95 C) during the PCR cycle.
As used herein, the term "template DNA molecule" refers to that strand of a nucleic acid from which a complementary nucleic acid strand is synthesized by a DNA polymerase, for example, in a primer extension reaction.
As used herein, the term "template dependent manner" is intended to refer to a process that involves the template dependent extension of a primer molecule (e.g., DNA synthesis by DNA polymerase). The term "template dependent manner" refers to polynucleotide synthesis of RNA or DNA wherein the sequence of the newly synthesized strand of polynucleotide is dictated by the well-known rules of complementary base pairing (see, for example, Watson, J. D. et al., In: Molecular Biology of the Gene, 4th Ed., W. A. Benjamin, Inc., Menlo Park, Calif. (1987)).
The term "fidelity" as used herein refers to the accuracy of DNA polymerization by template-dependent DNA polymerase. The fidelity of a DNA polymerase is measured by the error rate (the frequency of incorporating an inaccurate nucleotide, i.e., a nucleotide that is not incorporated at a template-dependent manner). The accuracy or fidelity of DNA polymerization is maintained by both the polymerase activity and the 3 '-5 ' exonuclease activity of a DNA polymerase. The term "high fidelity" refers to an error rate of 5 x 10"6 per base pair or lower. The fidelity or error rate of a DNA polymerase may be measured using assays known to the art. For example, the error rates of DNA polymerase mutants can be tested using the lacl PCR fidelity assay described in Cline, J., Braman, J.C., and Hogrefe, H.H. (96) NAR 24:3546-3551. Briefly, a 1.9kb fragment encoding the lacIOlacZa target gene is amplified from pPRlAZ plasmid DNA using 2.5L DNA polymerase (i.e. amount of enzyme necessary to incorporate 25 nmoles of total dNTPs in 30 min. at 72°C) in the appropriate PCR buffer. The /αcl-containing PCR products are then cloned into lambda GT10 arms, and the percentage of lacl mutants (MF, mutation frequency) is determined in i color screening assay, as described (Lundberg, K.S., Shoemaker, D.D., Adams, M.W.W., Short, J.M., Sorge, J.A., and Mathur, EJ. (1991) Gene 180:1-8). Error rates are expressed as mutation frequency per bp per duplication (MF/bp/d), where bp is the number of detectable sites in the lacl
15 gene sequence (349) and d is the number of effective target doublings. For each DNA polymerase mutant, at least two independent PCR amplifications are performed.
As used herein, an "amplified product" refers to the double strand polynucleotide population at the end of a PCR amplification reaction. The amplified product contains the original polynucleotide template and polynucleotide synthesized by DNA polymerase using the polynucleotide template during the PCR reaction.
As used herein, "polynucleotide template" or "target polynucleotide template" or "template" refers to a polynucleotide containing an amplified region. The "amplified region," as used herein, is a region of a polynucleotide that is to be either synthesized by polymerase chain reaction (PCR). For example, an amplified region of a polynucleotide template resides between two sequences to which two PCR primers are complementary to.
As used herein, the term "primer" refers to a single stranded DNA or RNA molecule that can hybridize to a polynucleotide template and prime enzymatic synthesis of a second polynucleotide strand. A primer useful according to the invention is between 10 to 100 nucleotides in length, preferably 17-50 nucleotides in length and more preferably 17-45 nucleotides in length.
"Complementary" refers to the broad concept of sequence complementarity between regions of two polynucleotide strands or between two nucleotides through base-pairing. It is known that an adenine nucleotide is capable of forming specific hydrogen bonds ("base pairing") with a nucleotide which is thymine or uracil. Similarly, it is known that a cytosine nucleotide is capable of base pairing with a guanine nucleotide.
The term "wild-type" refers to a gene or gene product which has the characteristics of that gene or gene product when isolated from a naturally occurring source. In contrast, the term "modified" or "mutant" refers to a gene or gene product which displays altered characteristics when compared to the wild-type gene or gene product. For example, a mutant DNA polymerase in the present invention is a DNA polymerase which exhibits a reduced uracil detection activity.
As used herein "FEN-1 nuclease" refers to thermostable FEN-1 endonucleases useful according to the invention and include, but are not limited to, FEN-1 endonuclease purified from
16 the "hyperthermophiles", e.g., from M. j 'annas chii, P. furiosus and P. woesei. See U.S. Patent No. 5,843,669, hereby incorporated by reference.
According to the methods of the present invention, the addition of FEN-1 in the amplification reaction dramatically increases the efficiency of the multi-site mutagenesis. 400 ng to 4000 ng of FEN-1 may be used in each amplification reaction. Preferably 400-1000 ng, more preferably, 400-600 ng of FEN-1 is used in the amplification reaction. I-n a preferred embodiment of the invention, 400 ng FEN-1 is used.
As used herein, "Thermus DNA ligase" refers to a thermostable DNA ligase that is used in the multi-site mutagenesis amplification reaction to ligate the mutant fragments synthesized by extending each mutagenic primer so to form a circular mutant strand. Tth and Taq DNA ligase require NAD as a cofactor.
Preferably, 1-20 U DNA ligase is used in each amplification reaction, more preferably, 2- 15 U DNA ligase is used in each amplification reaction.
In a preferred embodiment, 15 U Taq DNA ligase is used in an amplification reaction. Taq DNA ligase cofactor NAD is used at a concentration of 0-1 mM, preferably between 0.02- 0.2 mM, more preferably at 0.1 mM.
As used herein, a "PCR enhancing factor" or a "Polymerase Enhancing Factor" (PEF) refers to a complex or protein possessing polynucleotide polymerase enhancing activity including, but not limited to, PCNA, RFC, helicases etc (Hogrefe et al., 1997, Strategies 10:93- 96; and U.S. Patent No. 6,183,997, both of which are hereby incoφorated by reference). '
The invention also contemplates mutant archael DNA polymerases in combination with accessory factors, for example as described in U.S. 6,333,158, and WO 01/09347 A2, hereby incoφorated by reference in its entirety.
As used herein, a mutant archaeal or Pfu DNA polymerase comprising a truncation refers to a truncated DNA polymerase with reduced base analog detection activity, preferably reduced uracil detection activity, that is 3 '-5' exonuclease deficient and comprises an N terminal truncation from amino acid 1 - 4, preferably amino acid 1 - 93 or most preferably amino acid 1 - 337.
17 In one embodiment, a mutant archaeal or Pfu DNA polymerase comprising a truncation refers to a truncated DNA polymerase with reduced base analog detection activity, preferably reduced uracil detection activity, that is 3 '-5' exonuclease deficient and comprises an N terminal truncation wherein at least the first N terminal amino acid is removed and wherein no more than the first 337 N terminal amino acids are removed or wherein at least the first 1-7 N-terminal amino acids are removed and wherein no more than the first 337 N-terminal amino acids are removed.
hi one embodiment, a mutant archaeal or Pfu DNA polymerase comprising a truncation is a truncated DNA polymerase with 3 '-5' exonuclease activity and reduced base analog detection activity, preferably reduced uracil detection activity, that comprises an N terminal truncation from amino acid 1-7, preferably 1-38, more preferably 1-93 , more preferably 1-116 or most preferably amino acid 1 to amino acid 136.
In another embodiment, a mutant archaeal or Pfu DNA polymerase comprising a truncation is a truncated DNA polymerase with 3 '-5' exonuclease activity and reduced base analog detection activity, preferably reduced uracil detection activity, that comprises an N terminal truncation wherein at least the first 1 to 7 N-terminal amino acid is/are removed and wherein no more than the first 136 N-terminal amino acids are removed.
As used herein, a mutant archaeal or Pfu DNA polymerase with an internal deletion refers to a mutant archaeal or Pfu DNA polymerase with reduced base analog detection activity, preferably reduced uracil detection activity, that contains an internal deletion of 1 amino acid, 2-4 amino acids, 5-10 amino acids, 10-25 amino acids, 25-50 amino acids, 50-75 amino acids, 75-100 amino acids, or most preferably 136 amino acids within the first N terminal 136 amino acids of the mutant archaeal or Pfu DNA polymerase.
In another embodiment, a mutant archaeal or Pfu DNA polymerase with an internal deletion refers to a mutant archaeal or Pfu DNA polymerase with reduced base analog detection activity, preferably reduced uracil detection activity, that is 3 '-5' exonuclease deficient and comprises an internal deletion of 1 amino acid, 1-5 amino acids, 5-10 amino acids, 10-25 amino acids, 25-50 amino acids, 50-100 amino acids, 100-150 amino acids, 150-200 amino acids, preferably 200-250 amino acids, preferably 250-300 amino acids, or most preferably 337 amino acids within the first N terminal 337 amino acids of the mutant archaeal or Pfu DNA polymerase.
18 In another embodiment, the mutant archaeal or Pfu DNA polymerase with an internal deletion is a DNA polymerase with 3 '-5' exonuclease activity and reduced base analog detection activity, preferably reduced uracil detection activity, and comprises an internal deletion of one or more amino acids in the regions of amino acids 6-8, amino acids 36-38, amino acids 90-97 and amino acids 111-116.
In another embodiment, the mutant archaeal or Pfu DNA polymerase with an internal deletion is a DNA polymerase with reduced base analog detection activity, preferably reduced uracil detection activity, that is 3 '-5' exonuclease deficient and comprises an internal deletion of one or more amino acids in the regions of amino acids 6-8, amino acids 36-38, amino acids 90- 97 and amino acids 111-116.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1: Oligonucleotide Primers for QuikChange Mutagenesis (SEQ ID Nos: 6-14, 43-55)
Figure 2: (a) dUTP incoφoration of V93E and V93R mutants compared to wild type Pfu
DNA polymerase.
(b) PCR Amplification of Pfu V93R mutant extract in the presence of 100% dUTP.
Figure 3: Protein concentration, unit concentration, and specific activity of the purified Pfu
V93R and V93E mutants.
Figure 4: Comparison of the efficacy of PCR amplification of Pfu DNA polymerase mutants and wt enzyme in the presence of different TTP:dUTP concentration ratios.
Figure 5 : Comparison of the efficacy of "long" PCR amplification of Pfu DNA polymerase mutants and wt enzyme.
Figure 6: 6A. DNA sequence of mutant archeael DNA polymerases
6B. Amino acid sequence of mutant archeael DNA polymerases
19 6C. DNA and Amino acid sequence of mutant Tgo DNA polymerase
Figure 7: DNA and Amino acid sequence of wild type Pfu DNA polymerase
Figure 8: dUTP incoφoration of Pfu mutants compared to wild type Pfu DNA polymerase
8A. dUTP incoφoration of Pfu mutants V93W, V93Y, V93M, V93K and V93R compared to wild type Pfu DNA polymerase
8B. dUTP incoφoration of the Pfu V93D and V93R mutants compared to wild type Pfu DNA polymerase.
8C. dUTP incoφoration of the Pfu V93N and V93G mutant compared to wild type Pfu DNA polymerase
Figure 9: DNA polymerase activity of N-terminal Pfu DNA polymerase truncation mutants.
Figure 10: Oligonucleotide Primers for QuikChange Mutagenesis (SEQ ID Nos: 56-74).
Figure 11 : DNA polymerase activity of KOD V93 polymerase mutants.
Figure 12: DNA polymerase activity of Tgo V93 DNA polymerase mutants and comparison with JDF-3 V93 polymerase mutants.
Figure 13 : DNA polymerase activity of JDF-3 polymerase mutants.
Figure 14: DNA polymerase activity of Pfu polymerase deletion mutants.
DETAILED DESCRIPTION
Base deamination and other base modifications greatly increase as a consequence of PCR reaction conditions, for example, elevated temperature. This results in the progressive accumulation of base analogs (for example uracil or inosine) in the PCR reaction that ultimately inhibit archaeal proofreading DNA polymerases, such as Pfu, Vent and Deep Vent DNA polymerases, severely limiting their efficiency.
20 The present invention provides a remedy to the problem of base analog contamination of PCR reactions by disclosing methods for the isolation and characterization of archaeal DNA polymerases with reduced base analog detection activities.
The mutant archael DNA polymerases of the invention may provide for the use of fewer units of polymerase, may allow assays to be done using shorter extension times and/or may provide greater success in achieving higher yields and or longer products.
ARCHAEAL DNA POLYMERASES
There are 2 different classes of DNA polymerases which have been identified in archaea: 1. Family B/pol I type (homologs of Pfu from Pyrococcus furiosus) and 2. pol II type (homologs of P. furiosus DP1/DP2 2-subunit polymerase). DNA polymerases from both classes have been shown to naturally lack an associated 5' to 3' exonuclease activity and to possess 3' to 5' exonuclease (proofreading) activity. Suitable DNA polymerases (pol I or pol II) can be derived from archaea with optimal growth temperatures that are similar to the desired assay temperatures.
Thermostable archaeal DNA polymerases isolated from Pyrococcus species (furiosus, species GB-D, woesii, abysii, horikoshii), Thermococcus species (kodakaraensis KODl, litoralis, species 9 degrees North-7, species JDF-3, gorgonarius), Pyrodictium occultum, and Archaeoglobus fulgidus. It is estimated that suitable archaea would exhibit maximal growth temperatures of >80-85°C or optimal growth temperatures of >70-80°C. Appropriate PCR enzymes from the archaeal pol I DNA polymerase group are commercially available, including Pfu (Stratagene), KOD (Toyobo), Pfx (Life Technologies, Inc.), Vent (New England BioLabs), Deep Vent (New England BioLabs), Tgo (Roche), and Pwo (Roche).
Additional archaea DNA polymerases related to those listed above are described in the following references: Archaea: A Laboratory Manual (Robb, F.T. and Place, A.R., eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1995 and Thermophilic Bacteria (Kristjansson, J.K.,ed.) CRC Press, Inc., Boca Raton, Florida, 1992.
The invention therefore provides for thermostable archaeal DNA polymerases of either Family B/pol I type or pol II type with a reduced base analog detection activity.
21 Table 1. ACCESSION INFORMATION FOR CLONED FAMILY B POLYMERASES
Vent Thermococcus litoralis ACCESSION AAA72101 PH) g348689
VERSION AAA72101.1 GI:348689 DBSOURCE locus THCVDPE accession M74198.1
THEST THERMOCOCCUS SP. (STRAIN TY) ACCESSION 033845
PH) g3913524 VERSION 033845 GL3913524 DBSOURCE swissprot: locus DPOL_THEST, accession 033845
Pab Pyrococcus abyssi
ACCESSION P77916
PID g3913529
VERSION P77916 GL3913529
DBSOURCE swissprot: locus DPOL_PYRAB, accession P77916
PYRHO Pyrococcus horikoshii
ACCESSION O59610
PID g3913526
VERSION O59610 GL3913526 DBSOURCE swissprot: locus DPOLJPYRHO, accession O59610
PYRSE PYROCOCCUS SP. (STRAIN GE23) ACCESSION P77932 PUD g3913530 VERSION P77932 GL3913530
DBSOURCE swissprot: locus DPOLJPYRSE, accession P77932
22 DeepVent Pyrococcus sp. ACCESSION AAA67131 PE) g436495
VERSION AAA67131.1 G 436495 DBSOURCE locus PSU00707 accession U00707.1
Pfu Pyrococcus furiosus ACCESSION P80061 PID g399403 VERSION P80061 G 399403
DBSOURCE swissprot: locus DPOL_PYRFU, accession P80061
JDF-3 Thermococcus sp.
Unpublished Baross gi|2097756|pat|US|5602011|12 Sequence 12 from patent US 5602011
9degN THERMOCOCCUS SP. (STRAIN 9ON-7).
ACCESSION Q56366
PE) g3913540
VERSION Q56366 GL3913540 DBSOURCE swissprot: locus DPOL_THES9, accession Q56366
KOD Pyrococcus sp. ACCESSION BAA06142 PH) gl620911 VERSION BAA06142.1 GI: 1620911
DBSOURCE locus PYWKODPOL accession D29671.1
Tgo Thermococcus gorgonarius. ACCESSION 4699806 PH) g4699806
VERSION G 4699806
DBSOURCE pdb: chain 65, release Feb 23, 1999
23 THEFM Thermococcus fumicolans ACCESSION P74918 PH) g3913528 VERSION P74918 GI.3913528
DBSOURCE swissprot: locus DPOL_THEFM, accession P74918
METTH Methanobacterium thermoautotrophicum ACCESSION 027276 PH) g3913522
VERSION 027276 GI.3913522
DBSOURCE swissprot: locus DPOL_METTH, accession 027276
Metj a Methanococcus j annaschii ACCESSION Q58295
PID g3915679 VERSION Q58295 GP.3915679 DBSOURCE swissprot: locus DPOL_METJA, accession Q58295
POC Pyrodictium occultum
ACCESSION B56277
PH) gl363344
VERSION B56277 GI: 1363344
DBSOURCE pir: locus B56277
Apel Aeropyrum pernix
ACCESSION BAA81109
PH) g5105797
VERSION BAA81109.1 GI.5105797 DBSOURCE locus AP000063 accession AP000063.1
ARCFU Archaeoglobus fulgidus
24 ACCESSION 029753 PH) g3122019 VERSION 029753 GI:3122019
DBSOURCE swissprot: locus DPOL_ARCFU, accession 029753
Desulfurococcus sp. Tok. ACCESSION 6435708 PID g64357089 VERSION GT.-6435708 DBSOURCE pdb. chain 65, release Jun 2, 1999
Mutant DNA Polymerases
In one embodiment of the invention, the archaeal polymerase is a mutant polymerase having reduced uracil base detection.
In one embodiment of the invention, the mutant DNA polymerase is encoded by a nucleic acid sequence selected from SEQ ID Nos 17-24, wherein the codon encoding amino acid residue Valine at position 93 is replaced by the one of the following codons:
Codons encoding Arginine: AGA, AGG, CGA, CGC, CGG, CGT Codons encoding Glutamic acid: GAA, GAG Codons encoding Aspartic acid: GAT, GAC Codons encoding Lysine: AAA, AAG Codons encoding Glutamine: CAA, CAG Codons encoding Asparagine AAC, AAU
In one embodiment, a mutant DNA polymerase has an amino acid sequence selected from the sequences of SEQ ID NOS: 27-34, wherein Valine at position 93 is replaced by one of Arginine, Glutamic acid, Aspartic acid, Lysine, Glutamine, and Asparagine.
Alternatively, the mutant DNA polymerase may be a Pfu DNA polymerase having a deletion of Valine at position 93 as shown in SEQ ID NO: 35, or alternatively, having a deletion of Aspartic acid at position 92, Valine at position 93, and Proline at position 94 as shown in SEQ H) NO: 36. Similarly, the mutant DNA polymerase may be a Pfu DNA polymerase having a
25 deletion of the codon GTT encoding Valine at position 93 as shown in SEQ ID NO: 25, or alternatively having a deletion of the successive codons GAT, GTT, and CCC which encode residues Aspartic acid, Valine, and Proline at positions 92, 93, and 94 respectively as shown in SEQ ID NO: 26.
II. PREPARING MUTANT DNA POLYMERASE WITH REDUCED BASE ANALOG DETECTION ACTIVITY
Cloned wild-type DNA polymerases may be modified to generate forms exhibiting reduced base analog detection activity by a number of methods. These include the methods described below and other methods known in the art. Any proofreading archaeal DNA polymerase can be used to prepare for DNA polymerase with reduced base analog detection activity in the invention.
GENETIC MODIFICATIONS - MUTAGENESIS
Direct comparison of DNA polymerases from diverse organisms indicates that the domain structure of these enzymes is highly conserved and in many instances, it is possible to assign a particular function to a well-defined domain of the enzyme. For example, the six most conserved C-terminal regions, spanning approximately 340 amino acids, are located in the same linear arrangement and contain highly conserved motifs that form the metal and dNTP binding sites and the cleft for holding the DNA template and are therefore essential for the polymerization function. In another example, the three amino acid regions containing the critical residues in the E. coli DNA polymerase I involved in metal binding, single-stranded DNA binding, and catalysis of the 3'->5' exonuclease reaction are located in the amino-terminal half and in the same linear arrangement in several prokaryotic and eukaryotic DNA polymerases. The location of these conserved regions provides a useful model to direct genetic modifications for preparing DNA polymerase with reduced base analog detection activity whilst conserving essential functions e.g. DNA polymerization and proofreading activity.
The preferred method of preparing a DNA polymerase with reduced base analog detection activity is by genetic modification (e.g., by modifying the DNA sequence of a wild- type DNA polymerase). A number of methods are known in the art that permit the random as well as targeted mutation of DNA sequences (see for example, Ausubel et. al. Short Protocols in
26 Molecular Biology (1995) 3rα" Ed. John Wiley & Sons, Inc.). h addition, there are a number of commercially available kits for site-directed mutagenesis, including both conventional and PCR- based methods. Examples include the EXSITE™ PCR-Based Site-directed Mutagenesis Kit available from Stratagene (Catalog No. 200502) and the QUIKCHANGE™ Site-directed mutagenesis Kit from Stratagene (Catalog No. 200518), and the CHAMELEON® double- stranded Site-directed mutagenesis kit, also from Stratagene (Catalog No. 200509).
In addition DNA polymerases with reduced base analog detection activity may be generated by insertional mutation or truncation (N-terminal, internal or C-terminal) according to methodology known to a person skilled in the art.
Older methods of site-directed mutagenesis known in the art rely on sub-cloning of the sequence to be mutated into a vector, such as an Ml 3 bacteriophage vector, that allows the isolation of single-stranded DNA template. In these methods, one anneals a mutagenic primer (i.e., a primer capable of annealing to the site to be mutated but bearing one or mismatched nucleotides at the site to be mutated) to the single-stranded template and then polymerizes the complement of the template starting from the 3' end of the mutagenic primer. The resulting duplexes are then transformed into host bacteria and plaques are screened for the desired mutation.
More recently, site-directed mutagenesis has employed PCR methodologies, which have the advantage of not requiring a single-stranded template. In addition, methods have been developed that do not require sub-cloning. Several issues must be considered when PCR-based site-directed mutagenesis is performed. First, in these methods it is desirable to reduce the number of PCR cycles to prevent expansion of undesired mutations introduced by the polymerase. Second, a selection must be employed in order to reduce the number of non- mutated parental molecules persisting in the reaction. Third, an extended-length PCR method is preferred in order to allow the use of a single PCR primer set. And fourth, because of the non- template-dependent terminal extension activity of some thermostable polymerases it is often necessary to incoφorate an end-polishing step into the procedure prior to blunt-end ligation of the PCR-generated mutant product.
The protocol described below accommodates these considerations through the following steps. First, the template concentration used is approximately 1000-fold higher than that used in
27 conventional PCR reactions, allowing a reduction in the number of cycles from 25-30 down to 5- 10 without dramatically reducing product yield. Second, the restriction endonuclease Dpn I (recognition target sequence: 5-Gm6ATC-3, where the A residue is methylated) is used to select against parental DNA, since most common strains of E. coli Dam methylate their DNA at the sequence 5-GATC-3. Third, Taq Extender is used in the PCR mix in order to increase the proportion of long (i.e., full plasmid length) PCR products. Finally, Pfu DNA polymerase is used to polish the ends of the PCR product prior to intramolecular ligation using T4 DNA ligase.
A non-limiting example for the isolation of mutant archaeal DNA polymerases exhibiting reduced uracil detection activity is described in detail as follows:
■ Plasmid template DNA (approximately 0.5 pmole) is added to a PCR cocktail containing: lx mutagenesis buffer (20 mM Tris HCl, pH 7.5; 8 mM MgCl2; 40 μg/ml BSA); 12-20 pmole of each primer (one of skill in the art may design a mutagenic primer as necessary, giving consideration to those factors such as base composition, primer length and intended buffer salt concentrations that affect the annealing characteristics of oligonucleotide primers; one primer must contain the desired mutation, and one (the same or the other) must contain a 5' phosphate to facilitate later ligation), 250 μM each dNTP, 2.5 U Taq DNA polymerase, and 2.5 U of Taq Extender (Available from Stratagene; See Nielson et al. (1994) Strategies 7: 27, and U.S. Patent No. 5,556,772). Primers can be prepared using the triester method of Matteucci et al., 1981, J. Am. Chem. Soc. 103:3185-3191, incoφorated herein by reference. Alternatively automated synthesis may be preferred, for example, on a Biosearch 8700 DNA Synthesizer using cyanoethyl phosphoramidite chemistry.
The PCR cycling is performed as follows: 1 cycle of 4 min at 94°C, 2 min at 50°C and 2 min at 72°C; followed by 5-10 cycles of 1 min at 94°C, 2 min at 54°C and 1 min at 72°C. The parental template DNA and the linear, PCR-generated DNA incoφorating the mutagenic primer are treated with Dpnl (10 U) and Pfu DNA polymerase (2.5U). This results in the Dpnl digestion of the in vivo methylated parental template and hybrid DNA and the removal, by Pfu DNA polymerase, of the non-template-directed Taq DNA polymerase-extended base(s) on the linear PCR product. The reaction is incubated at 37°C for 30 min and then transferred to 72°C for an additional 30 min. Mutagenesis buffer (115 ul of lx) containing 0.5 mM ATP is added to the Dpnl-digested, Pfu DNA polymerase-polished PCR products. The solution is mixed and 10
28 ul are removed to a new microfuge tube and T4 DNA ligase (2-4 U) is added. The ligation is incubated for greater than 60 min at 37°C. Finally, the treated solution is transformed into competent E. coli according to standard methods.
Methods of random mutagenesis, which will result in a panel of mutants bearing one or more randomly situated mutations, exist in the art. Such a panel of mutants may then be screened for those exhibiting reduced uracil detection activity relative to the wild-type polymerase (e.g., by measuring the incoφoration of lOnmoles of dNTPs into polymeric form in 30 minutes in the presence of 200μM dUTP and at the optimal temperature for a given DNA polymerase). An example of a method for random mutagenesis is the so-called "error-prone PCR method". As the name implies, the method amplifies a given sequence under conditions in which the DNA polymerase does not support high fidelity incoφoration. The conditions encouraging error-prone incorporation for different DNA polymerases vary, however one skilled in the art may determine such conditions for a given enzyme. A key variable for many DNA polymerases in the fidelity of amplification is, for example, the type and concentration of divalent metal ion in the buffer. The use of manganese ion and/or variation of the magnesium or manganese ion concentration may therefore be applied to influence the error rate of the polymerase.
Genes for desired mutant DNA polymerases generated by mutagenesis may be sequenced to identify the sites and number of mutations. For those mutants comprising more than one mutation, the effect of a given mutation may be evaluated by introduction of the identified mutation to the wild-type gene by site-directed mutagenesis in isolation from the other mutations borne by the particular mutant. Screening assays of the single mutant thus produced will then allow the determination of the effect of that mutation alone.
hi a preferred embodiment, the enzyme with reduced uracil detection activity is derived from archaeal DNA polymerase containing one or more mutations.
In a preferred embodiment, the enzyme with reduced uracil detection activity is derived from Pfu DNA polymerase.
The amino acid and DNA coding sequence of a wild-type Pfu DNA polymerase are shown in Figure 7 (Genbank Accession # P80061). A detailed description of the structure and
29 function of Pfu DNA polymerase can be found, among other places in U.S. Patent Nos. 5,948,663; 5,866,395; 5,545,552; 5,556,772, all of which thereby incoφorated by references. A non-limiting detailed procedure for preparing Pfu DNA polymerase with reduced uracil detection activity is provided in Example 1.
A person of average skill in the art having the benefit of this disclosure will recognize that polymerases with reduced uracil detection activity derived from other exo+ DNA polymerases including Vent DNA polymerase, JDF-3 DNA polymerase, Tgo DNA polymerase, and the like may be suitably used in the subject compositions. In particular, the invention provides DNA polymerase selected from Tgo , JDF-3 and KOD comprising one or more mutations at V93, and which demonstrate reduced uracil detection activity.
The enzyme of the subject composition may comprise DNA polymerases that have not yet been isolated.
In preferred embodiments of the invention, the mutant Pfu DNA polymerase harbors an amino acid substitution at amino acid position, V93. In a preferred embodiment, the mutant Pfu DNA polymerase of the invention contains a Valine to Arginine, Valine to Glutamic acid, Valine to Lysine, Valine to Aspartic Acid, or Valine to Asparagine substitution at amino acid position 93.
The invention further provides for mutant archaeal DNA polymerases with reduced base analog detection activity that contains a Valine to Arginine, Valine to Glutamic acid, Valine to Lysine, Valine to Aspartic Acid, Valine to Glutamine, or Valine to Asparagine substitution at amino acid position 93. h particular, Figure 6 shows mutant archaeal DNA polymerases of the invention with reduced base analog detection activity.
According to the invention, V93 mutant Pfu DNA polymerases with reduced uracil detection activity may contain one or more additional mutations that reduce or abolish one or more additional activities of V93 Pfu DNA polymerases, e.g., DNA polymerization activity or 3 '-5' exonuclease activity. In one embodiment, the V93 mutant Pfu DNA polymerase according to the invention contains one or more mutations that renders the DNA polymerase 3 '-5' exonuclease deficient. I-n another embodiment, the V93 mutant Pfu DNA polymerase according
30 to the invention contains one or more mutations that the DNA polymerization activity of the V93 Pfu DNA polymerase.
In another embodiment, a mutant archael DNA polymerase is a chimera that further comprises a polypeptide that increases processivity and/or increases salt resistance. A polypeptide useful according to the invention and methods of preparing chimeras are described in WO 01/92501 Al and Pavlov et al., 2002, Proc. Natl. Acad. Sci USA, 99:13510-13515. Both references are herein incoφorated in their entirety.
The invention provides for V93Rmutant Pfu DNA polymerases with reduced uracil detection activity containing one or mutations that reduce DNA polymerization as disclosed in the pending U.S. patent application Serial No.: 10/035,091 (Hogrefe, et al.; filed: December 21, 2001); the pending U.S. patent application Serial No.: 10/079,241 (Hogrefe, et al.; filed February 20, 2002); the pending U.S. patent application Serial No.: 10/208,508 (Hogrefe et al.; filed July 30, 2002); and the pending U.S. patent application Serial No.: 10/227,110 (Hogrefe et al.; filed August 23, 2002), the contents of which are hereby incoφorated in their entirety.
In a preferred embodiment, the invention provides for a V93R/ G387P, V93E/ G387P,
V93D/G387P, V93K7G387P and V93N/G387P double mutant Pfu DNA polymerase with reduced DNA polymerization activity and reduced uracil detection activity.
The invention further provides for V93R, V93E, V93D, V93K and V93N mutant Pfu DNA polymerases with reduced uracil detection activity containing one or mutations that reduce or eliminate 3 '-5' exonuclease activity as disclosed in the pending U.S. patent application Serial No.: 09/698,341 (Sorge et al; filed October 27, 2000).
In a preferred embodiment, the invention provides for a V93R/D141 A/E143A triple mutant Pfu DNA polymerase with reduced 3 '-5' exonuclease activity and reduced uracil detection activity.
The invention further provides for combination of one or more mutations that may increase or eliminate base analog detection activity of an archaeal DNA polymerase.
31 DNA polymerases containing additional mutations are generated by site directed mutagenesis using the Pfu DNA polymerase or Pfu V93R cDNA as a template DNA molecule, according to methods that are well known in the art and are described herein.
Methods used to generate Pfu DNA polymerases with reduced DNA polymerization activity are disclosed in the pending U.S. patent application Serial No.: 10/035,091 (Hogrefe, et al.; filed: December 21, 2001); the pending U.S. patent application Serial No.: 10/079,241 (Hogrefe, et al.; filed February 20, 2002); the pending U.S. patent application Serial No.: 10/208,508 (Hogrefe et al.; filed July 30, 2002); and the pending U.S. patent application Serial No.: 10/227,110 (Hogrefe et al.; filed August 23, 2002), the contents of which are hereby incoφorated in their entirety.
Methods used to generate 3 '-5' exonuclease deficient JDF-3 DNA polymerases including the D141A and E143A mutations are disclosed in the pending U.S. patent application Serial No.: 09/698,341 (Sorge et al; filed October 27, 2000). A person skilled in the art in possession of the V93 Pfu DNA polymerase cDNA and the teachings of the pending U.S. patent application Serial No. : 09/698,341 (Sorge et al; filed October 27, 2000) would have no difficulty introducing both the corresponding D141A and E143A mutations or other 3 '-5' exonuclease mutations into the V93 Pfu DNA polymerase cDNA, as disclosed in the pending U.S. patent application Serial No.: 09/698,341, using established site directed mutagenesis methodology.
Methods of preparing chimeras according to the invention are described in WO 01/92501 Al and Pavlov et al., 2002, Proc. Natl. Acad. Sci USA, 99:13510-13515. Both references are herein incoφorated in their entirety.
In one embodiment, the Pfu mutants are expressed and purified as described in U.S. Patent No. 5,489,523, hereby incoφorated by reference in its entirety.
III. METHODS OF EVALUATING MUTANTS FOR REDUCED BASE ANALOG DETECTION ACTIVITY.
Random or site-directed mutants generated as known in the art or as described herein and expressed in bacteria may be screened for reduced uracil detection activity by several different assays. Embodiments for the expression of mutant and wild type enzymes is described herein. In one method, exo+ DNA polymerase proteins expressed in lytic lambda phage plaques
32 generated by infection of host bacteria with expression vectors based on, for example, Lambda ZapII , are transferred to a membrane support. The immobilized proteins are then assayed for polymerase activity on the membrane by immersing the membranes in a buffer containing a DNA template and the unconventional nucleotides to be monitored for incorporation.
Mutant polymerase libraries may be screened using a variation of the technique used by
Sagner et al (Sagner, G., Ruger, R, and Kessler, C. (1991) Gene 97:119-123). For this approach, lambda phage clones are plated at a density of 10-20 plaques per square centimeter and replica plated. Proteins present in the plaques are transferred to filters and moistened with polymerase screening buffer (50mM Tris (pH 8.0), 7mM MgC12, 3mM β-ME). The filters are kept between layers of plastic wrap and glass while the host cell proteins are heat-inactivated by incubation at 65°C for 30 minutes. The heat-treated filters are then transferred to fresh plastic wrap and approximately 35μl of polymerase assay cocktail are added for every square centimeter of filter. The assay cocktail consists of IX cloned Pfu (cPfu) magnesium free buffer (IX buffer is 20 mM Tris-HCl (pH 8.8), 10 mM KCI, 10 mM (NH4)2SO4, 100 μg/ml bovine serum albumin (BSA), and 0.1% Triton X- 100; Pfu Magnesium-free buffer may be obtained from Stratagene (Catalog No. 200534)), 125 ng/ml activated calf thymus or salmon sperm DNA, 200μM dATP, 200μM dGTP, 200μM dCTP and 5 μCi/ml α-33P dCTP and 200μM dUTP or 200μM dTTP. The filters, in duplicate, are placed between plastic wrap and a glass plate and then incubated at 65°C for one hour, and then at 70°C for one hour and fifteen minutes. Filters are then washed three times in 2X SSC for five minutes per wash before rinsing twice in 100%) ethanol and vacuum drying. Filters are then exposed to X-ray film (approximately 16 hours), and plaques that incoφorate label in the presence of 200μM dUTP or 200μM dTTP are identified by aligning the filters with the original plate bearing the phage clones. Plaques identified in this way are re-plated at more dilute concentrations and assayed under similar conditions to allow the isolation of purified plaques.
In assays such as the one described above, the signal generated by the label is a direct measurement of the polymerization activity of the polymerase in the presence of 200 μM dUTP as compared to the polymerase activity of the same mutant polymerase in the presence of 200 μM dTTP. A plaque comprising a mutant DNA polymerase with reduced uracil detection activity as compared to that of the wild-type enzyme can then be identified and further tested in primer extension assays in which template dependent DNA synthesis is measured in the presence
33 of 200 μMdUTP. For example, 1 μl of appropriately diluted bacterial extract (i.e., heat-treated and clarified extract of bacterial cells expressing a cloned polymerase or mutated cloned polymerase) is added to 10 μl of each nucleotide cocktail (200μM dATP, 200μM dGTP, 200μM dCTP and 5 μCi/ml α-33P dCTP, 3H-dCTP and 200μM dUTP or 200μM dTTP, activated calf thymus DNA, IX appropriate buffer (see above)), followed by incubation at the optimal temperature for 30 minutes (e.g., 73°C for Pfu DNA polymerase), for example, as described in Hogrefe et al., 2001, Methods in Enzymology, 343:91-116. Extension reactions are then quenched on ice, and 5μl aliquots are spotted immediately onto DE81 ion-exchange filters (2.3cm; Whatman #3658323). Unincoφorated label is removed by 6 washes with 2 x SCC (0.3M NaCl, 30mM sodium citrate, pH 7.0), followed by a brief wash with 100% ethanol.
Incoφorated radioactivity is then measured by scintillation counting. Reactions that lack enzyme are also set up along with sample incubations to determine "total cpms" (omit filter wash steps) and "minimum cpms"(wash filters as above). Cpms bound is proportional to the amount of polymerase activity present per volume of bacterial extract. Mutants that can incoφorate significant radioactivity in the presence of dUTP are selected for further analysis.
Mutant DNA polymerases with reduced uracil recognition can also be identified as those that can synthesize PCR products in the presence of 100%) dUTP(See Example 3).
The "uracil detection" activity can also be determined using the long range primer extension assay on single uracil templates as described by Greagg et al., (1999) Proc. Natl. Acad. Sci. 96, 9045-9050. Briefly, the assay requires a 119- mer template that is generated by PCR amplification of a segment of pUC19 spanning the polylinker cloning site. PCR primer sequences are:
A, GACGTTGTAAAACGACGGCCAGU (SEQ ID NO: 3);
B, ACGTTGTAAAACGACGGCCAGT(SEQ IDNO: 4); and
C, CAATTTCACACAGGAAACAGCTATGACCATG (SEQ IDNO: 5).
The 119- mer oligonucleotide incoφorating either a U or T nucleotide 23 bases from the terminus of one strand, was synthesized by using Taq polymerase under standard PCR conditions, using primer C and either primer A or primer B. PCR products are then purified on agarose gels and extracted by using Qiagen columns.
34 For long range primer extension, primer C is annealed to one strand of the 119- bp PCR product by heating to 65 °C in reaction buffer and cooling to room temperature. The dNTPs, [ α- [ 32P] dATP, and 5 units of DNA polymerase ( Pfu, Taq and mutant Pfu DNA polymerase to be tested) are added in polymerase reaction buffer ( as specified by the suppliers of each polymerase) to a final volume of 20 μl, and the reaction is allowed to proceed for 60 min at 55 °C. Reaction products are subjected to electrophoresis in a denaturing acrylamide gel and scanned and recorded on a Fuji FLA- 2000 phosphorimager. The ability of the DNA polymerases from the thermophilic archaea Pyrococcus furiosus ( Pfu) and the test mutant Pfu DNA polymerase to extend a primer across a template containing a single deoxyuridine can then be determined and directly compared.
IV. EXPRESSION OF WILD-TYPE OR MUTANT ENZYMES ACCORDING TO THE INVENTION
Methods known in the art may be applied to express and isolate the mutated forms of DNA polymerase (i.e., the second enzyme) according to the invention. The methods described here can be also applied for the expression of wild-type enzymes useful (e.g., the first enzyme) in the invention. Many bacterial expression vectors contain sequence elements or combinations of sequence elements allowing high level inducible expression of the protein encoded by a foreign sequence. For example, as mentioned above, bacteria expressing an integrated inducible form of the T7 RNA polymerase gene may be transformed with an expression vector bearing a mutated DNA polymerase gene linked to the T7 promoter. Induction of the T7 RNA polymerase by addition of an appropriate inducer, for example, isopropyl-β-D-thiogalactopyranoside (IPTG) for a lac-inducible promoter, induces the high level expression of the mutated gene from the T7 promoter.
Appropriate host strains of bacteria may be selected from those available in the art by one of skill in the art. As a non-limiting example, E. coli strain BL-21 is commonly used for expression of exogenous proteins since it is protease deficient relative to other strains of E. coli. BL-21 strains bearing an inducible T7 RNA polymerase gene include WJ56 and ER2566 (Gardner & Jack, 1999, supra). For situations in which codon usage for the particular polymerase gene differs from that normally seen in E. coli genes, there are strains of BL-21 that are modified to carry tRNA genes encoding tRNAs with rarer anticodons (for example, argU,
35 ileY, leuW, and proL tRNA genes), allowing high efficiency expression of cloned protein genes, for example, cloned archaeal enzyme genes (several BL21 -CODON PLUSTM cell strains carrying rare-codon tRNAs are available from Stratagene, for example).
There are many methods known to those of skill in the art that are suitable for the purification of a modified DNA polymerase of the invention. For example, the method of Lawyer et al. (1993, PCR Meth. & Ann. 2: 275) is well suited for the isolation of DNA polymerases expressed in E. coli, as it was designed originally for the isolation of Taq polymerase. Alternatively, the method of Kong et al. (1993, J. Biol. Chem. 268: 1965, incorporated herein by reference) may be used, which employs a heat denaruration step to destroy host proteins, and two column purification steps (over DEAE-Sepharose and heparin- Sepharose columns) to isolate highly active and approximately 80%> pure DNA polymerase. Further, DNA polymerase mutants may be isolated by an ammonium sulfate fractionation, followed by Q Sepharose and DNA cellulose columns, or by adsoφtion of contaminants on a HiTrap Q column, followed by gradient elution from a HiTrap heparin column.
The invention further provides for mutant V93R, V93E, V93D, V93K or V93N Pfu DNA polymerases that contain one or more additional mutations with improved reverse transcriptase activity.
The invention further provides for compositions in which V93 archaeal or Pfu mutant DNA polymerases with reduced base analog detection activity contain additional mutations that reduced DNA polymerization activity for example, G387P (polymerase minus) or 3 '-5' exonuclease activity, for example, D141A/E143A (3'-5' exonuclease minus) The invention further provides for compositions comprising mutant archeal polymerases that are chimeras, as described herein.
The invention provides for compositions wherein n the archael or Pfu mutant DNA polymerases are mixed as described in Table 2.
Figure imgf000036_0001
36
Figure imgf000037_0001
The invention further provides for compositions in which any of the archaeal or Pfu mutant DNA polymerases with reduced base analog detection activity are mixed with either a.) Pfu G387P (polymerase minus)
37 b) Taq polymerase
c) PEF
d) a Pfu polymerase chimera (as described in WO 01/92501 Al or Pavlov et al. supra)
e) a mutant archael Pfu polymerase chimera as described herein
f) Pfu g387P/V93R double mutant.
The invention also provides for mixtures of V93 mutant archaeal or Pfu DNA polymerases, preferably V93R, with additional compositions that include, but are not limited to:
A.) blended with PCR enhancing factor (PEF)
B. ) blended with Taq (at any ratio, but preferably a higher ratio of Pfu mutant to Taq) with or without PEF
C.) blended with Pfu G387P, Pfu G387P/V93R, G387P/V93E, Pfu G387P/V93D, Pfu G387P/N93K or G387P/N93Ν mutants (for higher fidelity PCR)
D.) blended with Thermus DNA ligase and FEN-1 (for multisite site-directed mutagenesis)
E) blended with a Pfu polymerase chimera (as described in WO 01/92501 Al or Pavlov et al. supra) or a mutant archael Pfu polymerase chimera as described herein
F.) blended with additives like antibodies for increased specificity (for hot start PCR, described in Borns et al. (2001) Strategies 14, pages 5-8 and also in manual accompanying commercially available kit, Stratagene Catalogue # 600320), DMSO for GC-rich PCR or single stranded DNA binding protein for higher specificity (commercially available, Stratagene Catalog # 600201)
The invention also contemplates a mixture comprising the combination of a mutant archael DNA polymerase of the invention, dUTP and uracil N-glycosylase.
The invention further provides for the archaeal DNA polymerases of the invention with reduced base analog detection activity be combined with the Easy A composition that contains a blend of Taq (5U/ul), recombinant PEF (4U/ul), and Pfu G387P/V93R, E, N, D, K or N mutant (40ng/ul) as disclosed in the pending U.S. patent application Serial No.: 10/035,091 (Hogrefe, et
38 al; filed: December 21, 2001); the pending U.S. patent application Serial No.: 10/079,241 (Hogrefe, et al.; filed February 20, 2002); the pending U.S. patent application Serial No.: 10/208,508 (Hogrefe et al.; filed July 30, 2002); and the pending U.S. patent application Serial No.: 10/227,110 (Hogrefe et al.; filed August 23, 2002), the contents of which are hereby incoφorated in their entirety. With cloned archaeal DNA polymerase with reduced base analog detection activity at 2.5U/ul i.e. ~20-50ng per ul, the ratio of Taq:Pfu is preferably 1 : 1 or more preferably 2: 1 or more.
V. APPLICATIONS OF THE SUBJECT INVENTION
h one aspect, the invention provides a method for DNA synthesis using the compositions of the subject invention. Typically, synthesis of a polynucleotide requires a synthesis primer, a synthesis template, polynucleotide precursors for incoφoration into the newly synthesized polynucleotide, (e.g. dATP, dCTP, dGTP, dTTP), and the like. Detailed methods for carrying out polynucleotide synthesis are well known to the person of ordinary skill in the art and can be found, for example, in Molecular Cloning second edition, Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).
A. APPLICATION IN AMPLIFICATION REACTIONS
"Polymerase chain reaction" or "PCR" refers to an in vitro method for amplifying a specific polynucleotide template sequence. The technique of PCR is described in numerous publications, including, PCR: A Practical Approach, M. J. McPherson, et al., IRL Press (1991 ), PCR Protocols: A Guide to Methods and Applications, by Innis, et al., Academic Press (1990), and PCR Technology: Principals and Applications for DNA Amplification, H. A. Erlich, Stockton Press (1989). PCR is also described in many U.S. Patents, including U.S. Patent Nos. 4,683,195; 4,683,202; 4,800,159; 4,965,188; 4,889,818; 5,075,216; 5,079,352; 5,104,792; 5,023,171; 5,091,310; and 5,066,584, each of which is herein incoφorated by reference.
For ease of understanding the advantages provided by the present invention, a summary of PCR is provided. The PCR reaction involves a repetitive series of temperature cycles and is typically performed in a volume of 50-100 μl. The reaction mix comprises dNTPs (each of the four deoxynucleotides dATP, dCTP, dGTP, and dTTP), primers, buffers, DNA polymerase, and polynucleotide template. PCR requires two primers that hybridize with the double-stranded
39 target polynucleotide sequence to be amplified. In PCR, this double-stranded target sequence is denatured and one primer is annealed to each strand of the denatured target. The primers anneal to the target polynucleotide at sites removed from one another and in orientations such that the extension product of one primer, when separated from its complement, can hybridize to the other primer. Once a given primer hybridizes to the target sequence, the primer is extended by the action of a DNA polymerase. The extension product is then denatured from the target sequence, and the process is repeated.
hi successive cycles of this process, the extension products produced in earlier cycles serve as templates for DNA synthesis. Beginning in the second cycle, the product of amplification begins to accumulate at a logarithmic rate. The amplification product is a discrete double-stranded DNA molecule comprising: a first strand which contains the sequence of the first primer, eventually followed by the sequence complementary to the second primer, and a second strand which is complementary to the first strand.
Due to the enormous amplification possible with the PCR process, small levels of DNA carryover from samples with high DNA levels, positive control templates or from previous amplifications can result in PCR product, even in the absence of puφosefully added template DNA. If possible, all reaction mixes are set up in an area separate from PCR product analysis and sample preparation. The use of dedicated or disposable vessels, solutions, and pipettes (preferably positive displacement pipettes) for RNA/DNA preparation, reaction mixing, and sample analysis will minimize cross contamination. See also Higuchi and Kwok, 1989, Nature, 339:237-238 and Kwok, and Orrego, in: frmis et al. eds., 1990, PCR Protocols: A Guide to Methods and Applications, Academic Press, Inc., San Diego, Calif, which are incoφorated herein by reference.
The enzymes provided herein are also useful for dUTP/UNG cleanup methods that require PCR enzymes that incoφorate dUTP (Longo et al., Supra).
In addition, Mutations that reduce uracil sensitivity are expected to improve the success rate of long-range amplification (higher yield, longer targets amplified). It is expected that mutations eliminating uracil detection will also increase the error rate of archaeal DNA polymerases. If uracil stalling contributes to fidelity by preventing synthesis opposite promutagenic uracil (arising from cytosine deamination), then uracil insensitive mutants are
40 likely to exhibit a higher GC--»TA transition mutation rate. It is therefore envisioned that optimal PCR performance and fidelity may be achieved by adding to uracil-insensitive archaeal DNA polymerase mutants either thermostable exonucleases (e.g., polymerase reduced proofreading DNA polymerases, exonuclease in) or additional mutations that increase fidelity.
1. THERMOSTABLE ENZYMES
For PCR amplifications, the enzymes used in the invention are preferably thermostable. As used herein, "thermostable" refers to an enzyme which is stable to heat, is heat resistant, and functions at high temperatures, e.g., 50 to
Figure imgf000041_0001
The thermostable enzyme according to the present invention must satisfy a single criterion to be effective for the amplification reaction, i.e., the enzyme must not become irreversibly denatured (inactivated) when subjected to the elevated temperatures for the time necessary to effect denaturation of double-stranded polynucleotides. By "irreversible denaturation" as used in this connection, is meant a process bringing a pennanent and complete loss of enzymatic activity. The heating conditions necessary for denaturation will depend, e.g., on the buffer salt concentration and the length and nucleotide composition of the polynucleotides being denatured, but typically range from 85 C? for shorter polynucleotides, to 105°C for a time depending mainly on the temperature and the polynucleotide length, typically from 0.25 minutes for shorter polynucleotides, to 4.0 minutes for longer pieces of DNA. Higher temperatures may be tolerated as the buffer salt concentration and/or GC composition of the polynucleotide is increased. Preferably, the enzyme will not become irreversibly denatured at 90 to 100°C. An enzyme that does not become irreversibly denatured, according to the invention, retains at least 10%, or at least 25%, or at least 50% or more function or activity during the amplification reaction.
2. PCR REACTION MIXTURE
hi addition to the subject enzyme mixture, one of average skill in the art may also employ other PCR parameters to increase the fidelity of synthesis/amplification reaction. It has been reported PCR fidelity may be affected by factors such as changes in dNTP concentration, units of enzyme used per reaction, pH, and the ratio of Mg2+ to dNTPs present in the reaction (Mattila et al., 1991, supra).
41 Mg2+ concentration affects the annealing of the oligonucleotide primers to the template DNA by stabilizing the primer-template interaction, it also stabilizes the replication complex of polymerase with template-primer. It can therefore also increases non-specific annealing and produced undesirable PCR products (give's multiple bands in gel). When non-specific amplification occurs, Mg2+ may need to be lowered or EDTA can be added to chelate Mg2+ to increase the accuracy and specificity of the amplification.
Other divalent cations such as Mn2+, or Co2+ can also affect DNA polymerization. Suitable cations for each DNA polymerase are known in the art (e.g., in DNA Replication 2nd edition, supra). Divalent cation is supplied in the form of a salt such MgCl , Mg(OAc)2, MgSO4, MnCl2, Mn(OAc)2, or MnSO . Usable cation concentrations in a Tris-HCl buffer are for MnCl2 from 0.5 to 7 mM, preferably, between 0.5 and 2 mM, and for MgCl from 0.5 to 10 mM. Usable cation concentrations in a Bicine/KOAc buffer are from 1 to 20 mM for Mn(OAc)2, preferably between 2 and 5 mM.
Monovalent cation required by DNA polymerase may be supplied by the potassium, sodium, ammonium, or lithium salts of either chloride or acetate. For KCI, the concentration is between 1 and 200 mM, preferably the concentration is between 40 and 100 mM, although the optimum concentration may vary depending on the polymerase used in the reaction.
Deoxyribonucleotide triphosphates (dNTPs) are added as solutions of the salts of dATP, dCTP, dGTP, dUTP, and dTTP, such as disodium or lithium salts. In the present methods, a final concentration in the range of 1 μM to 2 mM each is suitable, and 100-600 μM is preferable, although the optimal concentration of the nucleotides may vary in the PCR reaction depending on the total dNTP and divalent metal ion concentration, and on the buffer, salts, particular primers, and template. For longer products, i.e., greater than 1500 bp, 500 μM each dNTP may be preferred when using a Tris-HCl buffer.
dNTPs chelate divalent cations, therefore amount of divalent cations used may need to be changed according to the dNTP concentration in the reaction. Excessive amount of dNTPs (e.g., larger than 1.5 mM) can increase the error rate and possibly inhibit DNA polymerases. Lowering the dNTP (e.g., to 10-50 μM) may therefore reduce error rate. PCR reaction for amplifying larger size template may need more dNTPs.
42 One suitable buffering agent is Tris-HCl, preferably pH 8.3, although the pH may be in the range 8.0-8.8. The Tris-HCl concentration is from 5-250 mM, although 10-100 mM is most preferred. A preferred buffering agent is Bicine-KOH, preferably pH 8.3, although pH may be in the range 7.8-8.7. Bicine acts both as a pH buffer and as a metal buffer. Tricine may also be used.
PCR is a very powerful tool for DNA amplification and therefore very little template DNA is needed. However, in some embodiments, to reduce the likelihood of error, a higher DNA concentration may be used, though too many templates may increase the amount of contaminants and reduce efficiency.
Usually, up to 3 μM of primers may be used, but high primer to template ratio can results in non-specific amplification and primer-dimer formation. Therefore it is usually necessary to check primer sequences to avoid primer-dimer formation.
The invention provides for Pfu V93R, V93E, V93K , V93D , or V93N DNA polymerases with reduced uracil detection activity that enhance PCR of GC rich DNA templates by minimizing the effect of cytosine deamination in the template and by allowing the use of higher denaturation times and denaturation temperatures.
3. CYCLING PARAMETERS
Denaturation time may be increased if template GC content is high. Higher annealing temperature may be needed for primers with high GC content or longer primers. Gradient PCR is a useful way of determining the annealing temperature. Extension time should be extended for larger PCR product amplifications. However, extension time may need to be reduced whenever possible to limit damage to enzyme.
The number of cycle can be increased if the number of template DNA is very low, and decreased if high amount of template DNA is used.
4. PCR ENHANCING FACTORS AND ADDITIVES
PCR enhancing factors may also be used to improve efficiency of the amplification. As used herein, a "PCR enhancing factor" or a "Polymerase Enhancing Factor" (PEF) refers to a complex or protein possessing polynucleotide polymerase enhancing activity (Hogrefe et al.,
43 1997, Strategies 10::93-96; and U.S. Patent No. 6,183,997, both of which are hereby incorporated by references). For Pfu DNA polymerase, PEF comprises either P45 in native form (as a complex of P50 and P45) or as a recombinant protein. In the native complex of Pfu P50 and P45, only P45 exhibits PCR enhancing activity. The P50 protein is similar in structure to a bacterial flavoprotein. The P45 protein is similar in structure to dCTP deaminase and dUTPase, but it functions only as a dUTPase converting dUTP to dUMP and pyrophosphate. PEF, according to the present invention, can also be selected from the group consisting of: an isolated or purified naturally occurring polymerase enhancing protein obtained from an archeabacteria source (e.g., Pyrococcus furiosus); a wholly or partially synthetic protein having the same amino acid sequence as Pfu P45, or analogs thereof possessing polymerase enhancing activity; polymerase- enhancing mixtures of one or more of said naturally occurring or wholly or partially synthetic proteins; polymerase-enhancing protein complexes of one or more of said naturally occurring or wholly or partially synthetic proteins; or polymerase-enhancing partially purified cell extracts containing one or more of said naturally occurring proteins (U.S. Patent No. 6,183,997, supra). The PCR enhancing activity of PEF is defined by means well lαiown in the art. The unit definition for PEF is based on the dUTPase activity of PEF (P45), which is determined by monitoring the production of pyrophosphate (PPi) from dUTP. For example, PEF is incubated with dUTP (lOmM dUTP in lx cloned Pfu PCR buffer) during which time PEF hydrolyzes dUTP to dUMP and PPi. The amount of PPi formed is quantitated using a coupled enzymatic assay system that is commercially available from Sigma (#P7275). One unit of activity is functionally defined as 4.0 nmole of PPi formed per hour (at 85°C).
Other PCR additives may also affect the accuracy and specificity of PCR reaction. EDTA less than 0.5 mM may be present in the amplification reaction mix. Detergents such as Tween-20™ and Nonidet™ P-40 are present in the enzyme dilution buffers. A final concentration of non-ionic detergent approximately 0.1% or less is appropriate, however, 0.01- 0.05% is preferred and will not interfere with polymerase activity. Similarly, glycerol is often present in enzyme preparations and is generally diluted to a concentration of 1-20% in the reaction mix. Glycerol (5-10%), formamide (1-5%) or DMSO (2-10%) can be added in PCR for template DNA with high GC content or long length (e.g., > lkb). These additives change the Tm (melting temperature) of primer-template hybridization reaction and the thermostability of polymerase enzyme. BSA (up to 0.8 μg/μl) can improve efficiency of PCR reaction. Betaine (0.5-2M) is also useful for PCR over high GC content and long fragments of DNA.
44 Tetramethylammonium chloride (TMAC, >50mM), Tetraethylammonium chloride (TEAC), and Trimethlamine N-oxide (TMANO) may also be used. Test PCR reactions may be performed to determine optimum concentration of each additive mentioned above.
The invention provides for additive including, but not limited to antibodies (for hot start PCR) and ssb (higher specificity). The invention also contemplates mutant archael DNA polymerases in combination with accessory factors, for example as described in U.S. 6,333,158, and WO 01/09347 A2, hereby incorporated by reference in its entirety.
Various specific PCR amplification applications are available in the art (for reviews, see for example, Erlich, 1999, Rev Immuno enet., 1:127-34; Prediger 2001, Methods Mol. Biol. 160:49-63; Jurecic et al., 2000, Curr. Opin. Microbiol. 3:316-21; Triglia, 2000, Methods Mol. Biol. 130:79-83; MaClelland et al., 1994, PCR Methods Appl. 4.S66-81; Abramson and Myers, 1993, Current Opinion in Biotechnology 4:41-47; each of which is incoφorated herein by references).
The subject invention can be used in PCR applications including, but are not limited to, i) hot-start PCR which reduces non-specific amplification; ii) touch-down PCR which starts at high annealing temperature, then decreases annealing temperature in steps to reduce non-specific PCR product; iii) nested PCR which synthesizes more reliable product using an outer set of primers and an inner set of primers; iv) inverse PCR for amplification of regions flanking a known sequence. In this method, DNA is digested, the desired fragment is circularized by ligation, then PCR using primer complementary to the known sequence extending outwards; v) AP-PCR (arbitrary primed)/RAPD (random amplified polymorphic DNA). These methods create genomic fingeφrints from species with little-known target sequences by amplifying using arbitrary ohgonucleotides; vi) RT-PCR which uses RNA-directed DNA polymerase (e.g., reverse transcriptase) to synthesize cDNAs which is then used for PCR. This method is extremely sensitive for detecting the expression of a specific sequence in a tissue or cells. It may also be use to quantify mRNA transcripts; vii) RACE (rapid amplification of cDNA ends). This is used where information about DNA/protein sequence is limited. The method amplifies 3' or 5' ends of cDNAs generating fragments of cDNA with only one specific primer each (plus one adaptor primer). Overlapping RACE products can then be combined to produce full length cDNA; viii) DD-PCR (differential display PCR) which is used to identify differentially expressed genes in different tissues. First step in DD-PCR involves RT-PCR, then amplification is performed using
45 short, intentionally nonspecific primers; ix) Multiplex-PCR in which two or more unique targets of DNA sequences in the same specimen are amplified simultaneously. One DNA sequence can be use as control to verify the quality of PCR; x) Q/C-PCR (Quantitative comparative) which uses an internal control DNA sequence (but of different size) which compete with the target DNA (competitive PCR) for the same set of primers; xi) Recusive PCR which is used to synthesize genes. Ohgonucleotides used in this method are complementary to stretches of a gene (>80 bases), alternately to the sense and to the antisense strands with ends overlapping (~20 bases); xii) Asymmetric PCR; xiii) In Situ PCR; xiv) Site-directed PCR Mutagenesis.
It should be understood that this invention is not limited to any particular amplification system. As other systems are developed, those systems may benefit by practice of this invention.
B . APPLICATION IN DIRECT CLONING OF PCR AMPLIFIED PRODUCT
It is understood that the amplified product produced using the subject enzyme can be cloned by any method known in the art. In one embodiment, the invention provides a composition which allows direct cloning of PCR amplified product.
The most common method for cloning PCR products involves incoφoration of flanking restriction sites onto the ends of primer molecules. The PCR cycling is carried out and the amplified DNA is then purified, restricted with an appropriate endonuclease(s) and ligated to a compatible vector preparation.
A method for directly cloning PCR products eliminates the need for preparing primers having restriction recognition sequences and it would eliminate the need for a restriction step to prepare the PCR product for cloning. Additionally, such method would preferably allow cloning PCR products directly without an intervening purification step.
U.S. Patent Nos. 5,827,657 and 5,487,993 (hereby incoφorated by their entirety) disclose methods for direct cloning of PCR products using a DNA polymerase which takes advantage of the single 3'-deoxy-adenosine monophosphate (dAMP) residues attached to the 3' termini of PCR generated nucleic acids. Vectors are prepared with recognition sequences that afford single 3'- terminal deoxy-thymidine monophosphate (dTMP) residues upon reaction with a suitable restriction enzyme. Thus, PCR generated copies of genes can be directly cloned into the vectors without need for preparing primers having suitable restriction sites therein.
46 Taq DNA polymerase exhibits terminal transferase activity that adds a single dATP to the 3' ends of PCR products in the absence of template. This activity is the basis for the TA cloning method in which PCR products amplified with Taq are directly ligated into vectors containing single 3'dT overhangs. Pfu DNA polymerase, on the other hand, lacks terminal transferase activity, and thus produces blunt-ended PCR products that are efficiently cloned into blunt-ended vectors.
In one embodiment, the invention provides for a PCR product, generated in the presence of a mutant DNA polymerase with reduced uracil detection activity, that is subsequently incubated with Taq DNA polymerase in the presence of dATP at 72°C for 15-30 minutes. Addition of 3 '-dAMP to the ends of the amplified DNA product then permits cloning into TA cloning vectors according to methods that are well known to a person skilled in the art.
C. APPLICATION LN DNA SEQUENCING
The invention further provides for dideoxynucleotide DNA sequencing methods using thermostable DNA polymerases having a reduced base analog detection activity to catalyze the primer extension reactions. Methods for dideoxynucleotide DNA sequencing are well known in the art and are disclosed in U.S. Patent Nos. 5,075,216, 4,795,699 and 5,885,813, the contents of which are hereby incoφorated in their entirety.
D. APPLICATION IN MUTAGENESIS
The mutant archaeal DNA polymerases of the invention, preferably Y93R Pfu DNA polymerase, also provide enhanced efficacy for PCR-based or linear amplification-based mutagenesis. The invention therefore provides for the use of the mutant archaeal DNA polymerases with reduced base analog detection activity for site-directed mutagenesis and their incoφoration into commercially available kits, for example, QuikChange Site-directed Mutagenesis, QuikChange Multi-Site-Directed Mutagenesis (Stratagene). Site-directed mutagenesis methods and reagents are disclosed in the pending U.S. Patent Application No.
10/198,449 (Hogrefe et al; filed July 18, 2002), the contents of which are hereby incoφorated in its entirety. The invention also encompasses Mutazyme (exo fu in combination with PEF, GeneMoφh Kit). The GeneMoφh kits are disclosed in the pending U.S. Patent Application No.: 10/154,206 (filed May 23, 2002), the contents of which are hereby incoφorated in its entirety.
47 All of the mutant archaeal DNA polymerases contemplated herein are useful for PCR and RT-PCR.
VI. KITS
The invention herein also contemplates a kit format which comprises a package unit having one or more containers of the subject composition and in some embodiments including containers of various reagents used for polynucleotide synthesis, including synthesis in PCR. The kit may also contain one or more of the following items: polynucleotide precursors, primers, buffers, instructions, and controls. Kits may include containers of reagents mixed together in suitable proportions for performing the methods in accordance with the invention. Reagent containers preferably contain reagents in unit quantities that obviate measuring steps when performing the subject methods.
The invention contemplates a kit comprising a combination of a mutant archael DNA polymerase of the invention, dUTP and uracil N-glycosylase.
VII. EXAMPLES
Example 1.
Construction of Pfu DNA Polymerase Mutants with Reduced Uracil Detection
Mutations were introduced into Pfu DNA polymerase that were likely to reduce uracil detection, while having minimal effects on polymerase or proofreading activity. The DNA template used for mutagenesis contained the Pfu pol gene, cloned into pBluescript (pF72 clone described in US 5,489,523). Point mutations were introduced using the QuikChange or the
QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene). With the QuikChange kit, point mutations are introduced using a pair of mutagenic primers (V93E, H, K, R, and N). With the QuikChange Multi kit, specific point mutations are introduced by incoφorating one phosphorylated mutagenic primer or by selecting random mutants from a library of Pfu V93 variants, created by incoφorating a degenerate codon (N93G and L). Clones were sequenced to identify the incoφorated mutations.
48 Results. Naline 93 in Pfu DΝA polymerase was substituted with Glycine (G), asparagine (Ν), arginine [R], glutamic acid (E), histidine (H), and leucine (L) using the QuikChange primer sequences listed in Figure 1.
Example 2.
Preparation of Bacterial Extracts Containing Mutant Pfu DΝA Polymerases
Plasmid DΝA was purified with the StrataPrep® Plasmid Miniprep Kit (Stratagene), and used to transform BL26-CodonPlus-RIL cells. Ampicillin resistant colonies were grown up in 1- 5 liters of LB media containing Turbo Amp™ (lOOμg/μl) and chloramphenicol (30μg/μl) at 30°C with moderate aeration. The cells were collected by centrifugation and stored at -80°C until use.
Cell pellets (12-24 grams) were resuspended in 3 volumes of lysis buffer (buffer A: 50mM Tris HCl (pH 8.2), ImM EDTA, and lOmM βME). Lysozyme (1 mg/g cells) and PMSF (ImM) were added and the cells were lysed for 1 hour at 4°C. The cell mixture was sonicated, and the debris removed by centrifugation at 15,000 rpm for 30 minutes (4°C). Tween 20 and Igepal CA-630 were added to final concentrations of 0.1 % and the supernatant was heated at 72°C for 10 minutes. Heat denatured E. coli proteins were then removed by centrifugation at 15,000 φm for 30 minutes (4°C).
Example 3.
Assessment of dUTP Incorporation by PCR
Partially-purified Pfu mutant preparations (heat-treated bacterial extracts) were assayed for dUTP incoφoration during PCR. In this example, a 2.3kb fragment containing the Pfu pol gene was from plasmid DΝA using PCR primers: (ΕPfuLΪC) 5'- gACgACgACAAgATgATTTTAgATgTggAT-3' (SEQ ID NO: n and (RPfuLΪC) 5'- ggAACAAgACCCgTCTAggATTTTTTAATg-3' (SEQ ID NO: 2). Amplification reactions consisted of lx cloned Pfu PCR buffer, 7 ng plasmid DNA, lOOng of each primer, 2.5U of Pfu mutant (or wild type Pfu), and 200μM each dGTP, dCTP, and dATP. To assess relative dUTP incoφoration, various amounts of dUTP (0-400μM) and/or TTP (0-200μM) were added to the
PCR reaction cocktail. The amplification reactions were cycled as described in example 6.
49 Results. Partially-purified preparations of the N93E and N93R mutants showed improved dUTP incoφoration compared to wild type Pfu (Figure 2a). Each mutant successfully amplified a 2.3kb target in the presence of 200μM dUTP (plus 200μM each TTP, dATP, dCTP, dGTP). In contrast, extracts containing the Pfu N93Ν, N93G, N93H, and N93L mutants showed little-to-no amplification in the presence of 200μM dUTP, similar to wild type Pfu (data not shown). Additional testing showed that the Pfu N93R mutant extract amplified the 2.3kb target in the presence of 100% dUTP (0% TTP)(Figure 2b).
Example 4.
Purification of Pfu DΝA Polymerase Mutants
Bacterial expression of Pfu mutants. Pfu mutants can be purified as described in US
5,489,523 (purification of the exo~ Pfu D141A/E143A DΝA polymerase mutant) or as follows. Clarified, heat-treated bacterial extracts were chromatographed on a Q-Sepharose™ Fast Flow column (~20ml column), equilibrated in buffer B (buffer A plus 0.1% (v/v) Igepal CA-630, and 0.1%) (v/v) Tween 20). Flow-through fractions were collected and then loaded directly onto a Pll Phosphocellulose column (~20ml), equilibrated in buffer C (same as buffer B, except pH 7.5). The column was washed and then eluted with a 0-0.7M KCI gradient/Buffer C. Fractions containing Pfu DΝA polymerase mutants (95kD by SDS-PAGE) were dialyzed overnight against buffer D (50mM Tris HCl (pH 7.5), 5mM βME, 5% (v/v) glycerol, 0.2% (v/v) Igepal CA-630, 0.2% (v/v) Tween 20, and 0.5M ΝaCl) and then applied to a Hydroxyapatite column (~5ml), equilibrated in buffer D. The column was washed and Pfu DΝA polymerase mutants were eluted with buffer D2 containing 400 mM KPO4, (pH 7.5), 5mM βME, 5% (v/v) glycerol, 0.2% (v/v) Igepal CA-630, 0.2% (v/v) Tween 20, and 0.5 M ΝaCl. Purified proteins were spin concentrated using Centricon YM30 devices, and exchanged into Pfu final dialysis buffer (50mM Tris-HCl (pH 8.2), O.lmM EDTA, ImM dithiothreitol (DTT), 50% (v/v) glycerol, 0.1% (v/v) Igepal CA- 630, and 0.1% (v/v) Tween 20).
Protein samples were evaluated for size, purity, and approximate concentration by SDS- PAGE using Tris-Glycine 4-20% acrylamide gradient gels. Gels were stained with silver stain or Sypro Orange (Molecular Probes). Protein concentration was determined relative to a BSA standard (Pierce) using the BCA assay (Pierce).
50 Results: Pfu mutants V93E and V93R were purified to -90% purity as determined by SDS-PAGE.
Example 5.
Determining Pfu Mutant Polymerase Unit Concentration and Specific Activity
The unit concentration of purified Pfu mutant preparations was determined by PCR. In this assay, a 500bp lacZ target is amplified from transgenic mouse genomic DNA using the forward primer: 5'-GACAGTCACTCCGGCCCG-3' (SEQ ID NO: 15 and the reverse primer: 5'-CGACGACTCGTGGAGCCC-3' (SEQ ID NO: 16). Amplification reactions consisted of lx cloned Pfu PCR buffer, lOOng genomic DNA, 150ng each primer, 200μM each dNTP, and varying amounts of either wild type Pfu (1.25U to 5U) or Pfu mutant (0.625-12.5U).
Amplification was performed using a RoboCycler® temperature cycler (Stratagene) with the following program: (1 cycle) 95°C for 2 minute; (30 cycles) 95°C for 1 minute, 58°C for 1 minute, 72°C for 1.5 minutes; (1 cycle) 72°C for 7 minutes. PCR products were examined on 1%> agarose gels containing ethidium bromide.
Results: Figure 3 contains a table listing the protein concentration, unit concentration, and specific activity of the purified Pfu V93R and V93E mutants.
The purified mutants were also re-assayed to assess dUTP incoφoration during PCR, according to the method described in Example 3. Figure 4 shows that the Pfu V93R mutant produces similar yields of the 500bp amplicon in the presence of 100%> TTP (lane 8), 50%) TTP:50% dUTP (lane 5), and 100% dUTP (lane 7), while the Pfu V93E mutant produces high yields in the presence of 100% TTP (lane 1) and 50% TTP:50% dUTP (lane 3) and lower yields in the presence of 100% dUTP (lane 4). In contrast, cloned Pfu can only amplify in the presence of 100% TTP (lane 12). These results indicate that the V93R and V93E mutations significantly improve dUTP incoφoration compared to wild type Pfu, and that the V93R mutation appear to be superior to the V93E mutation with respect to reducing uracil detection.
51 Example 6.
PCR Amplification with Purified Pfu Mutants
PCR reactions are conducted under standard conditions in cloned Pfu PCR buffer (lOmM KCI, lOmM (NH4)2SO4, 20mM Tris HCl (pH 8.8), 2mM Mg SO4, 0.1% Triton X-100, and lOOμg/ml BSA) with various amounts of cloned Pfu, PfuTurbo, or mutant Pfu DNA polymerase. For genomic targets 0.3-9kb in length, PCR reactions contained lOOng of human genomic DNA, 200μM each dNTP, and lOOng of each primer. For genomic targets >9kb in length, PCR reactions contained 250ng of human genomic DNA, 500μM each dNTP, and 200ng of each primer.
Table 3 - Cycling Conditions:
Figure imgf000052_0001
52
Figure imgf000053_0001
Results. Comparisons were carried out to determine if mutations that improve dUTP incoφoration, and hence reduce uracil detection, also improve PCR performance. In Figure 5, a 12kb target was amplified from human genomic DNA using 2 min per kb extension times. Under these conditions, 1U, 2U, and 4U of the Pfu V93R mutant successfully amplified the target, while the same amount of cloned Pfu could not. In comparison, PfuTurbo successfully amplified the long target; however, PCR product yields were significantly lower than those produced with the V93R mutant (Figure 5). Similar experiments employing 1 min per kb extension times showed that the 12kb target could be amplified in high yield with 5U and 10U of Pfu V93R and amplified in low yield with 10U of PfuTurbo (data not shown). In total, these results demonstrate that the V93R mutation dramatically improves the PCR performance of Pfu DNA polymerase.
Similar testing of the purified Pfu V93E mutant showed that although the V93E mutation improves dUTP incoφoration (Figure 2), this mutant is not robust enough to amplify the long 12kb amplicon when assayed using enzyme amounts between 0.6U and 10U (data not shown). In comparison, the product was successfully amplified using 10U of PfuTurbo (data not shown).
Figure 8 shows the results of additional Pfu mutations on dUTP incorporation. Pfu V93K and V93R mutants show significantly improved dUTP incoφoration compared to wild type Pfu. In contrast, the Pfu V93W, V93 V93W, V93Y and V93M mutants showed little to no improvement in dUTP incoφoration (see Figure 8A). In addition, both V93D and V93R mutants showed significantly improved dUTP incoφoration, compared to wild type (Figure 8B), while the V93N mutation showed a very small improvement in dTUP incoφoration (Figure 8C). The Pfu V93G mutation showed little to no improvement in dUTP incoφoration.
53 Example 7
Construction of Tgo, JDF-3, and KOD DNA Polymerase Mutants with Reduced Uracil Detection
Mutations were introduced at V93 into Tgo, JDF-3, and KOD DNA polymerases using the QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene). The invention describes the construction and evaluation of Pfu, Tgo, JDF-3 and KOD DNA polymerase mutants with reduced uracil detection. Based on the relatively high degree of identity between archaeal Family B-type DNA polymerases, six mutations were introduced that reduced uracil sensitivity in Pfu (V93Q, R, K, E, D, and N) into Tgo, JDF-3 and KOD DNA polymerase. Figure 10 lists the primer sequences employed. Clones were sequenced to identify the incoφorated mutations.
Valine 93 was substituted with Glutamine (Q), asparagine (N), arginine [R], lysine (K), glutamic acid (E), and aspartic acid (D).
Example 8
Construction of Pfu DNA Polymerase Deletion and Insertion Mutants
Insertions and deletions were introduced in Pfu DNA polymerase in the region around
V93 using the QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene). Figure 10 lists the primer sequences employed to generate useful mutations. Clones were sequenced to identify the incoφorated mutations.
The following Pfu mutants were constructed: deletions of residues 93, 92, 94, 92-93, 93- 94, and 92-94, and insertions of one, two, or three glycines between residues 92 and 93.
Example 9.
Preparation of Bacterial Extracts Containing Mutant DNA Polymerases
Plasmid DNA was purified with the StrataPrep® Plasmid Miniprep Kit (Stratagene), and used to transform BL26-CodonPlus-RIL cells. Ampicillin resistant colonies were grown up in 1- 5 liters of LB media containing Turbo Amp™ (lOOμg/μl) and chloramphenicol (30μg/μl) at
54 30°C with moderate aeration. The cells were collected by centrifugation and stored at -80°C until use.
Cell pellets (12-24 grams) were resuspended in 3 volumes of lysis buffer (buffer A: 50mM Tris HCl (pH 8.2), ImM EDTA, and lOmM βME). Lysozyme (1 mg/g cells) and PMSF (ImM) were added and the cells were lysed for 1 hour at 4°C. The cell mixture was sonicated, and the debris removed by centrifugation at 15,000 ipm for 30 minutes (4°C). Tween 20 and Igepal CA-630 were added to final concentrations of 0.1% and the supernatant was heated at 72°C for 10 minutes. Heat denatured E. coli proteins were then removed by centrifugation at 15,000 φra for 30 minutes (4°C).
Example 10.
Assessment of uracil sensitivity by PCR
Partially-purified archaeal DNA polymerase mutant preparations (heat-treated bacterial extracts) were assayed for uracil sensitivity by PCR. Table 4 below summarizes the PCR primer sequences and cycling conditions employed:
Table 4
Figure imgf000055_0001
55
Figure imgf000056_0001
To identify mutants with significant reduction in uracil sensitivity, fragments of 0.6kb, 0.97kb, 2.6kb, or 6kb were amplified from genomic or lambda DNA in the presence of 100% dUTP. PCRs employing <6kb targets consisted of lx PCR buffer (Stratagene's cloned Pfu buffer for Pfu mutants; Stratagene's 7αg2000 buffer for JDF-3 mutants; Roche's Tgo buffer for Tgo mutants; Novagen's KOD Hi Fi buffer for KOD mutants), 50ng lambda DNA or lOOng genomic DNA, lOOng of each primer, 2μl of mutant extract (or 2.5U of purified DNA polymerase), and 200μM each dGTP, dCTP, dATP and either 200μM dUTP or 200μM TTP. PCRs employing the 6kb genomic target consisted of 1.5x PCR buffer, 240ng genomic DNA, 200ng of each primer, 2μl of mutant extract (or 2.5U of purified DNA polymerase), and 500μM each dGTP, dCTP, dATP and either 500μM dUTP or 500μM TTP. The amplification reactions were cycled using a RoboCycler (0.6kb, 0.97kb) or PE9600 (2.6kb, 6kb) thermocycler as described in the Table above.
DNA polymerase mutant preparations were also assayed for dU-primer utilization during PCR. Amplification was performed in the absence (100% TTP) or presence (0% TTP) of dUTP to determine the relative degree of uracil insensitivity. In this example, a 970bp fragment was amplified from lambda DNA using dU-containing primers (FU/RU) or T-containing primers (FT/RT). Amplification reactions consisted of lx PCR buffer, 50ng lambda DNA, lOOng of each primer, 2μl of mutant extract (or 2.5U of purified DNA polymerase), and 200μM each dGTP,
56 dCTP, dATP and either 200μM dUTP or 200μM TTP. The amplification reactions were cycled on a Robocycler as described in Table 4.
Results.
KOD: Partially-purified preparations of KOD V93D, E, K, Q, and R showed reduced uracil sensitivity as evidenced by successful amplification of the 970bp amplicon using dU- containing primers and TTP (Figure 11). In contrast, wild type KOD and the KOD V93N mutant were unable to amplify using dU-primers and TTP. Only the KOD V93K and V93R mutants showed complete or nearly complete elimination of uracil sensitivity as shown by successful amplification in the presence of 100% dUTP (Figure 11). In contrast, the KOD V93D, E, and Q substitutions only partially reduce uracil sensitivity since these mutants are unable to amplify in the presence of 100% dUTP.
The rationale for determining relative uracil sensitivity using PCR assays is as follows. Successful amplification with dU-primers indicates that reduction in uracil sensitivity is sufficient to allow the mutants to polymerize past the nine uracils in the PCR primers (to create the primer annealing sites). However, mutants that successfully amplify in the presence of 100% dUTP, must lack or almost completely lack uracil sensitivity, since they must polymerize past numerous uracils (-230 uracils per strand; 925bp segment synthesized with 25% T content) in the template strand.
Tgo: Only the Tgo V93R mutant successfully amplified the 0.97kb amplicon in the presence of 100%) dUTP (Figure 12), indicating that the arginine substitution was most effective in reducing uracil sensitivity.
JDF-3: Only the JDF-3 V93R and V93K mutants successfully amplified the 0.97kb amplicon in the presence of 100% dUTP (Figure 12), indicating that the arginine and lysine substitutions were the most effective in reducing uracil sensitivity. Product yields with 100% dUTP were noticeably lower than yields with 100% TTP suggesting that in JDF-3, the V93R mutation does not completely eliminate uracil sensitivity (Figure 13). In contrast, Pfu V93R, Tgo V93R, and KOD V93R produce similar yields with TTP and dUTP, indicating that uracil sensitivity is almost completely eliminated.
57 Pfu deletions. We constructed deletions (92,92,94, 92-93, 93-94, 92-94) and insertions (1-3 glycines between D92 and V93) in Pfu centering around V93. Only the Pfu delta V93 and delta D92-V93-P94 mutants showed a reduction in uracil sensitivity (Figure 14). Based on amplification of 0.6kb, 2.6kb, and 6kb genomic amplicons, relative uracil sensitivity was determined as follows: (least sensitive/highest dTUP incoφoration) Pfu V93R > Pfu delta 93 > Pfu delta 92-94 > wild type Pfu (most sensitive/no dUTP incoφoration).
All patents, patent applications, and published references cited herein are hereby incoφorated by reference in their entirety. While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled ir the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
58

Claims

CLAIMSWhat is claimed is:
1. A mutant archaeal DNA polymerase with a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution, a Valine to Glutamic acid substitution, a Valine to Lysine substitution, a Valine to Aspartic acid substitution, a Valine to Glutamine substitution, or a Valine to Asparagine substitution.
2. A mutant archaeal DNA polymerase with a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution, a Valine to Glutamic acid substitution, a Valine to Lysine substitution, a Valine to Aspartic acid substitution, a Valine to Glutamine substitution, or a Valine to Asparagine substitution, wherein said mutant archaeal DNA polymerase is selected from the group consisting of: KOD, and JDF-3 DNA polymerase.
3. A mutant Pfu DNA polymerase with a reduced base analog detection activity, wherein said mutant Pfu DNA polymerase comprises a Valine to Arginine substitution or a Valine to
Glutamic acid substitution or a Valine to Lysine substitution or a Valine to Aspartic acid substitution, or a Valine to Asparagine substitution at amino acid position V93.
4. A mutant Tgo DNA polymerase with a reduced base analog detection activity, wherein said mutant Tgo DNA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution or a Valine to Lysine substitution or a Valine to Aspartic acid substitution, or a Valine to Asparagine substitution at amino acid position V93.
5. A mutant archaeal DNA polymerase with a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, and wherein said mutant archaeal DNA polymerase is selected from the group consisting of KOD and JDF-3 DNA polymerase.
6. The mutant DNA polymerases of claim 1, 2, or 3, wherein said mutant DNA polymerase further comprises a Glycine to Proline substitution at amino acid position 387 (G387P) that confers a reduced DNA polymerization phenotype to said mutant DNA polymerase.
59
7. The mutant DNA polymerases of claim 1, 2, or 3, wherein said mutant DNA polymerase further comprises an Aspartate to alanine substitution at amino acid 141 (D141 A) and a Glutamic acid to Alanine substitution at amino acid position 143 (D141 A/E143A) that renders said mutant DNA polymerase 3 '-5' exonuclease deficient.
8. The mutant DNA polymerases of claim 1, 2, or 3, wherein said mutant DNA polymerase is a chimera that further comprises a polypeptide that increases processivity and/or salt resistance.
9. A mutant archael DNA polymerase with a reduced base analog detection activity comprising a deletion or an insertion.
10. The mutant archaeal DNA polymerase of claim 9, wherein said polymerase comprises a deletion of one or more of D92, V93, and P94.
11. The mutant archaeal DNA polymerase of claim 9, wherein said polymerase comprises a Pfu DNA polymerase comprising a deletion at one or more of D92, V93, and P94.
12. An isolated polynucleotide comprising a nucleotide sequence encoding a mutant archaeal DNA polymerase having a reduced base analog detection activity, wherein said mutant archaeal
DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution, a Valine to Glutamic acid substitution, a Valine to Lysine substitution, a Valine to Aspartic acid substitution, a Valine to Glutamine substitution, or a Valine to Asparagine substitution.
13. An isolated polynucleotide comprising a nucleotide sequence encoding a mutant archaeal DNA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution, a Valine to Glutamic acid substitution, a Valine to Lysine substitution, a Valine to Aspartic acid substitution, a Valine to Glutamine substitution, or a Valine to Asparagine substitution, wherein said mutant archaeal DNA polymerase is selected from the group consisting of: KOD, and JDF-3 DNA polymerase.
14. An isolated polynucleotide comprising a nucleotide sequence encoding a mutant Tgo DNA polymerase with a reduced base analog detection activity, wherein said mutant Tgo DNA
60 polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution or a Valine to Lysine substitution or a Valine to Aspartic acid substitution, or a Valine to Asparagine substitution at amino acid position V93.
15. An isolated polynucleotide comprising a nucleotide sequence encoding a mutant Pfu DNA polymerase having a reduced base analog detection activity, wherein said mutant Pfu DNA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution or Valine to Lysine substitution or Valine to Aspartic acid substitution, or Valine to Asparagine substitution at amino acid position V93.
16. The isolated polynucleotide of claim 12 or 15, wherein said nucleotide sequence further comprises a Glycine to Proline substitution at amino acid position 387 (G387P) that confers a reduced DNA polymerization phenotype to said mutant archaeal DNA polymerase.
17. The isolated polynucleotide of claim 12 or 15 further comprising a nucleotide sequence encoding an Aspartate to alanine substitution at amino acid 141 (D141A) and a Glutamic acid to Alanine substitution at amino acid position 143 (El 43 A) that confers a 3 '-5' exonuclease deficient phenotype to said mutant archaeal DNA polymerase.
18. The isolated polynucleotide of claims 12 or 15, further comprising a nucleotide sequence encoding a chimera that further encodes a polypeptide that increases processivity and/or salt resistance.
19. An isolated polynucleotide comprising a nucleotide sequence encoding a mutant archael DNA polymerase comprising an insertion or a deletion.
20. The isolated polynucleotide of claim 19, wherein said mutant archaeal DNA polymerase comprises a deletion of the codons encoding one or more of D92, V93, and P94.
21. The isolated polynucleotide of claim 18, wherein said polynucleotide encodes a Pfu DNA polymerase comprising a deletion at one or more of D92, V93, or P94.
22. A composition comprising a mutant archaeal DNA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution or a Valine to
61 Glutamic acid substitution or Valine to Lysine substitution or Valine to Aspartic acid substitution or a Valine to Glutamine substitution or Valine to Asparagine substitution.
23. A composition comprising a mutant archaeal DNA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution or a Valine to
Glutamic acid substitution or Valine to Lysine substitution or Valine to Aspartic acid substitution or a Valine to Glutamine substitution or Valine to Asparagine substitution, wherein said mutant archaeal DNA polymerase is selected from the group consisting of: KOD, and JDF-3 DNA polymerase.
24. A composition comprising a mutant Pfu DNA polymerase having a reduced base analog detection activity, wherein said mutant Pfu DNA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution or Valine to Lysine substitution or Valine to Aspartic acid substitution or Valine to Asparagine substitution at amino acid position V93.
25. A composition comprising a mutant Tgo DNA polymerase with a reduced base analog detection activity, wherein said mutant Tgo DNA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution or a Valine to Lysine substitution or a Valine to Aspartic acid substitution, or a Valine to Asparagine substitution at amino acid position V93.
26. A composition comprising a mutant archeal DNA polymerase having a reduced base analog detection activity wherein said mutant DNA polymerase is a chimera that comprises a polypeptide that increases processivity and/or salt resistance.
27. A composition comprising a mutant archael DNA polymerase having reduced base analog detection activity wherein said mutant DNA polymerase comprises an insertion or a deletion.
28. The composition of claim 27, wherein said mutant DNA polymerase comprises a deletion of one or more of D92, V93, and P94.
29. The composition of claim 27, wherein said polymerase comprises a Pfu DNA polymerase comprising a deletion at one or more of D92, V93, or P94.
62
30. The composition of claim 22-27, further comprising Taq DNA polymerase.
31. The composition of claim 30, wherein said Taq DNA polymerase is at a 2 fold, 5 fold, 10 fold or 100 fold lower concentration than said mutant Pfu DNA polymerase.
32. The composition of claim 22, 23, 24, 25, 26, or 27 further comprising a PCR enhancing factor and/or an additive.
33. The composition of claim 22, 23, 24, 25, 26, or 27, further comprising a PfuG387P DNA polymerase ox a Pfu G387P/V93R or G387P/V93E or G387P/ N93 K, G387P/ N93 D, or G387P/ N93Ν double mutant DNA polymerase.
34. The composition of claim 22, 23, 24, 25, 26, or 27 further comprising Taq and a mutant archael DNA polymerase selected from the group consisting of G387P/V93R, G387P/V93D,
G387P/V93E, G387P/V93K and G387P/V93N.
35. The composition of claim 34, further comprising PEF.
36. The composition of claim 34, further comprising a PCR enhancing factor and/or an additive.
37. A composition comprising a Pfu V93R D141 A/E143A, a V93E/D141 A/E143A, a V93 K7D141A/E143A, a V93 D/D141 A/E143A, or a V93N/D141 A E143A triple mutant.
38. The composition of claim 37, further comprising a PCR enhancing factor and/or an additive.
39. The composition of claims 22, 23, 24, 25, 26, or 27, further comprising a Thermus DNA ligase or a FEN-1 nuclease.
40. The composition of claim 39, further comprising a PCR enhancing factor and/or an additive.
41. A kit comprising a mutant archaeal DNA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution or a Valine to Glutamic
63 acid substitution or Valine to Lysine substitution or Valine to Aspartic acid substitution Valine to Glutamine substitution or Valine to Asparagine substitution, and packaging materials therefor.
42. A kit comprising a mutant archaeal DNA polymerase with a reduced base analog detection activity wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution or a Valine to Glutamic acid substitution or Valine to Lysine substitution or Valine to Aspartic acid substitution Valine to Glutamine substitution or Valine to Asparagine substitution, and packaging materials therefor, and wherein said polymerase is selected from the group consisting of KOD and JDF-3.
43. A kit comprising a mutant Tgo DNA polymerase with a reduced base analog detection activity, wherein said mutant Tgo DNA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution or a Valine to Lysine substitution or a Valine to Aspartic acid substitution, or a Valine to Asparagine substitution at amino acid position V93, and packaging material therefore.
44. A kit comprising a mutant Pfu DNA polymerase having a reduced base analog detection activity, wherein said mutant Pfu DNA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution or Valine to Lysine substitution or Valine to Aspartic acid substitution or Valine to Asparagine substitution at amino acid position V93.
45. The kit of claim 41, 42, 43, or 44, further comprising a PCR enhancing factor and/or an additive.
46. The kit of claim 41, 42, 43, or 44, further comprising Taq DNA polymerase.
47. The kit of claim 46, wherein said Taq DNA polymerase is at a 2 fold, 5 fold, 10 fold or 100 fold lower concentration than said mutant Pfu DNA polymerase.
48. The kit of claim 47, further comprising a PCR enhancing factor and/or an additive.
49. The kit of claim 41, 42, 43, or 44 further comprising a Pfu G387 single mutant or a Pfu G387P/V93R or G387P/ V93 E or G387P/ V93 K or G387P/ V93 D or G387P/ V93N double mutant DNA polymerase.
50. The kit of claim 49, further comprising a PCR enhancing factor and/or an additive.
64
51. The kit of claim 41 , 42, 43 , or 44, further comprising Thermus DNA ligase, FEN- 1 nuclease or a PCR enhancing factor and/or an additive and packaging materials therefor.
52. A kit comprising a mutant archaeal DNA polymerase with a reduced base analog detection activity wherein said mutant DNA polymerase is a chimera that comprises a polypeptide that increases processivity and/or salt resistance.
53. The kit of claim 52, further comprising a PCR enhancing factor and/or an additive.
54. The kit of claim 52, further comprising Thermus DNA ligase, FEN-1 nuclease or a PCR enhancing factor and/or an additive and packaging materials therefor.
55. A method for DNA synthesis comprising:
(a) providing a mutant archaeal DNA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position N93, wherein said mutation is a Naline to Arginine substitution or a Naline to Glutamic acid substimtion or Naline to Lysine substitution or Naline to Aspartic acid substitution Naline to Glutamine substitution or Naline to Asparagine substitution; and
(b) contacting said enzyme with a nucleic acid template, wherein said enzyme permits DΝA synthesis.
56. A method for DΝA synthesis comprising:
(a) providing a mutant archaeal DΝA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DΝA polymerase comprises a mutation at position N93, wherein said mutation is a Naline to Arginine substitution or a Naline to Glutamic acid substitution or Naline to Lysine substitution or Naline to Aspartic acid substitution Naline to Glutamine substitution or Naline to Asparagine substitution, wherein said polymerase is selected from the group consisting of KOD and JDF-3; and
(b) contacting said enzyme with a nucleic acid template, wherein said enzyme permits DΝA synthesis.
65
57. A method for DNA synthesis comprising:
(a) providing a mutant Pfu DNA polymerase having a reduced base analog detection activity, wherein said mutant Pfu DNA polymerase comprises a mutation at position V93, wherein said mutation is a Naline to Arginine substitution or a Naline to Glutamic acid substitution or Naline to Lysine substitution or Naline to Aspartic acid substitution or Naline to Asparagine substitution; and
(b) contacting said enzyme with a nucleic acid template, wherein said enzyme permits DΝA synthesis.
58. A method for DΝA synthesis comprising:
(a) providing a mutant Tgo DΝA polymerase having a reduced base analog detection activity, wherein said mutant Tgo DΝA polymerase comprises a mutation at position N93, wherein said mutation is a Naline to Arginine substitution or a Naline to Glutamic acid substitution or Naline to Lysine substitution or Naline to Aspartic acid substitution or Naline to Asparagine substitution; and
(b) contacting said enzyme with a nucleic acid template, wherein said enzyme permits DΝA synthesis.
59. The method of claim 55-58, wherein said DΝA synthesis is performed in the presence of dUTP.
60. A method for cloning of a DΝA synthesis product comprising:
(a) providing a mutant archaeal DΝA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DΝA polymerase comprises a mutation at position N93, wherein said mutation is a Naline to Arginine substitution or a Naline to Glutamic acid substitution or Naline to Lysine substimtion or Naline to Aspartic acid substitution Naline to Glutamine substitution or Naline to Asparagine substitution; and
66 (b) contacting said mutant archaeal DNA polymerase with a nucleic acid template, wherein said mutant archaeal DNA polymerase permits DNA synthesis to generate a synthesized DNA product; and
(c) inserting said synthesized DNA product into a cloning vector.
61. A method for cloning of a DNA synthesis product comprising:
(a) providing a mutant archaeal DNA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position N93, wherein said mutation is a Naline to Arginine substitution or a Naline to Glutamic acid substitution or Naline to Lysine substitution or Naline to Aspartic acid substitution Naline to Glutamine substitution or Naline to Asparagine substitution, and wherein said polymerase is selected from the group consisting of KOD and JDF-3; and
(b) contacting said mutant archaeal DΝA polymerase with a nucleic acid template, wherein said mutant archaeal DΝA polymerase permits DΝA synthesis to generate a synthesized DΝA product; and
(c) inserting said synthesized DΝA product into a cloning vector.
62. A method for cloning of a DΝA synthesis product comprising:
(a) providing a mutant Pfu DΝA polymerase having a reduced base analog detection activity, wherein said mutant Pfu DΝA polymerase comprises a Naline to Arginine substitution or a Naline to Glutamic acid substitution or Naline to Lysine substitution or Naline to Aspartic acid substitution or Naline to Asparagine substitution at amino acid position N93;
(b) contacting said mutant Pfu DΝA polymerase with a nucleic acid template, wherein said mutant Pfu DΝA polymerase permits DΝA synthesis to generate a synthesized DΝA product; and
(c) inserting said synthesized DΝA product into a cloning vector.
67
63. A method for cloning of a DNA synthesis product comprising:
(a) providing a mutant Tgo DNA polymerase having a reduced base analog detection activity, wherein said mutant Tgo DNA polymerase comprises a Naline to Arginine substitution or a Naline to Glutamic acid substimtion or Naline to Lysine substimtion or Naline to Aspartic acid substitution or Naline to Asparagine substitution at amino acid position N93;
(b) contacting said mutant Tgo DΝA polymerase with a nucleic acid template, wherein said mutant Tgo DΝA polymerase permits DΝA synthesis to generate a synthesized DΝA product; and
(c) inserting said synthesized DΝA product into a cloning vector.
64. A method for sequencing DΝA comprising the step of:
(a) providing a mutant archaeal DΝA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DΝA polymerase comprises a mutation at position N93, wherein said mutation is a Naline to Arginine substitution or a Naline to Glutamic acid substitution or Naline to Lysine substitution or Naline to Aspartic acid substitution or Naline to Glutamine substimtion or Naline to Asparagine substimtion;
(b) generating chain terminated fragments from the DΝA template to be sequenced with said mutant archaeal DΝA polymerase in the presence of at least one chain terminating agent and one or more nucleotide triphosphates, and
(c) determining the sequence of said DΝA from the sizes of said fragments.
65. A method for sequencing DΝA comprising the step of:
(a) providing a mutant archaeal DΝA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DΝA polymerase comprises a mutation at position N93, wherein said mutation is a Naline to Arginine substitution or a Naline to Glutamic acid substitution or Naline to Lysine substitution or Naline to Aspartic acid substitution or Naline to Glutamine substitution or Naline to Asparagine substimtion, wherein said polymerase is selected from the group consisting of KOD and JDF-3;
68 (b) generating chain terminated fragments from the DNA template to be sequenced with said mutant archaeal DNA polymerase in the presence of at least one chain terminating agent and one or more nucleotide triphosphates, and
(c) determining the sequence of said DNA from the sizes of said fragments.
66. A method for sequencing DNA comprising the step of:
(a) providing a mutant Pfu DNA polymerase having a reduced base analog detection activity, wherein said mutant Pfu DNA polymerase comprises a Naline to Arginine substitution or a Naline to Glutamic acid substitution or Naline to Lysine substitution or Naline to Aspartic acid substitution or Valine to Asparagine substitution at amino acid position V93;
(b) generating chain terminated fragments from the DΝA template to be sequenced with said mutant Pfu DΝA polymerase in the presence of at least one chain terminating agent and one or more nucleotide triphosphates, and
(c) determining the sequence of said DΝA from the sizes of said fragments.
67. A method for sequencing DΝA comprising the step of:
(a) providing a mutant Tgo DΝA polymerase having a reduced base analog detection activity, wherein said mutant Tgo DΝA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution or Valine to Lysine substitution or Valine to Aspartic acid substitution or Valine to Asparagine substitution at amino acid position V93;
(b) generating chain terminated fragments from the DΝA template to be sequenced with said mutant Tgo DΝA polymerase in the presence of at least one chain tenrήnating agent and one or more nucleotide triphosphates, and
(c) determining the sequence of said DΝA from the sizes of said fragments.
68. The method of claim 55-58, 60-63 or 64-67, further providing Taq DΝA polymerase.
69. The method of claim 68, wherein said Taq DΝA polymerase is at a 2 fold, 5 fold, 10 fold or 100 fold lower concentration than said mutant Pfu DΝA polymerase.
69
70. The method of claim 55-58, 60-63, or 64-67, further comprising a PCR enhancing factor and/or an additive.
71. The method of claim 55-58, 60-63, or 64-67, further providing a Pfu G387P single mutant, a Pfu G387P/V93R or G387P/ V93 E or G387P/ V93 K or G387P/ V93 D or G387P/ V93N double mutant DNA polymerase or an archeal DNA polymerase mutant that is a chimera comprising a polypeptide that increases processivity and/or salt resistance.
72. The method of claim 71 , further comprising a PCR enhancing factor and/or an additive.
73. The method of claim 55-58, 60-63, or 64-67 further providing a Pfu D141A E143A double mutant DNA polymerase.
74. The method of claim 73, further comprising a PCR enhancing factor and/or an additive.
75. A method of linear or exponential PCR amplification for site-directed or random mutagenesis comprising the steps of: incubating a reaction mixture comprising a nucleic acid template, at least one PCR primer, and the polymerase of claim 1 under conditions which permit amplification of said nucleic acid template by said mutant DNA polymerase to produce a mutated amplified product.
76. The method of claim 75, further comprising a PCR enhancing factor and/or an additive.
70
PCT/US2003/033997 2002-10-25 2003-10-24 Dna polymerases with reduced base analog detection activity WO2004038007A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03809647A EP1578951A4 (en) 2002-10-25 2003-10-24 Dna polymerases with reduced base analog detection activity
JP2005501697A JP2006507012A (en) 2002-10-25 2003-10-24 DNA polymerase with reduced base analog detection activity
AU2003301590A AU2003301590A1 (en) 2002-10-25 2003-10-24 Dna polymerases with reduced base analog detection activity
CA002503038A CA2503038A1 (en) 2002-10-25 2003-10-24 Dna polymerases with reduced base analog detection activity

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/280,962 US20040081965A1 (en) 2002-10-25 2002-10-25 DNA polymerases with reduced base analog detection activity
US10/280,962 2002-10-25
US10/298,680 US20040091873A1 (en) 2002-10-25 2002-11-18 DNA polymerases with reduced base analog detection activity
US10/298,680 2002-11-18
US10/408,601 2003-04-07
US10/408,601 US20040086890A1 (en) 2002-10-25 2003-04-07 DNA polymerases with reduced base analog detection activity

Publications (2)

Publication Number Publication Date
WO2004038007A2 true WO2004038007A2 (en) 2004-05-06
WO2004038007A3 WO2004038007A3 (en) 2005-02-10

Family

ID=46205001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/033997 WO2004038007A2 (en) 2002-10-25 2003-10-24 Dna polymerases with reduced base analog detection activity

Country Status (5)

Country Link
EP (1) EP1578951A4 (en)
JP (1) JP2006507012A (en)
AU (1) AU2003301590A1 (en)
CA (1) CA2503038A1 (en)
WO (1) WO2004038007A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2084283A1 (en) * 2006-10-02 2009-08-05 Korea Ocean Research and Development Institute Mutant dna polymerases and their genes
US7960157B2 (en) 2002-12-20 2011-06-14 Agilent Technologies, Inc. DNA polymerase blends and uses thereof
WO2016077795A1 (en) * 2014-11-14 2016-05-19 Illumina, Inc. Polymerases
US9963686B2 (en) 2012-09-28 2018-05-08 Toyobo Co., Ltd. Modified DNA polymerase
CN114891761A (en) * 2022-03-25 2022-08-12 上海威高医疗技术发展有限公司 Tth DNA polymerase mutant and application thereof
CN116410952A (en) * 2022-12-28 2023-07-11 郑州玛特瑞斯生物科技有限公司 Mutant Taq DNA polymerase, coding gene, recombinant expression vector, recombinant bacterium and application thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5258512B2 (en) * 2008-10-30 2013-08-07 株式会社日立製作所 DNA polymerase mutant with enhanced exonuclease activity
CN102272319B (en) * 2009-01-08 2014-08-27 伯乐实验室公司 Methods and compositions for improving efficiency of nucleic acids amplification reactions
JP6428997B2 (en) * 2013-08-06 2018-11-28 東洋紡株式会社 Nucleic acid amplification method
JP6493209B2 (en) * 2013-08-06 2019-04-03 東洋紡株式会社 Nucleic acid amplification method
JP6968536B2 (en) * 2014-11-28 2021-11-17 東洋紡株式会社 Nucleic acid amplification reagent
WO2016104272A1 (en) * 2014-12-25 2016-06-30 東洋紡株式会社 Pcr method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333183B1 (en) * 1999-11-23 2001-12-25 Amersham Pharmacia Biotech, Inc. Dideoxynucleotide-triphosphate utilization by the hyper-thermophilic DNA polymerase from the archaeon Pyrococcus furiosus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4949585B2 (en) * 1999-10-29 2012-06-13 アジレント・テクノロジーズ・インク Compositions and methods using DNA polymerases
JP2001269188A (en) * 2000-03-11 2001-10-02 Roche Diagnostics Gmbh Dna polymerase b variant exhibiting enhanced performance in pcr
US6627424B1 (en) * 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
US7932070B2 (en) * 2001-12-21 2011-04-26 Agilent Technologies, Inc. High fidelity DNA polymerase compositions and uses therefor
GB0208768D0 (en) * 2002-04-17 2002-05-29 Univ Newcastle DNA polymerases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333183B1 (en) * 1999-11-23 2001-12-25 Amersham Pharmacia Biotech, Inc. Dideoxynucleotide-triphosphate utilization by the hyper-thermophilic DNA polymerase from the archaeon Pyrococcus furiosus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EVANS ET AL.: 'Improving dideoxynucleotide-triphosphate utilisation by the hyperthermophilic DNA polymerase from the archaeon Pyrococcus furiosus' NUCLEIC ACIDS RESEARCH vol. 28, no. 5, March 2000, pages 1059 - 1066, XP002164138 *
See also references of EP1578951A2 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960157B2 (en) 2002-12-20 2011-06-14 Agilent Technologies, Inc. DNA polymerase blends and uses thereof
EP2084283A1 (en) * 2006-10-02 2009-08-05 Korea Ocean Research and Development Institute Mutant dna polymerases and their genes
EP2084283A4 (en) * 2006-10-02 2009-11-25 Korea Ocean Res Dev Inst Mutant dna polymerases and their genes
US9963686B2 (en) 2012-09-28 2018-05-08 Toyobo Co., Ltd. Modified DNA polymerase
WO2016077795A1 (en) * 2014-11-14 2016-05-19 Illumina, Inc. Polymerases
CN108064278A (en) * 2014-11-14 2018-05-22 亿明达股份有限公司 Polymerase
US10329545B2 (en) 2014-11-14 2019-06-25 Illumina, Inc. Polymerases
US10995324B2 (en) 2014-11-14 2021-05-04 Illumina, Inc. Polymerases
CN114891761A (en) * 2022-03-25 2022-08-12 上海威高医疗技术发展有限公司 Tth DNA polymerase mutant and application thereof
CN114891761B (en) * 2022-03-25 2024-01-12 上海威高医疗技术发展有限公司 Tth DNA polymerase mutant and application thereof
CN116410952A (en) * 2022-12-28 2023-07-11 郑州玛特瑞斯生物科技有限公司 Mutant Taq DNA polymerase, coding gene, recombinant expression vector, recombinant bacterium and application thereof

Also Published As

Publication number Publication date
AU2003301590A1 (en) 2004-05-13
WO2004038007A3 (en) 2005-02-10
EP1578951A2 (en) 2005-09-28
EP1578951A4 (en) 2005-11-16
CA2503038A1 (en) 2004-05-06
JP2006507012A (en) 2006-03-02

Similar Documents

Publication Publication Date Title
EP1581630B1 (en) Dna polymerase blends and uses thereof
US8283148B2 (en) DNA polymerase compositions for quantitative PCR and methods thereof
EP1616033B1 (en) Dna polymerase fusions and uses thereof
US9040276B2 (en) DNA binding protein-polymerase chimeras
EP1463808B1 (en) High fidelity dna polymerase compositions and uses therefor
EP2110432B1 (en) High fidelity DNA polymerase compositions and uses therefor
WO2004038007A2 (en) Dna polymerases with reduced base analog detection activity
US20040081965A1 (en) DNA polymerases with reduced base analog detection activity
US20040086890A1 (en) DNA polymerases with reduced base analog detection activity
US9181534B1 (en) High fidelity DNA polymerase compositions and uses thereof
US20040091873A1 (en) DNA polymerases with reduced base analog detection activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003301590

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2503038

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005501697

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003809647

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003809647

Country of ref document: EP